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SerpinB2 [plasminogen activator inhibitor type-2 (PAI-2)] was first described as a 
placental protein, which regulated plasminogen activation via the inhibition of the 
urokinase (uPA) or tissue-type (tPA) plasminogen activators during pregnancy. 
Further work has confirmed that SerpinB2 is an efficient inhibitor of cell surface, 
receptor bound uPA and clearance of the serpin:protease complex occurs via 
members of the low density lipoprotein receptor (LDLR) family, specifically very 
low density lipoprotein receptor (VLDLR) and low density lipoprotein-related 
protein receptor (LRP). This property has allowed for the development of SerpinB2 
drug conjugates for the selective targeting of uPA positive carcinoma cells. 
However, potential utility of SerpinB2 in haematological disorders, such as acute 
myeloid leukaemia (AML), as well as its role as a physiological inhibitor of tPA is 
not well characterised. To date biochemical analysis has shown that SerpinB2 is 
able to inhibit the two-chain (active) form of tPA. However, whether this inhibitory 
function occurs within the cellular context was unknown. 
 
This thesis investigates the potential use of exogenous SerpinB2 as a delivery 
vehicle for the specific targeting of lymphoma or leukaemia, via cell surface uPA 
using the relatively low versus high uPA expressing, monocytic cell lines U-937 
and THP-1, respectively, as disease models. We show here that uPA:SerpinB2 is 
internalised via the Low Density Lipoprotein Receptor (LDLR) family members, 
specifically Low Density Lipoprotein-Related Protein (LRP) and Very Low Density 
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Lipoprotein Receptor (VLDLR) in a uPA dependent manner and these findings are 
consistent with those previously reported for epithelial cancer cell lines.  
 
In order to clarify the role of SerpinB2 in the inhibition and clearance of tPA from 
the cell surface of monocytes and macrophages, we next assessed the formation 
and endocytosis of tPA:SerpinB2 complexes at the cell surface of freshly isolated 
peripheral blood monocytes (PBM), as a non-transformed tPA-
dependent/negligible uPA-expressing cellular model representing normal myeloid 
lineages. We demonstrated that while both SerpinE1 (PAI type-1) and SerpinB2 
inhibit surface-bound tPA and are internalised predominately via LDLR family 
members, SerpinE1 enhanced the endocytosis of tPA, whereas SerpinB2 did not. 
Surface plasmon resonance biochemical analyses revealed differential binding 
affinities between VLDLR and tPA or tPA:SerpinE1 complexes in addition to those 
previously described for LRP. Moreover, tPA:SerpinB2 bound to both endocytosis 
receptors with similar kinetics to tPA. These differential biochemical interactions 
between tPA and the tPA:serpin complexes may underlie the observed differences 
in endocytosis mechanisms on the PBMs. This suggests that while SerpinE1 and 
SerpinB2 function similarly in the control of cellular plasmin generation by tPA, they 
may have disparate effects on the alternative functions of tPA via modulation of its 
engagement with endocytosis receptors in a physiological setting. Importantly, this 
work suggests that in the treatment of haematological disorders non-specific 
delivery of therapeutics via tPA using SerpinB2 would be negligible, thus 
contributing to the proof of concept for the use of SerpinB2 as a cancer targeting 
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molecule. However, assessment within an animal model of haematological 
disease is required to confirm this.  
 
SerpinB2 has been reported to have a multitude of other activities including 
regulation of monocyte and keratinocyte proliferation and differentiation, inhibition 
of apoptosis and necrosis, modulation of immune responses and to display 
cytoprotective properties in neurons. Some of these activities for SerpinB2 are 
strongly associated with its classical serpin inhibitory function within the pericellular 
space as, apart from pregnancy, it can be detected at very high concentrations in 
body fluids associated with inflammation, infection and other pathophysiological 
conditions. In many of these circumstances however, SerpinB2 protein is retained 
primarily in intracellular pools. SerpinB2 has been reported to interact with a 
number of intracellular proteins including components of the autophagy-lysosomal 
and ubiquitin-proteasome systems. These appear to be independent of SerpinB2 
protease inhibitory interactions, suggesting a novel non-serpin function for 
SerpinB2. It was thus postulated that SerpinB2 is one of the many intracellular 
proteins that maintain homeostasis during cellular damage or stress.  
 
The latter chapters of this thesis investigated this putative function for intracellular 
SerpinB2 as a chaperone-like protein using a series of cellular and biochemical 
assays. Biochemical experiments revealed that SerpinB2 binds preferentially to 
misfolded proteins and is an efficient inhibitor of amorphous protein aggregation in 
some but not all models tested. SerpinB2 was also able to completely inhibit fibril 
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formation of amyloid-β 1-40 peptide (Aβ1-40) and significantly delay fibril formation 
by Aβ1-42. Incubation of SerpinB2 with Aβ was found to obstruct protease:SerpinB2 
complex formation, suggesting that Aβ may bind within β-sheet-A, breach region, 
of the serpin. We further explored the potential for SerpinB2 as a modulator of 
cellular proteotoxic stress using a well-established huntingtin protein (Htt) 
aggregation model, comprising an exon 1 fragment fused to either 25 
polyglutamine (Httex125Q-mCherry) or 46 (Httex146Q-mCherry) polyglutamine 
sequences.  Wild-type or SerpinB2-/- mouse embryonic fibroblasts (MEF) were 
transiently transfected with expression vectors containing either Httex125Q-
mCherry or Httex146Q-mCherry, and cellular processing of aberrant Htt-fusion 
protein was examined. These experiments revealed a clear difference in 
phenotype, whereby inclusion body formation was evident in the wild-type MEF 
controls and minimal in the absence of SerpinB2, where small foci predominated. 
The impaired inclusion body formation was found to correspond with a significant 
loss in cell viability for the SerpinB2-/- MEFs. Importantly, recovery of the wild-type 
MEF phenotype and cell viability was achieved in a human SerpinB2 knock-in MEF 
line. Given previous literature that suggests a possible role for SerpinB2 within both 
the autophagy-lysosomal and proteasome degradation pathways, we compared 
activity of each in the wild-type and SerpinB2-/- cell lines. Interestingly, both 
systems were found to be impaired in the absence of SerpinB2. It was thus 
concluded that intracellular SerpinB2 plays an important role in proteostasis as its 
loss leads to a proteotoxic phenotype associated with an inability to 
compartmentalize aggregating proteins. This represents a major contribution 
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towards understanding the otherwise elusive cytoprotective role of intracellular 
SerpinB2 and it is likely that further research will uncover therapeutic targets for 
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PMSF alpha-toluenesulfonyl fluoride 
PSMB1 Proteasome subunit beta type-1 
PtdIns3K Phosphatidylinositol 3-kinase 
PVDF polyvinylidene difluoride 
RAP Receptor Associated Protein 
Rb Retinoblastoma protein 
RCL Reactive Centre Loop 
ROI Reactive oxygen intermediate 
RNA Ribonucleic acid 
Rt-PCR Reverse-transcription polymerase chain reaction 
(sc)-tPA Single Chain tPA 
(sc)-uPA Single Chain uPA 
suPAR Soluble uPAR 
SCCA Squamous cell carcinoma antigen 
SD Standard Deviation 
SDS Sodium Dodecyl Sulfate 
SEM Standard error mean 
SEM Scanning electron microscopy 
Serpin Serine protease inhibitor 
sHSP Small heatshock protein 
SOD Superoxide dismutase 
SPD Serine Protease Domain 
SPR Surface Plasmon Resonance 
  - XXII - 
(tc)-tPA Two Chain tPA 
(tc)-uPA Two Chain uPA 
TB Terrific Broth 
TBS Tris-buffered saline 
TBST Tris-buffered saline 20% Tween 
TEMED NNN’N’-tetramethylethylenediamine 
TFA Trifluoroacetic acid 
ThioT Thioflavin-T 
TLR Toll-like receptor 
TNF-α Tumour Necrosis Factor-α 
TPA 12-O-tetradecanoylphorbol-13-acetate 
tPA Tissue-type plasminogen activator 
uPA Urokinase-type plasminogen activator 
uPAR Urokinase-type plasminogen activator receptor 
UPS Ubiquitin-Proteasome System 














































SerpinB2 is a member of the Serine Protease Inhibitor super family and was 
originally isolated from placental tissue and described as an inhibitor of the serine 
proteinase urokinase-type plasminogen activator (uPA) (Kawano et al. 1968; 
Kawano et al. 1970).  Subsequent investigations revealed that SerpinB2 was also 
able to inhibit the tissue-type plasminogen activator (tPA) (Astedt et al. 1985; 
Astedt et al. 1985; Thorsen et al. 1988). On this basis SerpinB2 was named 
plasminogen activator inhibitor type-2 (PAI-2) distinguishing it from PAI-type-1 
(PAI-1) (referred to herein as SerpinE1), also a newly discovered inhibitor of 
plasminogen activators (PAs) (Loskutoff and Edgington 1977). Initial 
characterisation of SerpinB2 focussed on its role as an extracellular mediator of 
plasmin generation with frequent comparison to SerpinE1. With the finding that 
SerpinE1 was the faster acting inhibitor (Kruithof et al. 1995) and was present in 
normal and pregnancy plasma, whereas SerpinB2 was only detectable during late 
pregnancy (Kruithof et al. 1984), SerpinE1 was originally considered the primary 
physiological mediator of thrombosis and fibrinolysis. Increasing evidence 
supports a role for SerpinB2 as a physiological inhibitor of PAs however, 
consistently placing the serpin within the extracellular milieu of diseased tissue 
exhibiting localised inflammation and homeostatic imbalance (Kruithof et al. 1995; 
Croucher et al. 2008; Schroder et al. 2010; Siefert et al. 2014). 
 
The highest concentration of SerpinB2 protein is found intracellularly, in vitro, 
within cells of the monocytic lineage (Kruithof et al. 1986; Genton et al. 1987). 
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However, an intracellular serine protease target for this serpin is yet to be defined. 
Furthermore, intracellular SerpinB2 seems to be promiscuous with many non-
protease binding partners described over the years, since its discovery (Schroder 
et al. 2010). This combined with the finding that intracellular SerpinB2 up-
regulation in response to inflammation, infection and other pathophysiological 
conditions, suggest a non-classical role for this serpin, independent of its protease 
inhibitory capabilities.  
 
This review will focus on 1) the known roles of SerpinB2 as an extracellular 
protease inhibitor, specifically literature relating to inhibition of uPA and tPA; and 
2) the putative roles of intracellular SerpinB2 which suggest it’s possible placement 
as a pivotal protein functioning within proteostasis pathways. 
 
 
1.2. Serine Protease Inhibitor Super Family 
The Serine Protease Inhibitor (serpin) Super Family consists of a large group of 
multi-functional proteins with highly conserved structure  and variable amino acid 
sequence homology, with exception of highly conserved residues within the breach 
and shutter regions (Fig.1.1.A) (Gettins 2002). Typically, serpins range between 
330-500 amino acids, consist of three β sheets (A,B and C), 8-9 α helices (hA-hI) 
and a reactive centre loop (RCL) which contains the protease recognition site (Fig. 
1.1.A).  Formation of a serpin-protease complex involves a suicide substrate-like 
inhibitory mechanism, whereby the initial interaction results in an intermediate 
conformational change of the inhibitor from a stressed to relaxed state (Fig.1.1.B), 
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which allows the irreversible insertion of the RCL into β-sheet A of the serpin – 
initiating in the breach region -  in a 1:1 covalently linked, stable conformation (Fig. 
1.1.C) (Huntington et al. 2000).  The rate and efficiency of complex formation 
between a serpin and its target protease is dependent on the complete insertion of 
the RCL into β-sheet A and partial inhibition or blocking of this step results in the 
substrate-like cleavage of the RCL, followed by serpin release (Fig.1.1.D) 
(Silverman et al. 2001).  Whilst the suicide inhibitory mechanism of serpins is most 
typical, some serpins inhibit their target protease via the substrate mechanism, 








Serpin distribution is diverse with over 1000 members found across higher order 
plants, mammals, invertebrates, prokaryotes, archea, fungi and some viruses. 
Originally thought to only target serine proteases, some serpins have now been 
Figure 1.1: Highly conserved tertiary structure of Serpin Super Family. (A) 
Native serpin structure, represented by serpinA1 (Protein Data Bank (PDB) # 
1QLP (Elliott et al. 1996)) showing A-β-sheet (red), B-β-sheet (green), C-β-sheet 
(yellow) and helices A-I (blue). Positioning of the reactive center loop (RCL) 
(magenta) in stressed (solid line) and relaxed (dashed line) confirmation. The 
breach and shutter regions are labelled.  (B) Initial serpin:protease interaction via 
the RCL results in the intermediate Michaelis complex formation as represented 
by SerpinA1 and inactive trypsin (multicolours) (PDB # 1OPH (Ye et al. 2001)), 
which leads to either (C) the 1:1 covalently linked, stable serpin:protease 
complex (PDB # 1EZX (Huntington et al. 2000)) or (D) cleaved serpin in the 
relaxed and inactive confirmation (RCL insertion) (PDB code 7API (Loebermann 
et al. 1984)) and active protease. In this case the serpin has acted as a substrate 





shown to inhibit cysteine protease targets (Hook et al. 1993; Komiyama et al. 1994; 
Schick et al. 1998; Schick et al. 1998; Higgins et al. 2010; Kantyka et al. 2011), 
furthermore, non-inhibitory serpins have also been described, which function in 
hormone transport (Hammond et al. 1987; Pemberton et al. 1988) or stabilisation 
of structural support molecules (Tasab et al. 2000; Sauk et al. 2005). Given the 
diversity of serpins, they have been arranged into sub-families (Clades) based on 
their evolutionary relationships (Irving et al. 2000).  
 
As the focus of this thesis is specifically SerpinB2, a member of the serpin clade B 
(see below), a full discussion of all other clades is beyond the scope of this chapter, 
however for comprehensive reviews see Gettins (2002), Irving et al. (2000), 
Silverman et al. (2010) and Whisstock et al. (2010). 
 
1.3. Serpin Clade B 
The ovalbumin-serpin sub family (serpin clade B) consists of 14 members, 13 of 
which are found within the human genome (Tab. 1.1) and classified as such, due 
to their similarity to ovalbumin (SerpinB14). All members of this clade feature: (i) a 
high degree of amino acid homology (~ 50%), (ii) a lack of N- and C- terminal 
extensions found in many other serpins, (iii) a similar gene organization, three of 
the 13 human serpins within this clade map to position 6p25 (B1, B6 and B9), whilst 
all others map to position 18q21.3, and (iv) the presence in several members of an 
inter-helical domain connecting helices C and D, encoded by an exon 3 (Remold-
O'Donnell 1993; Scott et al. 1999).   
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Table 1.1: Members of the Serine Protease Inhibitor (serpin) Clade B; known function and expression profiles. 
Clade-B 
Member Alternative Names Target Protease 
Location/Cell 
specificity/functions (if known) Reference 











et al. 1992; Wang et 
al. 2013) 
SerpinB2 Plasminogen Activator 
Inhibitor Type-2 
Extracellular; 




Extracellular; inhibition of 
plasminogen activators; immune 
modulator 
Intracellular inflammation 
response protein, immune 
modulator. 
 
(Refer Table 1.2 for list of cells 
which have been shown to 
express SerpinB2) 
 
(Kruithof et al. 1984; 
Kruithof et al. 1995; 
Schroder et al. 2010) 
Reviewed in; 
(Croucher et al. 
2008; Schroder et al. 
2010; Medcalf 2011)  
SerpinB3 Squamous cell 
carcinoma antigen-1 
(SCCA-1) 
Cathepsin K, L, & S 
papain and JNK1. 
Intracellular; Squamous epithelial 
cells 
(Takeda et al. 1995; 
Schick et al. 1998; 
Schick et al. 1998; 
Zheng et al. 2009) 
SerpinB4 Squamous cell 
carcinoma antigen-2 
(SCCA-2) 
Cathepsin G, Mast 
Cell Chymase 
Intracellular; Squamous epithelial 
cells 
(Schick et al. 1997) 
SerpinB5 Maspin Non-inhibitory Intracellular; tumour suppressor 
Hypothesized functions; 
Extracellular matrix remodeling via 
Rac and Cdc42 signaling. Pro-
apoptotic mediator. Potential 
(Odero-Marah et al. 
2003; Liu et al. 2004; 
Bailey et al. 2005; 
Latha et al. 2005; 
Romani et al. 2006; 
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Clade-B 
Member Alternative Names Target Protease 
Location/Cell 
specificity/functions (if known) Reference 
involvement in cellular stress 
responses. 
Shi et al. 2007; Teoh 
et al. 2010) 
SerpinB6 Proteinase Inhibitor-6 Cathepsin G, kallikrein 





Intracellular; nucleocytoplasm of 
neutrophils, cytotoxic T cells, 
keratinocytes, skeletal muscle, 
placenta, heart, lung, liver, kidney 
pancreas, inner ear hair cells, 
normal mast cells and by mast 
cells in mastocytoma lesions. 
(Scott et al. 1999; 
Scarff et al. 2004; 
Zhang et al. 2006; 
Sirmaci et al. 2010) 




Mesangial cells within the 
glomerulus (kidney). Involved in 
mesangial - cell proliferation and 
extracellular matrix expansion. 
Secretion of collagen type- IV 
(Miyata et al. 1998; 
Miyata et al. 2002; 
Ohtomo et al. 2008; 
Xia et al. 2011) 
SerpinB8 Proteinase Inhibitor-8 Furin. Trypsin-like 
serine proteinases. 
Extracellular; released from 
platelets 
Intracellular; monocytes, platelets, 
squamous epithelial and 
neurocrine cells. 
(Dahlen et al. 1998; 
Strik et al. 2002; 
Leblond et al. 2006) 
SerpinB9 Proteinase Inhibitor-9 Cytotoxic lymphocyte 
protease granzyme B, 
subtilisin A, caspase-
1, 4, 8 & 10 
Intracellular; nucleocytoplasm of 
cytotoxic lymphocytes. Protects 
against granzyme B-mediated 
apoptosis. 
(Sun et al. 1996; 
Bird et al. 1998; Bird 
et al. 2001; Hirst et 
al. 2003) 





Intracellular; monocytic cells. 
Chromatin remodeling protein 
(MENT). 
(Riewald et al. 1998; 
Chuang and Schleef 




Member Alternative Names Target Protease 
Location/Cell 
specificity/functions (if known) Reference 
SerpinB11 Epipin Non-inhibitory 
(humans) 
Unknown. 
Avian SerpinB11 expression is 
restricted to oviduct epithelial cells. 
Hoof wall structure in Connemara 
Ponies. 
(Askew et al. 2007; 
Lim et al. 2011; 
Finno et al. 2015) 
SerpinB12 Yukopin Unknown. Trypsin-like 
serine proteinases 
Unknown. Wide tissue distribution; 
brain, bone marrow, lymph node, 
heart, lung, liver, pancreas, testis, 
ovary and intestines 
(Askew et al. 2001) 




Intracellular; Keratinocytes (Jayakumar et al. 
2003; Welss et al. 
2003) 
SerpinB14 Ovalbumin Non-inhibitory Storage/structural protein found in 
chicken eggs.  
(Hunt and Dayhoff 
1980) 
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Despite their sequence and structural similarities the independent Serpin clade B 
members appear to be quite diverse in cell distribution and specific protease 
targets and/or function (Table 1.1) whilst sharing common placement as either 
enhancers or suppressors of inflammation and tumorigenesis. Serpins within this 
clade can be either non-inhibitory, ie SerpinB5, B11 and B14 or have clearly 
defined protease targets (Table 1.1). Furthermore, some members are restricted 
to the cytoplasm, others localise within the nucleus, ie SerpinB2 and B10, whilst 
SerpinB8 (Leblond et al. 2006) and SerpinB2 are found within both the intracellular 
and extracellular environment. 
 
1.4. SerpinB2 
The SERPINB2 gene is located between 18q21.3 – 18q22.1 (Webb et al. 1994), 
within the known serpin B-clade cluster on chromosome 18q (van Gent et al. 
2003). SerpinB2 protein consists of 415 amino acids, and has a predicted 
molecular weight of 47 kDa. The conventional hydrophobic amino-terminal signal 
sequence, necessary for protein direction into the secretory pathway, is internally 
positioned within SerpinB2, resulting in inefficient processing down this classical 
pathway (von Heijne et al. 1991), whilst allowing for intra and extracellular 
distribution. SerpinB2 contains three potential N-linked glycosylation sites, at asn-
75, asn-115 and asn-339 positions, and occupation of all three gives rise to the 60 
kDa extracellular species of SerpinB2 (Ye et al. 1988). The RCL is positioned at 
P1 arg-380 and P1’ thr-381 (Kiso et al. 1988) and the loop is disordered in structure 
(Harrop et al. 1999). In SerpinB2, the inter-helical domain between helices C and 
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D is called the CD-loop. The CD-loop is highly mobile structure and can translocate 
by approximately 40 Ǻ between the side and the bottom of the molecule (Lobov et 
al. 2004). Due to this flexibility, the structure of the CD-loop has yet to be resolved, 
however the rest of SerpinB2 conforms to the general tertiary structure conserved 
across all known serpins (Harrop et al. 1999; Jankova et al. 2001) (Figure 1.1).  
 
1.5.  Expression of the SERPINB2 gene  
Isolation and characterisation of the SerpinB2 promoter region has identified 
mechanisms by which transcription of SerpinB2 mRNA can be up-regulated by a 
wide range of activating molecules, within a variety of cell types (Table 1.2). The 
SerpinB2 promoter region contains a putative MAZ site (Almeida-Vega et al. 2009), 
an ASC-1 site (Almeida-Vega et al. 2009), two AP1-like binding sites (Cousin et al. 
1991), an AP2-like binding site (Kruithof and Cousin 1988), CRE-like element 
(Cousin et al. 1991; Park et al. 2005) and a NF-κB binding site (Mahony et al. 1999; 
Park et al. 2005). Response elements to glucocorticoids (Schuster et al. 1993; 
Schuster et al. 1994), retinoic acid (Schuster et al. 1993; Schuster et al. 1994) and 
xenobiotics (Sutter et al. 1991) have also been localised to the 5’ promoter region 
of SerpinB2. Recently, the transcription factor C/EBP-β has been shown to 
mediate constitutive and LPS-inducible transcription of murine SerpinB2 (Udofa et 
al. 2013) and an AP-1 element binds FosB which is necessary for PMA induced 
up-regulation of SerpinB2 expression in U937 cells  (Stringer et al. 2012). 
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Table 1.2: The expression of SerpinB2 mRNA and/or protein can be regulated by a range of biological agents in a 
diverse set of cell types. 
 Expression   
Agent mRNA Protein Cell Type  Cell Line Ref. 
Pro-inflammatory Cytokines 
TNF-α ↑ ↑ Fibroblast HT-1080 (Medcalf et al. 1988) 






(Pytel et al. 1990) 
↑ ND Myeloid U-937, PC (Gyetko et al. 1992) 
↑ ↑ Vascular SM PC (Jang et al. 2004) 
↑ ↑ 
Keratinocyte PC (Wang and Jensen 
1998) 
Interferon-γ ↑ ↑ Monocyte U-937, PC (Gyetko et al. 1992) 






(Champelovier et al. 
2003) 
IL-1β ND ↑ Fibroblast (BM) PC (Hannocks et al. 1992) 






(Hamilton et al. 1993) 
IL-2 ↑ ND Monocyte PC (Gyetko et al. 1993) 




(Woodruff et al. 2007) 
G-CSF ↑ ↑ Monocyte PC (Hamilton et al. 1993) 
M-CSF ↑ ↑ Monocyte PC (Hamilton et al. 1993) 
Steroids/Growth Factors 








(George et al. 1990) 




(Piquette et al. 1993) 





(Woodruff et al. 2007) 
Pathogenic Stimuli 
LPS  ↑ ↑ 
Monocyte PC (Schwartz and Bradshaw 
1992) 
 ↑ ND Macrophage  RAW-267, PC (Costelloe et al. 1999) 
 ↑ ND Monocyte PC (Suzuki et al. 2000) 
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(Xiao and Bartold 2004) 
Signalling mediators 
cAMP ↑ ND Myeloid PL-21 (Niiya et al. 1994) 
Calcium ↑ ↑ 
Keratinocytes PC, HaCaT  (Wang and Jensen 
1998; Seo et al. 2002) 
 ↑ ND Neurons PC  (Zhang et al. 2009) 
Toxins      
Dioxin ↑ ND Keratinocyte SCC-12F (Sutter et al. 1991) 
 ↑ ND Epithelial (Breast) M13SV1 (Ahn et al. 2005) 
Kainate ↑ ND Neuronal Whole tissue (Sharon et al. 2002) 





Oxamflatin ↑ ↑ Myeloid U-937 (Dear and Medcalf 2000) 
Tumour promoting agents 
PMA ↑ ND Macrophage RAW-267, PC (Costelloe et al. 1999) 
 
↑ ↑ Myeloid U-937, THP-1, 
HL-60, K-562 
(Genton et al. 1987; 
Schleuning et al. 1987; 





Vasculature effectors and regulators 
Angiotensin II ↑ ND  Aortic SM  PC  (Feener et al. 1995) 
D-Dimer ND ↑ Myeloid NOMO-1 (Hamaguchi et al. 1991) 
Factor VIIa ↑ ND Keratinocytes HaCaT (Camerer et al. 2000) 
Thrombin   
Monocyte/Macrop
hage 
U-937, PC (Lundgren et al. 1994; 
Ritchie et al. 1995) 
Other      
Lipoprotein-a ↑ ↑ Monocyte PC (Buechler et al. 2001) 
Retinoic acid ↑ ↑ 
Myeloid U-937, THP-1, 
HL-60, K562 
(Schuster et al. 1993) 
 ↑ ND Keratinocytes PC (Braungart et al. 2001) 
 ↑ ↑ Monocyte PC  (Montemurro et al. 1999) 
VLDL and LDL ND ↑ Monocyte PC (Wada et al. 1994) 
ND: Not Determined 
PC: Primary Culture 
VLDL: Very low density lipoprotein 
LDL: Low density lipoprotein 
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In addition to the promoters described above, the SerpinB2 gene contains at least 
two repressor regions in the 5’ region of the SerpinB2 gene (positions,1859-1100 
and 259-219) (Antalis et al. 1996). The latter site also contains a binding site for 
an as yet unidentified nuclear protein (Dear et al. 1996). A repressor motif termed 
PAUSE-1 (SerpinB2 upstream silencer element-1, sequence: 5’-
CTCTCTAGAGAG-3’) (Antalis et al. 1996) is located at position -1832 and binds a 
specific, ~ 67 kDa binding factor (Ogbourne and Antalis 2001). This region 
overlaps with the repressor described by Dear et al. (1996), suggesting that these 
studies may have described the same repressor region.  
 
Full length SerpinB2 mRNA is unstable, with a half-life of approximately one h 
(Maurer et al. 1999). The best characterised mRNA degradation components are 
AU-rich regions in the 3’ region of mRNAs. The 3’-untranslated region of SerpinB2 
mRNA contains an AU-rich region which plays an important role in the degradation 
of SerpinB2 mRNA (Maurer and Medcalf 1996). Disruption of the nonameric motif 
UUAUUUAUU via mutagenesis led to an increase in SerpinB2 mRNA and protein 
expression levels (Maurer et al. 1999). Additionally, this motif is a binding site for 
HuR, which has been associated with mRNA decay (Maurer et al. 1999). 
Tristetraprolin, a CCCH tandem zinc finger protein that binds to ARE-containing 
transcripts, also interacts with the AU-rich region of the 3’-UTR and mediates 
SerpinB2 mRNA degradation (Yu et al. 2003). Exon 4 of SerpinB2 also contains 
an mRNA instability region, sharing homology with instability determinants of other 
mRNAs (Tierney and Medcalf 2001).  
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1.6. Polymorphisms 
SerpinB2 has not, as yet, been linked to any ‘serpinopathies’, that is, diseases 
directly related to or caused by aberrant SerpinB2 function. However, there are 
numerous studies showing correlation between disease states and polymorphisms 
of the SerpinB2 gene. Two forms of SerpinB2 have been described, with variations 
in three amino acids (Antalis et al. 1988; van den Berg et al. 1990). These 
variations occur at positions 120, 404 and 413 with Asn, Asn and Ser in form A 
and Asp, Lys and Cys in form B. Each of these changes is the result of a single 
base change in each codon (120, Aat/Gat; 404, aaC/aaG; 413, tCc/tGc), however 
it appears that all three mutations are linked and do not exist in isolation. Whilst 
the functional consequences of these residue changes are unknown, a number of 
studies have linked SerpinB2 genotype and disease. Form A has been associated 
with lupus erythematosus and thrombotic pneumonia in patients with this condition 
(Palafox-Sanchez et al. 2009), anti-phospholipid syndrome (Vazquez-Del Mercado 
et al. 2007) and mycocardial infarction (Buyru et al. 2003; McCarthy et al. 2004; 
Corsetti et al. 2013), although Foy and Grant (1997) found no evidence of the link 
between SerpinB2 variants and mycocardial infarction. These disease states all 
relate to disorders in haemostasis, highlighting the role of SerpinB2 in this system. 
In addition, Shioji et al.(2005) showed an association between the A form and 
prostate cancer. SerpinB2 form B is linked to preterm birth in subjects later 
diagnosed with cerebral palsy (Gibson et al. 2007) and poor overall survival in 
patients with non-small cell lung cancer (Di Bernardo et al. 2009). Many 
serpinopathies described for other serpins, result from serpin polymerisation that 
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gives rise to protein aggregation diseases (Belorgey et al. 2007). In this context, 
SerpinB2 is unique. 
 
1.7. Polymerisation of SerpinB2 
SerpinB2 can spontaneously form polymers in vitro (concentration and 
temperature dependent) and also in vivo when directed to the cell secretory 
pathway (Mikus et al. 1993; Mikus and Ny 1996; Wilczynska et al. 2003). Most 
serpins require amino acid substitution(s) in key structural positions to provide the 
ability to polymerise as is the case for natural mutants of α1-antitrypsin, C1-
inhibitor, α1-antichymotrypsin and neuroserpin (Stein and Carrell 1995; Davis et 
al. 1999). In these instances, serpin polymerisation underlines a variety of genetic 
disorders including emphysema (α1-antithrypsin deficiency), hereditary 
angioneurotic edema (C1-inhibitor deficiency), and dementia (neuroserpin 
mutations). In contrast, SerpinB2 does not require additional mutagenesis and wild 
type protein can exist in a highly polymerogenic conformation (Wilczynska et al. 
2003). Polymerisation of SerpinB2 has not been linked with any pathological 
outcomes. Furthermore, the role of SerpinB2 polymers and their relative 
abundance compared to non-polymerised SerpinB2 in the organism remains 
unknown.  
 
SerpinB2 can exist in two different monomeric and inhibitory active forms: the 
polymerogenic and the stable monomeric form (Wilczynska et al. 2003). The 
polymerogenic (prone to polymerisation) form is characterised by open β-sheet A 
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and is stabilised by a disulfide bond connecting C79 in SerpinB2 CD-loop to C161 
at the bottom of the molecule (Mikus et al. 1993; Wilczynska et al. 2003; Lobov et 
al. 2004). Under reducing conditions, the di-sulfide bond is not formed and the CD-
loop folds on the side of the molecule; in this form the β-sheet A is closed and the 
molecule remains as a monomer under physiological conditions providing the 
stable monomeric form of SerpinB2 (Mikus et al. 1993; Wilczynska et al. 2003; 
Lobov et al. 2004). The two forms are fully inter-changeable, depending on the 
redox status of the environment and thus reduction/oxidation of the di-sulfide bond 
determines whether SerpinB2 is present in the stable monomeric or the 
polymerogenic form (Lobov et al. 2004) or potentially, polymers. Interestingly, 
SerpinB2 seems to be able to form different types of polymers under different 
conditions. For example, polymers of recombinant SerpinB2 obtained upon 
incubation at 37 oC or induced by bis-ANS have no inhibitory activity (Wilczynska 
et al. 2003; Wilczynska et al. 2003), while polymers of SerpinB2 formed in the cell 
secretory pathway retain their inhibitory activity (Wilczynska et al. 2003). Different 
mechanisms for serpin polymers have been proposed, including the so called 
“loop-sheet” and “domain-swapping” polymers (Whisstock and Bottomley 2008). 
Interestingly however, SerpinB10 has also been shown to undergo redox sensitive 
conformational changes giving rise to polymers, similar to those described for 
SerpinB2 (Przygodzka et al. 2010). Whilst the functional significance of SerpinB10 
is also unknown, it’s close homology to SerpinB2 and shared polymerisation 
characteristics give strength to the physiological relevance of redox sensitive 
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conformational changes.  Thus, the mechanisms of SerpinB2 polymerisation and 
the activity of its different polymer types require further investigation.  
 
1.8. Extracellular SerpinB2  
The main physiological producers of SerpinB2 are activated monocytes and 
macrophages (Wohlwend et al. 1987; Hamilton et al. 1993; Ritchie et al. 1997). 
However, many other cell types including eosinophils (Swartz et al. 2004), 
adipocytes (Lijnen et al. 2007), microglia (Akiyama et al. 1993), neurons 
(Yamanaka et al. 2005; Zhang et al. 2009), astrocytes (Dietzmann et al. 2000), 
trophoblasts (Astedt et al. 1998) and mesothelial (Ivarsson et al. 1998) (in addition 
to those listed within Table 1.2), produce this serpin.  It has been suggested that a 
non-classical secretory pathway for SerpinB2 exists due to the presence of both 
the 47 kDa and 60 kDa forms of SerpinB2 within the extracellular matrix in localised 
tissues and the detection of similar concentrations of both forms in the blood of 
pregnant women (Kruithof et al. 1987; Ritchie and Booth 1998). Indeed, recent 
studies show the secretion of 47 kDa SerpinB2, in response to inflammatory 
stimulus (LPS), via transport-like vesicles (Boncela et al. 2013). Furthermore, 
Schroder et al. (2014) have now shown SerpinB2 associated with micro-particles, 
which facilitate its secretion from metastatic murine B16 melanoma cells. 
Importantly, SerpinB2 was secreted as an active serpin, able to inhibit urokinase-
type plasminogen activator (uPA) and therefore inhibit plasmin formation within the 
extracellular environment. 
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Plasmin is a broad-spectrum protease, which is derived from the circulating 
zymogen plasminogen, by activation via either tPA or uPA systems (Dano et al. 
2005). The role of tPA is predominantly associated with fibrinolysis (clot 
dissolution) (Hoylaerts et al. 1982) and has more recently been identified in 
important neurobiological processes, discussed below in section 1.11 and 
reviewed in (Melchor and Strickland 2005). Conversely, uPA is generally 
implicated in pericellular proteolysis resulting in ECM degradation (Andreasen et 
al. 1997).  
 
1.9. Urokinase Plasminogen Activator System 
Controlled expression of the uPA system is associated with cell surface proteolysis 
and tissue remodelling during normal physiological conditions such as wound 
healing and embryogenesis (Andreasen et al. 2000; Dano et al. 2005).  However, 
de-regulation of the uPA system is known to allow tumour invasion and metastasis 
through the proteolytic degradation of the ECM, effectively presenting a gateway 
for proximal and distal spread of malignant cells.  It is now accepted that the role 
of uPA in cancer is broader than ECM degradation and incorporates non-
proteolytic functions, including cell proliferation, cell migration and cell adhesion  
(Andreasen et al. 1997; Ranson and Andronicos 2003; Duffy 2004; Dano et al. 
2005). 
 
The uPA cascade is initiated by the high affinity binding of pro-uPA, the zymogen 
form of uPA, to the uPA receptor (uPAR) (discussed below) at the cell surface (Fig. 
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1.2) (Ellis et al. 1989; Andreasen et al. 1997).  Pro-uPA is subsequently activated 
to form the serine protease uPA through cleavage of the peptide bond Lys158 - 
Ile159, via a number of proteases, with plasmin being most common (Andreasen et 
al. 1997).  It has been suggested that pro-uPA contains intrinsic activity and that 
this may, in part, contribute to the activation of the uPA cascade (Behrendt et al. 
2003).  
 
The binding of pro/uPA to its cell surface receptor uPAR via the N-terminal growth 
factor domain (GFD), results in the placement of the serine protease domain (SPD) 
within the extracellular matrix (Andreasen et al. 1997) (Fig. 1.2). As its substrate, 
plasminogen binds to co-localised receptors, e.g. Annexin II hetratetramer (AIIt) 
resulting in the accelerated activation of plasmin at the cell surface (Plesner et al. 












Figure 1.2: Components of the uPA system at the cell 
surface. 1. uPAR bound uPA is co-localised with 
plasminogen allowing proteolytic activation of 
plasminogen, at its C-terminal serine protease domain 
(SPD), to form plasmin. 2. Plasmin directly breaks down 
the ECM through its SPD, or indirectly through activation 
of MMPs.  3. The uPA system is inhibited by SerpinE1 
(PAI-1) and SerpinB2 (PAI-2), which deactivates the 
SPD of uPA by direct binding. 4. Binding of serpins to 
uPA allows interaction with LDLRs due to conformational 
changes and facilitates the accelerated clearance of 
uPAR:uPA:serpin complex from the cell surface. 5. The 
complex and receptors are delivered to lysosomes via 
transport vesicles, where uPA:serpin complexes are 
enzymatically degraded. 6. uPAR and the LDLRs are 
recycled to the cell surface. 7. Non-proteolytic activity of 
uPA system; uPAR interactions with integrins result in 
cell signalling, uPAR interactions with vitronectin allows 
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1.10. Urokinase Plasminogen Activator Receptor 
The uPA receptor (uPAR) is a glycoprotein containing 283 amino acid residues 
and is bound to the cell surface through a carboxyl terminal 
glycosylphosphatidylinositol (GPI) anchor (Andreasen et al. 1997; Huai et al. 2006) 
(Fig. 1.2).  The uPAR protein is comprised of three extracellular domains (D1 – 
D3) (Fig. 1.2) and whilst bound through the GPI anchor, does not contain an 
intracellular domain or membrane spanning peptide segment (Behrendt and 
Stephens 1998).  Until recently it was widely accepted that D1 contained the 
binding domain for the growth factor region of (pro)-uPA, however using x-ray 
crystallography, Huai et al. (2006) have shown that all three domains are involved 
in binding interactions.  The GFD within uPA contains an omega loop with residues 
critical for binding to D1, D2 and D3 of uPAR (Behrendt and Stephens 1998).  
Soluble forms of uPAR (suPAR) have also been identified within plasma and are 
thought to originate through the cleavage of the GPI anchor at the cell surface by 
plasmin (Hoyer-Hansen et al. 2001; Rasch et al. 2008). Whilst SerpinE1 binding 
to uPA interrupts the vitronectin interactions (Andreasen et al. 1997), it also 
facilitates the internalisation of uPAR and associated integrins (Czekay et al. 
2001).  As SerpinE1 can also bind to vitronectin it is able to inhibit uPAR/vitronectin 
interactions from re-occurring and these two processes lead to cell detachment 





1.11. Tissue Type Plasminogen Activator 
The tissue type plasminogen activation system was predominantly associated with 
fibrinolysis and under normal physiological conditions plasma tPA concentration is 
~ 0.1 nM (Dano et al. 1985). However, it is now known that tPA is not restricted to 
maintaining homeostasis of coagulation and fibrinolysis. For example, tPA has 
been shown to play a role in angiogenesis via cell surface interactions with annexin 
II (p36) (Ling et al. 2004) and has emerged as a key component of neurobiology 
with a vast number of roles described such as; effector of learning and memory 
(Seeds et al. 2003; Obiang et al. 2012; Li et al. 2013); stress, as a modulator, via 
stabilisation of the NMDA (N-methyl-D-aspartate) receptor during stress and 
participating in behavioral changes and synaptic plasticity via NMDA signaling 
within the hippocampus (Norris and Strickland 2007). Furthermore, links to 
protection against neuronal degeneration have been found, whereby tPA has been 
shown to degrade amyloid-β (Aβ) in vivo, within two different mouse models of 
Alzheimer's disease (Melchor et al. 2003) and has recently been shown to 
neutralise Alzheimer's disease progression (Oh et al. 2014). Of interest however 
is the role plasminogen activators play in monocyte biology, given that cells of 
myeloid lineage interchangeably express tPA, uPA and SerpinB2/SerpinE1, 
specifically during activation or differentiation processes (McWilliam et al. 1998; 
Missen et al. 2006), although the physiological implications of this flexibility 
requires further investigation.  
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Many cells secrete tPA such as; melanocytes (Rijken and Collen 1981), endothelial 
cells (Ljungner et al. 1983; Larsson and Astedt 1985) and peripheral blood 
monocytes (Hart et al. 1989; Hart et al. 1989; Soo et al. 1996). As a single chain 
polypeptide, tPA is a glycosylated protein with molecular weight ~ 72 kDa (Rijken 
and Collen 1981; Dano et al. 1985; Vassalli et al. 1992). Cleavage of sc-tPA, via 
hydrolysis of the Arg275-Ile276 peptide bond, produces the 62.9 KDa two chain (tc) 
tPA conformation (Rijken and Collen 1981; Collen and Lijnen 2004).  Linked by 
one disulfide bridge, chain A and chain B have Mr ~ 33 kDa and 39 kDa, 
respectively (Rijken and Collen 1981; Pennica et al. 1983).   The basic structure 
of the tPA molecule contains 4 domains;  i) the N-terminal region of 47 residues 
comprising the finger domain (F Domain), which is homologous with the finger 
domain of fibronectin, ii) an epidermal growth factor domain (E-domain) residues 
50-87, iii) two kringle domains, residues 87-176 (K1), and 176-256 (K2), which 
share similar amino sequences to the five kringle domains within plasminogen and 
iv) the serine protease domain within the C-terminus, containing the active sites 
His322, Asp371 and Ser478 (Pennica et al. 1983).   Domains 1-3 are found in the A 
chain of activated tPA, whilst the protease domain is located within the B chain 
(Pennica et al. 1983).  The high affinity binding of tPA to fibrin is mediated by the 
finger domain and lysine sites within the kringle domains of tPA (Hoylaerts et al. 
1982; van Zonneveld et al. 1986; Kaczmarek et al. 1993).  Furthermore, the 
regions of homology identified within the kringle domains of plasminogen and tPA 
enable the co-localisation of these proteins via fibrin on the clot surface, which in 
turn facilitates the accelerated production of plasmin (Hoylaerts et al. 1982).   
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Soluble tPA is cleared from circulation via parenchymal and endothelial cells in the 
liver (Kuiper et al. 1988; Nguyen et al. 1992; Simon et al. 1995), whilst cell bound 
inactivated tPA is internalised via endocytosis and degraded in lysosomes 
(Camani et al. 1994; Hardy et al. 1997). The characterisation of a tPA receptor on 
the cell surface of human umbilical vein endothelial cells (HUVEC) by Hajjar and 
Hamel (1990) identified the annexin II heterotetramer (AIIt)  (Cesarman et al. 1994; 
Hajjar et al. 1994) as an important binding site for both tPA and plasminogen.  In 
addition, high density - low affinity binding sites for tPA have also been described 
for HUVECs, the U-937 and THP-1 monocytic cell lines and peripheral blood 
monocytes (Felez et al. 1991).  Investigation of the role of glycosaminoglycans in 
cell surface tPA interactions by Camani et al. (2000) concluded that these receptor 
types are not involved. 
  
Little is understood about the role of SerpinB2 as a physiological inhibitor of tPA 
due to limited reports of tPA:SerpinB2 complexes identified in vivo (Kruithof et al. 
1995). Yet, co-expression of tPA and SerpinB2 has been shown in normal bone 
marrow (McWilliam et al. 1998),  skin  (Chen et al. 1993), saliva and salivary gland 
tissue (Virtanen et al. 2006), gingival fluid (Brown et al. 1995; Kinnby 2002), as 
well as during pregnancy (Astedt et al. 1998), and SerpinB2 is able to inhibit cell 
surface bound tc-tPA in vitro (Lobov et al. 2008). Furthermore, enhanced 
expression of both tPA and SerpinB2 by epithelial cells is indicative of some 
disease states, e.g. periodontal disease (Kinnby 2002), psoriasis and 
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pre/eclampsia (Kruithof et al. 1995), strongly suggesting a role for SerpinB2 in the 
control of tPA activity at sites of localised inflammation and warrants further 
investigation. 
 
1.12. Inhibition of uPA or tPA 
SerpinB2 is an efficient inhibitor of soluble and receptor bound, activated (two-
chain) tc-uPA and soluble activated (two-chain) tc-tPA (Thorsen et al. 1988; 
Kruithof et al. 1995) (Table 1.3).  While SerpinB2 can inhibit the soluble pro-
enzyme (single-chain) sc-uPA, albeit less efficiently than tc-uPA, it cannot form 
stable covalent complexes with the former (Schwartz 1994). Since sc-uPA has 
some intrinsic plasminogen activation capacity, but is inefficiently inhibited by 
SerpinB2 (Table 1.3) (or SerpinE1), it has been suggested that this may allow 
initiation of cell surface proteolysis in PAI rich environments (Schwartz 1994). 
Once sufficient tc-uPA activity is formed, SerpinB2 can then efficiently inhibit 
further plasmin formation. It is important to note here that since most of the uPA in 
plasma/fluids appears to be in the sc-uPA form (Wojta et al. 1989), only cell surface 
associated activity is thus of relevance when considering the inhibitory effects of 
PAIs on uPA. This is supported by the findings of Siefert et al. (2014) that the 
absence of SerpinB2, not SerpinE1 coincided with an increase in uPA activity and 
faster venous thrombus resolution using a deep vein thrombosis model within wild-




Table 1.3: Inhibition kinetics of SerpinB2 for uPA and tPA (adapted from 
(Lee et al. 2011)). 
Plasminogen 
Activator 
Solution phase Receptor bound 
sc-tPA (4.6±0.6) x 103 M-1s-1 ⃰ 
(Thorsen et al. 1988) 
- 
tc-tPA (2.0± 0.02) x 105 M-1s-1 
(Thorsen et al. 1988) 
- 
 - 2.5 pM †‡ (Leung et al. 1987) 
sc-uPA ND ND 
tc-uPA (2.1± 0.2) x 106 M-1s-1 
(Thorsen et al. 1988) 
- 
 5.3 x 105 M-1s-1 (Ellis et al. 
1990) 
3.3 x 105 M-1s-1 ¥ (Ellis et al. 
1990) 
 ~ 20 pM ‡ (Leung et al. 
1987) 
60 - 80 pM ‡∞ (Al-Ejeh et al. 
2004) 
   
⃰  2nd order rate constant 
† Bound to poly-D-lysine 
‡ Inactivation constant Ki 
¥ Bound to human monocytoid cell lines 
∞ Bound to human carcinoma cell lines 
ND – not determined 
 
 
SerpinB2 is also a poor inhibitor of free circulating (single chain) sc-tPA (in contrast 
to SerpinE1) (Thorsen et al. 1988; Kruithof et al. 1995) (Table 1.3). The ability of 
SerpinB2 to inhibit bound tc-tPA appears to depend on the type of tPA binding 
interaction. For example, fibrin-bound tPA is protected from inhibition by SerpinB2 
(Leung et al. 1987) (although SerpinB2 crosslinked to fibrin can inhibit tPA (Ritchie 
et al. 2001)), while poly-D-lysine-bound-tPA is not protected (Leung et al. 1987) 
(Table 1.3). SerpinB2 has also been shown to inhibit tc-tPA bound to various cell 
types in vitro and to purified AIIt (Lobov et al. 2008). Where studied, SerpinB2 has 




1.13. Intracellular SerpinB2  
A new focus into SerpinB2 research was invoked when it became apparent that 
unlike SerpinE1, the highest expression levels of SerpinB2 are found intracellularly 
within monocytes and macrophages in vitro (Kruithof et al. 1986; Genton et al. 
1987). The potential roles described for intracellular SerpinB2 have typically not 
been associated with a classical inhibitory serpin function but rather with a variety 
of potential functions ranging from signal transduction (Antalis et al. 1998) to 
inhibition of apoptosis in some cell models (Dickinson et al. 1995) but not others 
(Fish and Kruithof 2006). Whilst a definitive function for intracellular SerpinB2 has 
not been forthcoming, it has become clear that SerpinB2 is an immune modulator 
(Schroder et al. 2010; Zhao et al. 2013; Shea-Donohue et al. 2014). This role is 
supported by the subsequent reports showing up-regulation of SerpinB2 in 
response to a barrage of inflammatory stimuli within these and other cell types 
(Table. 1.2).  
 
1.14. Inflammation and Pathogenesis 
The role of SerpinB2 in response to inflammatory mediators is well studied and a 
strong association between IL-1β suppression and SerpinB2 has been formed 
using in vivo mouse and in vitro cell models (Bystrom et al. 2004; Park et al. 2005; 
Greten et al. 2007; Sekine et al. 2009). The initial hypothesis for how SerpinB2 
controlled IL-1β activation, rotated around the inhibition of caspase-1 (interleukin-
1β-converting enzyme [ICE]) by SerpinB2 (Jensen et al. 1999).  Whilst this has 
never been proven, it is now known that SerpinB2 gene expression is regulated by 
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transcription factor NF-κβ under inflammatory conditions and the up-stream 
mediators of NF-κβ (i.e. IKKβ) are thought to be responsible for the control of IL-
1β secretion (Greten et al. 2007). This is supported by a study in which Schroder 
et al. (2010) were unable to detect any difference in IL-1β secretion when 
comparing resting peritoneal macrophages isolated from the SerpinB2-/- mouse 
model (Dougherty et al. 1999), to littermates (SerpinB2+/+). Importantly, this study 
reinforced the link between SerpinB2 expression and adaptive immunity, with the 
finding that SerpinB2 appears to function in the suppression of TH1-promoting 
cytokine production (Schroder et al. 2010). The mechanisms associated with this 
are currently unclear. Of interest however, is the recent finding that SerpinB2 
depletion in macrophages induces caspase-1 activation and IL-1β production in 
response to TLR agonists and Escherichia coli (Chuang et al. 2013). Furthermore, 
interactions between SerpinB2 and Beclin 1 lead to an increase in autophagy, 
which coincided with decreased IL-1β maturation. Thus providing possible insight 
into the functional mechanisms of SerpinB2 as an immune modulator and 
inflammatory mediator. 
 
The link between SerpinB2 with immune function is not new and up-regulation of 
SerpinB2 by monocytes and macrophages in response to a variety of pathogens 
such as Dengue Virus (Krishnamurti and Alving 1989; Krishnamurti et al. 1989), 
Legionella pneumophilia (Losick and Isberg 2006), Borrelia burgdorferi (Haile et 
al. 2006) and Mycobacterium avium infection (Gan et al. 1995) has been reported. 
Also, elevated SerpinB2 mRNA in eosinophilic leukocytes has been linked to 
 32 
protection from parasitic organisms, inflammation and asthma (Swartz et al. 2004). 
In asthma patients, SerpinB2 levels are suppressed by anti-inflammatory steroids 
such as glucocorticoids (Table. 1.3). More recently, elevated SerpinB2 expression 
has been observed in monocytes co-cultured with Aspergillus fumigatus, a fungi 
infecting immuno-compromised patients (Loeffler et al. 2009). Whilst the 
expression profiles for SerpinB2 in response to inflammation and pathogenesis are 
consistent, the function of SerpinB2 has not been defined, although the hypothesis 
that SerpinB2 protects against apoptosis within these environments appears to be 
supported in some cell models, but not others. 
 
1.14.1. Apoptosis 
The hypothesis that intracellular SerpinB2 may play a role in protection against 
apoptosis arose due to the chromosomal co-localisation of a potent inhibitor of 
apoptosis bcl-2 (B-cell lymphoma) and SerpinB2 genes, along with their co-
expression during cellular stress (Silverman et al. 1991).  Early work conducted 
using the HT1080 fibro sarcoma cell line transfected with SerpinB2 reported 
delayed apoptotic responses within these cells following TNF-α challenge, when 
compared to controls (Kumar and Baglioni 1991; Dickinson et al. 1995). 
Furthermore, SerpinB2 was found to protect primary cultures of human 
macrophages from apoptosis following in vitro infection with Mycobacterium avium 
and treatment with indomethacin (Gan et al. 1995). Therefore the hypothesis that 
SerpinB2 may inhibit an undefined intracellular protease was formed.  This was 
supported by the identification a cleaved 33 kDa intracellular SerpinB2 species in 
 33 
NB4 leukaemia cells following induction of apoptosis with okadaic acid, calyculin A 
and the protein synthesis inhibitor cycloheximide (Jensen et al. 1994). It was 
suggested SerpinB2 may undergo intracellular processing during apoptosis 
resulting in a cleaved yet active inhibitor, given the detection of cleaved SerpinB2 
in complex with uPA. Indeed, Jensen et al. (1999) found that SerpinB2 cleavage 
occurred within the first two hs of okadaic acid or camptothecin induced apoptosis 
in the HL-60 pro-myeloid cell line and that this occurrence was negated by the 
inhibition of caspase-1 using the peptide inhibitor YVAD-cmk.  However, an in vitro 
assay revealed that SerpinB2 was not a substrate for caspase-1 or caspase-3. The 
functional mechanisms, significance and protease/s involved in the production of 
the 33 kDa species of SerpinB2 during early apoptosis are still unknown.  
 
Interestingly, transfection of HeLa cells with the SerpinB2-∆C-D interhelical loop 
mutant did not replicate the protective effect of wild-type SerpinB2 against TNF-
α/cycloheximide induced apoptosis, indicating a functional role for the unique C-D 
loop (Dickinson et al. 1998). The identification of Gln residues at positions 83,84 
and 86 as substrate sites for transglutaminase within the C-D interhelical loop 
(Jensen et al. 1994) and subsequent characterisation of SerpinB2 in complex with 
members of the transmembrane annexin family (annexins I, II, IV and V) (Jensen 
et al. 1996) suggests a role for stabilisation of the apoptotic envelope during early 
apoptosis. This is supported by the observation of SerpinB2 incorporation into the 
cornified envelope of differentiated keratinocytes (Jensen et al. 1995), possibly 
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through transglutaminase cross-linking. It is thought that SerpinB2 may help to 
maintain membrane structure and integrity within keratinocytes.  
 
The epidermis is a high SerpinB2 expressing environment, under normal 
physiological conditions (Hibino et al. 1988). Therefore the role of SerpinB2 in 
keratinocyte biology presents another area of interest to researchers. A link 
between reduced proliferation and SerpinB2 expression in keratinocytes was 
reported by Hibino et al. (1999). Shortly after, Zhou et al. (2001) found that basal 
keratinocytes over expressing SerpinB2 in a transgenic mouse model, were highly 
susceptible to chemically induced cutaneous papilloma formation. Repeated 
application of 12-O-tetradecanoylphorbol-13-acetate (TPA) to the skin of the mice 
resulted in lesion formation on 97% of the transgenic mice versus 65% in the 
control group. Furthermore, the papilloma lesions observed on the skin of control 
mice were found to regress as a result of apoptosis once treatment was withdrawn, 
whilst those of the transgenic mice persisted. The authors reported very low 
detection of apoptotic cells within the papillomas of the transgenic mice compared 
to controls. It is important to note that the control mice were SerpinB2 positive and 
therefore representative of a normal expression profile, which was below 
detectable levels. However, taken together the persistence of the papilloma lesions 
on the skin of the transgenic mice contributes to the idea that in this context at 
least, SerpinB2 protects against commitment to cell death. Indeed, this is in line 
with the recent characterisation of Annexin I and SerpinB2 high molecular weight 
complexes extracted from cell lysates of human macrophages undergoing 
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apoptosis following in vitro infection with Mycobacterium avium (Gan et al. 2008) 
and corroborates the earlier works of Jensen et al. (1994) and Jensen et al. (1996). 
 
However, despite the accumulated support for SerpinB2 as an anti-apoptotic agent 
the specific function and mechanisms associated with this proposed role have not 
been identified or fully characterised.  Recently Fish and Kruithof et al. (2006) 
conducted a thorough investigation of SerpinB2 in the prevention of TNF-α induced 
apoptosis using HeLa, Isreco-1 and HT1080 cell lines. The study compared the 
effect of wild-type SerpinB2, SerpinB2-∆-C-D interhelical loop and reactive centre 
(R380A) mutants; SerpinB2 null, SerpinB2 expressing and SerpinB2 over-
expressing cell models in addition to the application of exogenous SerpinB2 to 
cultures. Despite this, however, they were unable to replicate any of the earlier 
work showing a protective role for SerpinB2 in apoptosis. Unlike earlier works, 
these investigators used a lenti-viral transfection system which may explain the 
contrast in results between their findings and others works. Furthermore, 
overexpression of SerpinB2 in pulmonary arterial smooth muscle cells was 
recently shown to enhance apoptosis whilst suppressing proliferation and 
migration (Zhang et al. 2015). Knockdown of SerpinB2 was then shown to 
suppress apoptosis and enhance proliferation and cell migration, suggesting 








1.14.2. Other intracellular binding partners of SerpinB2 
Irrespective of the conflicting results supporting a role for SerpinB2 in apoptosis, a 
protease binding partner for intracellular SerpinB2 remains to be identified.  The 
distribution of SerpinB2 within the nucleus, cytoplasm and the extracellular 
environment suggests alternate functions, independent of its role as a serpin, 
which may be dependent on the previously described binding sites within the C-D 
interhelical loop.   
 
The C-D interhelical loop contains three transglutaminase sites previously 
mentioned, a cysteine at position 79 (C79) which is functional in the polymerisation 
of SerpinB2 (Mikus and Ny 1996; Wilczynska et al. 2003; Lobov et al. 2004) 
(discussed in section 1.7), and a PENF motif:  in addition, asparagine at position 
75 (N75) is glycosylated in extracellular SerpinB2. It is not surprising therefore that 
non-serpin related interactions, most of which are dependent on the C-D 
interhelical loop of SerpinB2 have been reported and include; Interferon regulatory 
factor-3 (Zhang et al. 2003), PSMB1 (Fan et al. 2004; Schroder et al. 2010; O'Hara 
et al. 2013), Annexin I, II, IV and V (Jensen et al. 1996; Gan et al. 2008) and 
retinoblastoma protein (Rb) (Darnell et al. 2003).   
 
The tumour suppressor, Rb protein, was identified as a binding partner for 
SerpinB2, by Darnell et al. (2003). Stable transfection of the HeLa cervical 
carcinoma cell line with SerpinB2 resulted in an increase in Rb protein levels 
compared to control cells. This was supported by the detection of increased Rb 
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expression and stability in the Jurkat cell line when transfected with SerpinB2. 
Furthermore, co-localisation of SerpinB2 with Rb in the nucleus of HeLa and other 
cell lines, was observed. 
 
HeLa cells are positive for human papilloma virus (HPV) – 18 oncoproteins, of 
which, E6 and E7 fusion proteins are responsible for the degradation of Rb 
(Scheffner et al. 1992; Boyer et al. 1996). Interestingly the authors reported a 
decrease in mRNA for E6/E7 within the SerpinB2 positive HeLa cells. Taken 
together it was hypothesised that SerpinB2 was acting to inhibit degradation of Rb 
protein by an undefined cellular protease, recently hypothesised to be calpain 
(Tonnetti et al. 2008), and in the case of HPV-18 positive cells, through the 
suppression of E6/E7 mRNA expression. Further investigation by Darnell et al. 
suggested that SerpinB2 suppresses HPV oncogenes by stabilisation of Rb, which 
subsequently silences the HPV-18 up-stream regulatory region (URR) responsible 
for E6 and E7 transcription (Darnell et al. 2005).  
 
Whilst this represented the first solid indication of a role for intracellular SerpinB2, 
Fish et al. (2006) were unable to detect any difference in Rb expression when 
comparing IS-1 and HT1080 cell lines transfected with wild-type SerpinB2 or 
inactive SerpinB2 (R380A), relative to controls and between transfected cells. 
They did however; report a slight elevation of Rb protein within transduced HeLa 
cells compared to control cells, although there was no difference in Rb detection 
between wild-type SerpinB2 or inactive SerpinB2. In a recent study, no correlation 
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between SerpinB2 expression and prognostic outcomes could be found following 
assessment of 225 cervical biopsy specimens. SerpinB2 expression did however 
increase with lesion grade (Syrjanen et al. 2009).  
 
1.14.3. Neurology 
Very little is known about the role of SerpinB2 within neurobiology, however 
astrocytes (Dietzmann et al. 2000) and neurons (Yamanaka et al. 2005) have been 
reported to synthesise this protein.  Furthermore, an early study conducted by 
Akiyama et al. (1993) reported high SerpinB2 deposition within microglia, which 
surrounded the senile plaques associated with Alzheimer’s Disease (AD) and 
much lower antigen detection in control tissue. The authors surmised that 
SerpinB2 was inhibiting proteolysis within the localised extracellular environment 
and therefore contributing to the prevalence of the disease. Importantly, AD lesions 
represent high inflammatory environments (McGeer and McGeer 2002) and 
microglial cells are the macrophage equivalent within the central nervous system. 
Therefore, up-regulation of SerpinB2 by microglia in AD is most likely due to the 
inflammatory environment of AD lesions, which is in-line with the many cell models 
showing increases of SerpinB2 mRNA and/or antigen in response to pro-
inflammatory cytokines (Table. 1.2). Recently, SerpinB2 was identified as a binding 
partner for the cell adhesion molecule CHL1 which promotes CHL1-induced 
neurite outgrowth and neuronal migration in mice (Katic et al. 2014).  Whilst, Zhang 
et al. (2009) have identified SerpinB2 as one of nine key neuronal protective 
proteins expressed in response to brain trauma, that are required for survival of 
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cultured hippocampal neurons suggesting that SerpinB2 may be important in 
controlling haemostasis within the central nervous system also.  SerpinB2 is highly 
expressed within micro-environments undergoing acute and chronic homeostatic 
imbalances which suggest a broader function as an inflammation modulator, not 
limited to immune response pathways.  Most of the early in vivo studies utilised 
immunohistochemisty to assess expression of SerpinB2 in-conjunction with other 
aspects of the PA system and while this confirmed the presence of SerpinB2 within 
the tissue examined, it has not contributed to the development of functional role/s. 
Furthermore, it is difficult to accurately discern the location of SerpinB2 antigen as 
either intracellular or extracellular within the earlier immunohistochemistry works. 
Therefore, this line of investigation is warranted given the earlier reports of 
SerpinB2 deposition within amyloid plaques of Alzheimer’s patients and more 
recent associations with Amyloid Lateral Sclerosis (ALS) animal model and 
oxidative stress induced expression of SerpinB2 (Boutahar et al. 2011).   
  
1.15. Rationale and Specific Aims of the Thesis 
This thesis aims to examine; 1) the role of SerpinB2 within the extracellular 
environment as a plasminogen activator inhibitor in monocytes and 2) the role of 
SerpinB2 within the intracellular environment as a stress response protein.  
 
There have been many studies conducted which have defined and supported the 
role of SerpinB2 as a classical inhibitory serpin, at a biochemical level. More recent 
studies have clearly shown that SerpinB2 facilitates the rapid endocytosis of 
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uPA:uPAR complexes from the cell surface of PC-3 (Croucher et al. 2006) and 
MCF-7 (Croucher et al. 2007; Cochran et al. 2011) cell lines, via members of the 
Low Density Lipoprotein Receptor (LDLR) family. However, these findings 
contradict those described using  the THP-1 monocytic cell line by Ragno et al. 
(1995).  This inconsistency within the published literature led us to examine, using 
similar techniques to those described for the above mentioned breast and prostate 
cells, the role SerpinB2 may or may not play in uPA clearance from the surface of 
monocytic cell lines. Furthermore, the role of either SerpinE1 or SerpinB2 in the 
inhibition and endocytosis of tPA at the cell surface is unclear. Given that the main 
producers of SerpinB2 are monocytes and macrophages the control of plasmin 
generation via uPA or tPA, by SerpinB2 at the cell surface warrants further 
investigation.  
 
Therefore, the aims of chapter 2 were to investigate the inhibition of cell surface 
uPA by SerpinB2 and characterise the endocytosis pathways facilitating clearance 
of uPA:SerpinB2 complexes, once formed at the surface of monocytic cell lines. 
Confirmation of similar endocytosis pathways to those described by Croucher et 
al. (2006) and Croucher et al. (2007), will aid in establishing a robust model for 
SerpinB2 and contribute towards establishing its role as a physiological inhibitor of 
uPA. An additional aim addressed in chapter 2 was to assess the potential for use 




The specific aims of chapter 3 were to examine inhibition of tPA by SerpinB2 and 
characterise the role of LRP and VLDLR as potential endocytosis receptors for tPA 
and tPA:PAI complexes on these cells. Cell profiling of the U-937 and THP-1 cell 
line in addition to PBMs was undertaken to ascertain the basal PA levels present 
on the surface of malignant versus healthy myeloid cells with the aim of assessing 
the potential impact SerpinB2 directed therapeutics may have through non-uPA 
facilitated endocytosis pathways.  
 
Up-regulation of intracellular SerpinB2 in response to acute and chronic 
homeostatic imbalances suggests a potential function within cellular stress 
response pathways. This hypothesis is supported by the lack of an intracellular 
protease target for SerpinB2, suggesting a non-inhibitory role. Of interest is the 
finding that some non-inhibitory serpins appear to function as transport 
chaperones/molecules, cytoskeleton support molecules or heat shock proteins, all 
with very specific targets or niches (Hammond et al. 1987; Pemberton et al. 1988; 
Tasab et al. 2000; Sauk et al. 2005; Finno et al. 2015). In this context, SerpinB2 
presents as a co/chaperone or shuttle protein given the promiscuity of described 
binding interactions with many partners and no known associated function, despite 
40 years of research. Importantly, promiscuity is a common characteristic 
associated with molecular chaperones (Hartl et al. 2011). Therefore the specific 
aims of chapter 4 were to assess the possible chaperone-like activity of SerpinB2, 
using an array of amorphous and fibril forming substrate models.  
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The specific aims of chapter 5 were to gauge a better understanding of the cellular 
pathways in which SerpinB2 may function as a stress response protein. The 
intracellular processing of aberrant protein trafficking was assessed using wild-




2. Investigation of SerpinB2 as a potential therapy 





The high prevalence of drug resistance in Acute Myeloid Leukaemia (AML) has 
led to the development of toxin-fusion-proteins for the treatment of this disease.  
Here we report the preliminary investigation of SerpinB2 as a potential toxin 
delivery and internalisation mechanism in the treatment of AML.  The U-937 and 
THP-1 cell lines were found to endocytose SerpinB2 via the urokinase 
plasminogen activation system (uPA) and low density lipoprotein receptor (LDLR) 
family pathways.  This work indicates the potential for use of SerpinB2 based 
therapeutics in the treatment of AML. 
 
2.2. Introduction 
Acute myeloid leukaemia (AML) originates from the myeloid stem cells within the 
bone marrow and has traditionally been sub-typed based on morphology with 
respect to their stage of myeloid differentiation (Meshinchi and Arceci 2007).   
Despite the advances in therapy development for the treatment of AML, this 
disease accounts for more than half of the leukaemia related deaths in paediatric 
patients (Meshinchi and Arceci 2007).  This appears to be linked to the high 
occurrence of multiple drug resistance (MDR) within this patient cohort (Meshinchi 
and Arceci 2007).  Due to the problematic treatment of AML patients with MDR, 
research focus is growing in the development of targeted toxin-fusion protein 
therapies.   
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Of particular interest as a potential cell surface targeted antigen in AML patients is 
the urokinase plasminogen activation (uPA) system, which is associated with 
pericellular proteolysis via the conversion of plasminogen to plasmin (Ellis et al. 
1990).   Elevated expression of the uPA system by leukaemic cells has been widely 
documented and is thought to contribute to excessive bleeding and poor prognosis 
of patients (Wada et al. 1993; Hildenbrand et al. 1999; Scherrer et al. 1999; Graf 
et al. 2005; Ohba et al. 2005).  Control of cell surface plasmin generation may be 
mediated through the inhibitory functions of the serpins plasminogen activator 
inhibitors (PAI) type 1 (SerpinE1) and 2 (SerpinB2) (Ellis et al. 1990).   Inhibition of 
receptor bound uPA at the cell surface facilitates the rapid endocytosis of the 
inhibited complex via the family of low density lipoprotein receptors (LDLR) 
(Croucher et al. 2006).  Pre-clinical evaluations conducted using human breast and 
prostate carcinoma xenograft murine models, have shown that systemic (i.p.) 
administration of 213Bi-SerpinB2 causes tumour growth inhibition in a dose-
dependent manner (Allen et al. 2003; Stutchbury et al. 2007).   Furthermore, the 
delivery pathway was found to be uPA dependant (Al-Ejeh et al. 2004; Croucher et 
al. 2006; Croucher et al. 2007). Whilst SerpinB2 shows promise as a delivery 
mechanism for anti-cancer therapy directed at solid tumours, it’s suitability for use 
in the treatment of haematological malignancies has not been investigated.   
 
2.2.1. Specific Aims 
The aims of this study were to investigate the inhibition of cell surface uPA by 
SerpinB2 and characterise the endocytosis pathways facilitating clearance of 
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uPA:SerpinB2 complexes once formed at the surface of monocytic cell lines. Using 
a fluorescence quenching internalisation assay and inhibitory antibodies (Al-Ejeh 
et al. 2004), we show that SerpinB2 is endocytosed by the histocytic lymphoma U-
937 cell line and the AML cell line THP-1, in a uPA and LDLR family dependent 
manner indicating that further development of SerpinB2 based therapies is 
warranted for the treatment of AML. 
 
 
2.3. Experimental Procedures 
 
2.3.1. Proteins, Antibodies and Reagents 
Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd 
(Sydney, Australia).  Purified human receptor associated protein (RAP) was from 
Molecular Innovations (MD, USA). Monoclonal murine anti-human uPA B-chain 
IgG1 (#394), monoclonal murine anti-human uPAR IgG2a (#3936) and monoclonal 
murine anti-human LRP -chain IgG1 (#3402) were from American Diagnostica 
Inc. (USA).  Polyclonal rabbit anti-human VLDLR IgG was from Santa Cruz 
Biotechnology, Inc.  Polyclonal goat anti-rabbit FITC conjugate IgG (whole 
molecule), goat anti-mouse IgG (Fab specific) FITC conjugate, propidium iodide 
(PI), Hanks balanced salt modified and non-modified and bovine serum albumin 
(BSA) were from Sigma-Aldrich.  Anti-DNP rabbit polyclonal isotype control was 
from DakoCytomation (Glostrup, Denmark). Alexa-488 labeling kit and Alexa-488 
quenching polyclonal antibody were from Molecular Probes (OR, USA).  RPMI-
1640 powder and foetal calf serum were from Trace Bioscientific (NSW, Australia).  
The rabbit anti-human LRP polyclonal and murine anti-human VLDLR monoclonal 
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antibodies 1H5, 5H3 and 1H10 were a kind gift from Professor Dudley Strickland, 
USA (Ruiz et al. 2005; Croucher et al. 2006). 
 
2.3.2. Cell Lines and Tissue Culture Conditions  
The monocyte like U-937 histocytic lymphoma and THP-1 human monocytic 
leukaemic cell lines were used for all experiments.  Cells were maintained in 
medium consisting of RPMI-1640, 5% (U-937) or 10% (THP-1) heat inactivated 
fetal calf serum and 2 mM glutamine at 37 C and 5% CO2 enriched humidified air.   
 
2.3.3. Immunofluorescence Assays  
Cell surface antigens were measured by dual colour immunofluorescence and flow 
cytometry as previously described (Al-Ejeh et al. 2004).  Internalisation assays 
were conducted using the fluorescence quenching internalisation assay as 
described previously (Al-Ejeh et al. 2004; Croucher et al. 2006).  Briefly, cells were 
incubated at 37 C for 1 h in the absence (control) of presence of 10 nM 
SerpinB2Alexa488 in Hanks buffer. The cells were next washed twice and incubated 
on ice for 30 min with 4 g.mL-1 Alexa488 quenching antibody (quenches any 
remaining cell surface fluorescence and is thus a measure of internalised ligand) 
in ice cold Hanks buffer. Finally, the cells were washed twice with ice cold PBS 
and analysed using flow cytometry as described above.   All assays were 




2.3.4. Plasmin Generation Assays  
Briefly, cells were harvested, washed twice and resuspended at 1x106 cells.mL-1 
in Tris-buffered saline (TBS) (50 mM Tris HCl, 150 mM NaCl, pH 7.4). Cells were 
pre-incubated in the absence or presence of 10 nM uPA on ice for 30 min, washed 
twice in TBS and then resuspended in 100 μL TBS in the presence of 10 μg 
plasminogen.  Following 15 min pre-incubation at room temperature, 100 uL of 
Spectrozyme PL substrate was added to a final concentration of 0.25 mM.  
Substrate conversion by plasmin was measured kinetically at 405 nm over a 2 h 
period at 37 C in a Molecular Devices SpectraMax 250 plate reader, and analysed 
using SoftMax® Pro software (Molecular Devices, USA).   Negative controls 
contained TBS buffer and either 0.25 mM Spectrozyme PL or whole cell 
suspension made to a final volume of 200 μL with TBS buffer.  Positive control 
consisted of 1 μg uPA, 10 μg plasminogen in 100 μL TBS and 100 μL 0.5 mM 
Spectrozyme Pl.  All assays were conducted in triplicate and appropriate 
background controls subtracted. 
 
2.3.5. Statistical analysis  
Students paired t-tests were performed using Graphpad Prism (USA) to determine 




To confirm basal cell surface expression levels of the uPA and uPAR by the U-937 
and THP-1 cell lines, immunofluorescence assays were undertaken using flow 
cytometry.  Both components were detected at the cell surface of both cell lines, 
but compared to the U-937 cell line, the THP-1 cell line showed 7 and 16.5 fold 
higher levels of uPAR and uPA antigens, respectively (Fig. 2.1).   
 
Previous studies have shown that the rapid endocytosis of uPA:SerpinB2 
complexes on human carcinoma cell lines are facilitated by interactions with LRP 
(Croucher et al. 2006) and VLDLR (Croucher et al. 2007). Therefore LRP and 
VLDLR were considered the most probable LDLR candidates for the endocytosis 
of uPA:SerpinB2 complexes on the U-937 and THP-1 cell lines. Indeed VLDLR 
and LRP were detectable on both cell lines (Fig. 2.1).  While low on both cell lines 
the expression level of LRP was 2-fold higher on the THP-1 cell line compared to 
the U-937 cell line (Fig. 2.1).  Both cell lines displayed distinctly measurable 
VLDLR, with the THP-1 cell line displaying a 6-fold increase in VLDLR expression 
compared to the U-937 cell line (Fig. 2.1). 
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GM: 13.4 ± 0.79  GM: 4.27 ± 1.27  GM: 4.13 ± 0.79  GM: 19.28 ± 3.30  A 
u-PAR u-PA LRP VLDLR 
GM: 92.93 ± 16.98 GM: 71.19 ± 0.96 GM: 9.14 ± 1.17 GM: 145 ± 18 B 
Figure 2.1: Histogram plots showing cell surface expression levels of u-PAR, u-PA, LRP and 
VLDLR, on the (A) U-937 and (B) THP-1 monocytic cell lines.  Cells were assayed using indirect 
immunofluorescence and flow cytometry.  Geometric means (GM) indicate fluorescence intensity 
values for specific antibodies (unfilled) with isotype-matched control antibody (filled) values 
subtracted, ± SD, (n=3).   
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To obtain a quantitative indication of the cell surface plasminogen activation 
potential of U-937 and THP-1 cell lines and to compare the SerpinB2 inhibitory 
capacity, whole cell plasmin generation assays were conducted.  Low levels of 
intrinsic plasmin generation by the U-937 (Fig. 2.2) cell line was detected which is 
indicative of low endogenous uPA, or indeed tPA levels (refer Fig.2.1). While still 
low, the THP-1 cell line had higher levels of endogenous plasmin generation than 
the U-937 cell line (Fig. 2.2), reflecting higher levels of uPA on these cells.  
Importantly this activity was found to be inhibited in the presence of SerpinB2 (Fig. 
2.2), confirming previous studies (Ellis et al. 1990).   Pre-treatment with 10 nM uPA 
significantly increased the plasminogen activating potential of both cell lines (Fig. 
2.2), indicating that a portion of the uPAR detected at the cell surface was 
unoccupied in both cell lines.  In both cases SerpinB2 significantly abrogated this 


















uPA:SerpinB2 complex clearance pathways were investigated. Inhibition in the 
presence of RAP, a commonly used antagonist of ligand binding specific to the 
LDLR family, significantly inhibited SerpinB2 internalisation seen in both the U-937 
and THP-1 cell lines (Fig. 2.3A).  The dependence of uPA was demonstrated using 
a monoclonal antibody specific for the catalytic domain of uPA that, at the 
concentration used, is known to block SerpinB2 complex formation with uPA at the 
cell surface of other cell lines (Al-Ejeh et al. 2004).  SerpinB2 internalisation was 
significantly reduced by the MAb in both the U-937 (20%) and THP-1 (80%) cell 
Figure 2.2: Inhibition of cellular plasminogen activation by SerpinB2.  U-937 
(unfilled bars) and THP-1 (filled bars) cells were pre-treated in the absence or 
presence of 10 nM u-PA and 10 nM SerpinB2 as indicated.  Then glu-plasminogen 
was added at a final concentration of 0.25 μM and the rate of plasmin formation in 
the absence or presence of 10 nM SerpinB2 where indicated was analysed using 
Spectrozyme PL substrate (ADI).  Assays were conducted over 2 hs at 37C.  Data 
represents mean ± SEM, (n=3), background (cells only) subtracted. Statistical 
analysis by 2-way ANOVA (solid lines) or t-test (dotted line) * = p<0.05, *** = 
p<0.001, ns = not significantly different.  
ns 
ns 
*** *** *** 


































u-PA  -   - + + - - +  + 
SerpinB2  -   + - + - +  -  + 
Treatment 
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lines (Fig. 2.3B).  Again, this effect was more pronounced in the THP-1 cell line 
which expresses significantly greater levels of endogenous uPA and uPAR 
compared to the U-937 cell line. Taken together these results confirmed the role 
of receptor bound uPA and LDLRs in the endocytosis of uPA:SerpinB2 by 
monocytic cell types and that the effect was dependent on endogenous uPA 
expression.  
 
The involvement of VLDLR and LRP in the endocytosis of SerpinB2 was 
investigated further using inhibitory antibodies.  Anti-VLDLR monoclonal 
antibodies 1H5 and 1H10 were reported to be effective inhibitors of binding 
interactions with VLDLR and apolipoprotein E (apoE) (Ruiz et al. 2005) and 
uPA:SerpinB2 complexes in the MCF-7 cell line (Croucher et al. 2007). Therefore 
an antibody cocktail comprising of 1H5, 1H10 and 5F3 was used to inhibit 
uPA:SerpinB2 complex interactions with VLDLR.   Although 5F3 alone was not 
found to efficiently inhibit apoE:VLDLR interactions this monoclonal epitope is 
specific for the ligand binding repeats within VLDLR (Ruiz et al. 2005) suggesting 
it may efficiently inhibit the uPA:SerpinB2 complex interactions.  As expected, the 
application of the antibody cocktail inhibited a proportion of SerpinB2 
internalisation showing some VLDLR dependence in the endocytosis of SerpinB2 
by the U-937 and THP-1 cell lines (Fig. 2.3C).   Higher concentrations of the 
antibody cocktail gave similar results.  Consistent with this, the rabbit anti-LRP 
polyclonal antibody previously found to inhibit uPA:SerpinB2 complexes (Croucher 

















Figure 2.3: Internalisation of SerpinB2:Alexa488 by U-937 (unfilled) and THP-1 
(filled) cell lines. (A) Representative data shows SerpinB2 internalisation signal 
pattern.  Assays were conducted in the absence (control) or presence of 200 nM 
RAP and either (B) 20 μg.mL-1 anti-uPA monoclonal antibody or 20 μg.mL-1 
matched isotype control (MIC) where indicated, or (C) 15 μg.mL-1 anti-VLDLR 
monoclonal antibodies (5H1, 5F3, and 1H10, 5 μg.mL-1 each) or 15 μg.mL-1 MIC 
where indicated or (D) 50 μg.mL-1 anti-LRP polyclonal antibody or 50 μg.mL-1 MIC.  
Cells were cultured for 1 h at 37 C in the presence of 10 nM SerpinB2:Alexa488, 
surface bound SerpinB2:Alexa488 was quenched by incubating cells with 4 μg.mL-
1 anti-Alexa488 monoclonal antibody for 30 min prior to analysis by flow cytometry. 
All values shown are means ± SEM (n=3). For panels B-D values are normalised 
to the control (representing no inhibitory antibody and therefore total internalised 
SerpinB2) for each cell line. Statistical analysis by 2-way ANOVA (solid lines) or t-

























































































































































































































but not in the THP-1 cell line (Fig. 2.3D).  The difference in antibody blocking 
efficiency between the cell lines may be a result of substantially more VLDLR and 
LRP on the THP-1 cell line (refer Fig. 2.1.B) and therefore less efficient inhibition.   
 
2.5. Discussion 
In this study, we confirmed the presence of uPA, uPAR and LDLR family members 
at the surface of U-937 and THP-1 monocytic cell lines.  The basal levels of uPAR 
and uPA detected at the cell surface were higher on the THP-1 cell line compared 
to the U-937 cell line.  This is likely due to their differences in maturation along the 
myeloid differentiation lineage. However, it is important to note that the THP-1 cell 
line is a naturally occurring SerpinB2 null model, in that the SerpinB2 mRNA is 
truncated and the translation product inactive (Gross and Sitrin 1990; Katsikis et 
al. 2000).   Therefore the lack of endogenous SerpinB2 in the THP-1 cell line may 
also contribute to the higher uPA levels detected, compared to the U-937 cell line. 
Importantly, the differences in detectable uPA and uPAR expression levels 
observed between these cell lines was supported by the clear difference in 
plasminogen activation potential, therefore presenting two distinctive cell models 
for the examination of uPA facilitated SerpinB2 internalisation. The data presented 
here is consistent with previous studies on carcinoma cell lines (Croucher et al. 
2006; Croucher et al. 2007), using similar techniques and reagents. However, this 
contradicts the work of Ragno et al (1995), who reported that the majority of 
preformed uPA:SerpinB2 complexes added to THP-1 cells were cleaved and 
released into the supernatant as a 70 KDa species rather than being internalised. 
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Conditioned supernatants were not examined within our study, therefore the 
presence of a 70 KDa species representing cleaved uPA complexed with SerpinB2 
cannot be ruled out, however distinct differences in methodology may explain the 
conflicting results. Specifically, Ragno et al (1995) used widely accepted acid 
stripping techniques to remove uPAR bound uPA from the cell surface, prior to 
incubation with pre-formed uPA:SerpinB2 or uPA:SerpinE1 complexes. The 
method described here (and as per (Croucher et al. 2006)) did not require harsh 
pre-treatment of the cell line, which could compromise the balance of membrane 
associated proteases, thus leading to premature degradation of the uPA:SerpinB2 
complex.  Furthermore, we pre-loaded uPAR with uPA, prior to addition of 
SerpinB2 which is therefore indicative of mechanisms associated with cell surface 
inhibition of uPA, which may alter endocytosis dynamics, specific to the THP-1 cell 
line, or indeed myeloid cells. Regardless, our results clearly show the involvement 
of VLDLR and LRP in the endocytosis of SerpinB2 via a uPA dependant 
mechanism by both the U937 and THP-1 cell lines.  
 
Thorough investigation of expression for both antigens by malignant haemopoietic 
cell types has revealed a correlation between differentiation and uPAR expression.  
AML - M0 subtype displays low levels of uPAR expression compared to M5 
subtype, whilst all AML subtypes have been found to express uPA (Lanza et al. 
1998; Scherrer et al. 1999).   Importantly, uPA is the predominant plasminogen 
activator in leukemic marrow, a characteristic not found in healthy marrow 
(McWilliam et al. 1998; Scherrer et al. 1999), therefore SerpinB2 targeted 
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therapeutics may prove successful in eradicating MDR leukaemic blasts and stem 
cells within the marrow of patients.  As SerpinB2 interaction with uPA at the cell 
surface facilitates the rapid endocytosis of the uPA:SerpinB2 complexes (Croucher 
et al. 2006) this allows for fast uptake of therapeutics. The use of 213Bi-SerpinB2 
directed at solid tumours in preclinical trials has shown that SerpinB2 can target 
uPA and deliver attached cytotoxins (Stutchbury et al. 2007), it is therefore 
hypothesised that SerpinB2 directed therapies may be as effective for the 
treatment of haematological malignancies expressing uPA if not more so due to 
the enhanced cell surface accessibility of single cell malignancies.   
 
Furthermore, as the endocytosis of uPA:SerpinB2 complexes is in part VLDLR and 
LRP dependent in the U-937 and THP-1 cell lines, utilisation of this specific 
endocytosis process in the design of fusion toxins will allow increased specificity 
for SerpinB2 directed therapeutics, giving potential for tailoring to the individual. 
This is of particular importance given the potential for alternative endocytosis 
pathways for internalisation of SerpinB2, as indicated by this work. Whereby, 
complete inhibition of SerpinB2 internalisation using either RAP or LDLR inhibitory 
antibodies was not possible. Investigation of the role scavenger receptors may play 
is therefore required to further the development of SerpinB2 directed therapeutics. 
 
Current treatment regimes for AML comprise of intensive combination induction 
therapies and in some cases stem cell transplantations, despite this at least half 
of paediatric patients who reach complete remission will relapse with poor 
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prognostic outcomes  (Meshinchi and Arceci 2007).  For patients exhibiting high 
uPA expression, SerpinB2:toxins may prove successful in targeting residual 
leukaemic cells post-induction therapy, therefore reducing the cases of disease 
relapse.  
 
The preliminary work presented here contributed towards the proof of concept data 
for the use of SerpinB2:cytotoxin targeting of the U-937 and THP-1 cell line. 
Importantly, further work within our research group has since shown successful 
uPA specific targeting of these cell lines (Vine et al. 2012).  
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3. Differential Endocytosis of Tissue Plasminogen 
Activator by Serpin E1 and SerpinB2 on Human 




















Generation of the broad spectrum protease plasmin is facilitated by the tissue (tPA) 
and urokinase (uPA) plasminogen activators, within multiple physiological and 
disease states. Finely tuned control of this proteolytic cascade is exerted by the 
plasminogen activator inhibitors type-1 (PAI-1/SerpinE1) and 2 (PAI-2/SerpinB2). 
Expression of this network of activators and inhibitors by cells of myeloid lineage 
appears to be highly interchangeable between physiological environments, and 
whilst the role of SerpinE1 and SerpinB2 in regulating uPA-dependent functions is 
well established, the interaction between tPA and SerpinB2 on myeloid cell types 
is poorly characterised. To this end, we used freshly isolated peripheral blood 
monocytes (PBM) as a model of a tPA-dependent cellular environment. We 
demonstrate that while both SerpinE1 and SerpinB2 could inhibit surface-bound 
tPA and are internalised predominately via low density lipoprotein receptor family 
members, SerpinE1 enhanced the endocytosis of tPA, whereas SerpinB2 did not. 
Surface plasmon resonance analyses revealed differential binding affinities 
between the very low density lipoprotein receptor (VLDLR) and tPA and 
tPA:SerpinE1 complexes in addition to those previously described with low density 
lipoprotein receptor-related protein (LRP). Moreover, tPA:SerpinB2 bound to both 
endocytosis receptors with similar kinetics to tPA. These differential biochemical 
interactions between tPA and the tPA:PAI complexes may underlie the observed 
differences in endocytosis mechanisms on the PBMs. This suggests that while 
SerpinE1 and SerpinB2 function similarly in the control of cellular plasmin 
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generation by tPA, they may have disparate effects on the alternative functions of 
tPA via modulation of its engagement with endocytosis receptors.  
 
3.2. Introduction 
The tissue plasminogen activator (tPA) converts plasminogen to plasmin, which is 
involved in fibrinolysis, tissue remodelling and cell migration (Kruithof et al. 1995). 
tPA is secreted as a single chain (sc-tPA), 72 kDa glycosylated protein, by 
peripheral blood monocytes (Hart et al. 1989) and endothelial cells (Hajjar 1993). 
Cleavage of sc-tPA produces the 62.9 kDa two chain (tc-tPA) conformation (Rijken 
and Collen 1981). Both sc-tPA and tc-tPA display enzymatic activity towards 
plasminogen, which is enhanced when they are bound to fibrin (Hoylaerts et al. 
1982). In addition to fibrin interactions, both forms of tPA also bind and efficiently 
activate plasminogen at the cell surface of monocyte (Felez et al. 1991; Felez et 
al. 1996), macrophage (Noorman et al. 1995), endothelial (Ljungner et al. 1983) 
and human tumour (Lobov et al. 2008) cell lines. 
  
Control of plasmin generation by either form in vivo is thought to be mediated 
predominantly through the inhibitory functions of the plasminogen activator 
inhibitor type 1 (PAI-1/SerpinE1) and potentially to a lesser extent by plasminogen 
activator inhibitor type 2 (PAI-2/SerpinB2) (Jorgensen et al. 1987). Both SerpinE1 
and SerpinB2 efficiently inhibit tc-tPA in solution phase with second order rate 
constants of ~107 and 105 M-1.s-1 , respectively, and both are inefficient inhibitors 
of fibrin bound tPA (Thorsen et al. 1988; Ritchie et al. 1999). Therefore tPA:PAI 
complexes are typically formed after tPA dissociates from the fibrin clot.  However, 
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SerpinE1 is considered the primary inhibitor of tPA as it is able to form serpin-
protease complexes with both sc-tPA and tc-tPA and is found in normal human 
plasma at concentrations ranging from 140 pM to 1.9 nM (Estelles et al. 1989). 
SerpinB2 is only detected within plasma during late stage pregnancy but, with 
concentrations ranging between 100-250 ng/mL (Kruithof et al. 1987; Hunt et al. 
2009). A role in maintaining placental integrity has been described for SerpinB2, 
as a regulator of fibrinolysis in normal pregnancy (Astedt et al. 1998), however, 
little is understood about the potential of SerpinB2 as a physiological inhibitor of 
tPA due to limited reports of tPA:SerpinB2 complexes identified in vivo (Kruithof et 
al. 1995). Yet, co-expression of tPA and SerpinB2 has been shown in normal bone 
marrow (McWilliam et al. 1998),  skin  (Chen et al. 1993), saliva and salivary gland 
tissue (Virtanen et al. 2006), gingival fluid (Brown et al. 1995; Kinnby 2002), as 
well during pregnancy (Astedt et al. 1998), and SerpinB2 is able to inhibit cell 
surface bound tc-tPA in vitro (Lobov et al. 2008). Furthermore, enhanced 
expression of both tPA and SerpinB2 by epithelial cells is indicative of some 
disease states, e.g. periodontal disease (Kinnby 2002), psoriasis and 
pre/eclampsia (Kruithof et al. 1995), strongly suggesting that SerpinB2 may control 
tPA activity at sites of localised inflammation.  
  
Whilst SerpinB2 expression can be up-regulated by a variety of cell types under 
stress conditions, the predominant physiological producers of SerpinB2 are 
monocytes and macrophages (Kruithof et al. 1995). Monocytes also express and 
secrete tPA (Hart et al. 1989) which has been shown to bind to the surface of these 
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cells via numerous and varied receptors (Felez et al. 1991; Otter et al. 1991; 
Noorman et al. 1995). Furthermore, Ritchie et al. (1995) reported the up-regulation 
of SerpinB2 expression by monocytes cultured in the presence of thrombin. This 
suggests a potential role for SerpinB2 in the homeostatic balance between 
thrombosis and fibrinolysis at local sites of inflammation or during wound healing 
processes, possibly through the inhibition and clearance of tc-tPA from the 
pericellular environment. 
 
Clearance of tPA and tPA:SerpinE1 from the circulation via endocytic processes 
in the liver is well characterised (Wing et al. 1991; Nguyen et al. 1992). The 
mechanisms for endocytosis of these ligands have been shown to be dependent 
on members of the low density lipoprotein receptor (LDLR) family, specifically LRP 
(Bu et al. 1992; Orth et al. 1992) and scavenger receptors such as the mannose 
receptor (CD206) (Otter et al. 1991). The rate of endocytosis of SerpinE1-inhibited 
tPA was shown to be accelerated compared to tPA only, on rat hepatoma cells 
(Camani et al. 1994).  This acceleration in clearance was found to be due to the 
increased affinity of tPA:SerpinE1 complexes for LRP (Horn et al. 1998). 
Interestingly, Camani et al. (2000) found that Novikoff rat hepatoma cells, MEF-1 
mouse embryonic fibroblasts, HT1080 fibroblasts and COS African green monkey 
kidney cells were all able to degrade [125I]tPA and [125I]tPA:SerpinE1 via LRP-
mediated uptake, whilst the THP-1 and U-937 monocytic cell lines were not. The 
authors suggested that a co-receptor, absent on the THP-1 and U-937 cell lines, 
may be required for these ligands to interact with LDLRs. However, tPA was shown 
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to specifically bind to the surface of freshly isolated peripheral blood monocytes 
(PBM), THP-1 and U-937 cell lines (Felez et al. 1991). Macrophages derived from 
human PBMs were shown to take up and degrade [125I]tPA via the mannose 
receptor (Noorman et al. 1995). Furthermore, Simon et al. (1995) showed LDLR-
family dependant endocytosis and degradation of [125I]tPA:SerpinE1 by the THP-
1 cell line. Thus, the potential function of SerpinE1 or SerpinB2 in the inhibition 
and enhanced endocytosis of tPA bound to myeloid cell types remains unclear.   
 
3.2.1. Specific Aims 
In order to clarify and compare the role of these serpins as regulators of cellular 
tPA, freshly isolated PBMs were utilised as a non-transformed tPA-dependent 
cellular model representing myeloid lineages (McWilliam et al. 1998). The specific 
aims of this chapter were to examine inhibition of tPA by SerpinB2 and 
characterise the role of LRP and VLDLR as potential endocytosis receptors for tPA 
and tPA:PAI complexes on these cells. Cell profiling of the U-937 and THP-1 cell 
line in addition to PBMs were undertaken to ascertain basal PA levels present on 
the surface of malignant versus healthy myeloid cells with the aim of assessing the 
potential impact, if any SerpinB2 directed therapeutics may have through non-uPA 






Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd 
(Sydney, Australia). Purified human receptor associated protein (RAP), 
recombinant human serpinE1 (stable mutant) and human tc-tPA were obtained 
from Molecular Innovations (MD, USA). Spectrozyme PL substrate, murine anti-
human uPA B-chain IgG1 (#394), murine anti-human tPA IgG1 (#E-4) and murine 
anti-human LRP -chain IgG1 (#3402) were supplied by American Diagnostica Inc. 
(USA). Rabbit anti-human VLDLR IgG and rabbit anti-annexin II (p36) were from 
Santa Cruz Biotechnology, Inc.  Goat anti-S100A10 (p11) was from R&D Systems. 
Goat anti-rabbit FITC conjugate IgG (whole molecule), goat anti-mouse IgG (Fab 
specific) FITC conjugate, rabbit anti-goat IgG (whole molecule) FITC conjugate, 
goat IgG, propidium iodide (PI), Hanks balanced salt modified and non-modified, 
bovine serum albumin (BSA), human fibrin, D-phenylalanyl-L-prolyl-L-arginine 
chloromethyl keytone (PPACK) and OptiPrepTM density gradient medium were 
from Sigma-Aldrich. Alexa 488 protein labelling kit and Alexa 488 quenching 
polyclonal antibody were from Molecular Probes (OR, USA). Murine α-CD14-texas 
red conjugated monoclonal antibody was purchased from Invitrogen (USA). 
Murine α-CD206 monoclonal antibody was purchased from Hycult-biotech 
(Netherlands). Recombinant human tPA (Actylise, a mixture of sc and tc-tPA) was 
a kind gift from Boehringer-Ingelheim, Australia.  
  
 66 
3.3.2. Isolation of Human Peripheral Blood Monocytes 
Peripheral venous blood was collected from donors into EDTA vacuum tubes (BD 
Biosciences, Nth Ryde, Australia) under controlled conditions by a trained 
phlebotomist at the University of Wollongong (UOW) (protocol approved by UOW, 
Human Ethics Committee, approval number HE00/221). Buffy coats were 
prepared by centrifuging whole blood samples at 1300 g for 30 min. White blood 
cells were removed under sterile conditions and monocytes isolated using 
OptiPrepTM as per the manufacturer’s instructions. This methodology yielded cell 
preparations containing 60 to 80% CD14 positive (monocyte) cells as determined 
by flow cytometry. Freshly isolated PBMs were used immediately for all 
experiments. 
 
3.3.3. Plasminogen Activation Assays 
Cells were washed and resuspended at 1x106 cells.mL-1 in Tris Buffered Saline 
(TBS) (50 mM Tris, 150 mM NaCl, pH 7.4), incubated on ice in the absence or 
presence of 100 nM tPA for 40 min and then washed twice in TBS to remove 
excess unbound protein. Triplicate 50 μL cell suspensions were then aliquoted into 
96-well microtitre plates and incubated for 15 min at room temperature, in the 
absence or presence of increasing concentrations of serpinE1, SerpinB2 and 10 
μg.mL-1 plasminogen made up to a final volume of 100 μL with TBS buffer. 
Spectrozyme PL substrate (100 μL) was then added to a final concentration of 0.25 
mM and substrate conversion by plasmin measured kinetically at 405 nm over 2 h 
at 37 C using a SpectraMax 250 plate reader; data was recorded using SoftMax® 
Pro software (Molecular Devices, USA). Negative controls contained cells alone 
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(no tPA or plasminogen). Other controls consisted of tPA (100 nM) in the absence 
or presence of 1.4 M fibrin, plasminogen (10 μg.mL-1) and Spectrozyme PL (0.25 
mM), as previously described (Lobov et al. 2008). Background absorbance (buffer 
only wells) was subtracted from all data. 
 
3.3.4. Flow Cytometry Analysis  
3.3.4.1. Cell surface antigen detection  
Membrane bound antigens were detected using indirect immunofluorescence 
assays, essentially as previously described (Ranson et al. 1998). Briefly, cells were 
suspended at a final concentration of 1x106 cells.mL-1 in ice cold binding buffer 
(phenol red-free Hanks buffered salt solution, pH 7.4, containing 1 mM CaCl2, 1 
mM MgCl2 and 0.1% BSA) containing 10 g.mL-1 of primary antibody and 
incubated on ice for 40 min. After washing steps, the cells were resuspended with 
ice-cold binding buffer containing 1:100 dilution of FITC conjugated secondary 
antibody, followed by incubation with 10 μg.mL-1 α-CD14-texas red conjugated 
antibody (for identification of PBMs). Cells were then washed prior to analysis by 
flow cytometry, with viable cell populations selected through propidium iodide (PI) 
exclusion. Isotype matched control antibodies were used to assess non-specific 
binding due to the primary antibody. All data obtained was analysed using FLOJO 
software version 7.1 (Treestar, Inc) and was restricted to CD14 positive/PI 
negative cells. All geometric mean fluorescence values reported represent mean 




3.3.4.2. Ligand binding assay 
Cell surface binding analyses were conducted by incubating cells on ice in binding 
buffer containing increasing amounts of Alexa488-labelled tPA (tPAAlexa488) or BSA 
(BSAAlexa488) (negative control) for 40 min. This was done in order to allow maximal 
cell surface binding by also minimising internalisation of tPA. Cells were then 
washed twice with ice cold PBS and analysed using flow cytometry as described 
above. 
 
3.3.4.3. Internalisation assays 
This assay has previously been utilised to characterise the clearance pathways of 
uPA:SerpinB2 complexes on PC-3 cells (Croucher et al. 2006) and was therefore 
adapted for characterisation of Actylise-tPA:Alexa488 clearance pathways in this 
study. Briefly, cells were incubated for 40 min at 1x106 cells.mL-1 in binding buffer, 
containing 0 (control) or 100 nM tPA or tPAAlexa488, on ice to minimise 
internalisation. After washing to remove excess unbound tPA, cells were incubated 
with either SerpinB2 or SerpinB2Alexa488 (where stated), SerpinE1 or no additions 
and incubated at 37 C for the time periods indicated. All subsequent steps were 
performed at 4 C. The cells were next washed twice and incubated for 30 min with 
4 g.mL-1 Alexa488 quenching antibody (quenches any remaining cell surface 
fluorescence and is thus a measure of internalised ligand). Then, after washing, 
the cells were incubated for 40 min with 10 μg.mL-1 α-CD14 monoclonal antibody. 
Finally, the cells were washed twice with ice cold PBS and analysed using flow 
cytometry as described above.    
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3.3.5. Surface Plasmon Resonance Assays 
Kinetic analysis was performed using a BIAcore 2000 (BIAcore AB, Uppsala, 
Sweden). LRP or VLDLR was immobilised on to a CM5 BIAcore chip according to 
the manufacturer’s instructions. Briefly, the chip was activated using a 1:1 mixture 
of 0.2 M N-ethyl-N’-(3-dimethylaminopropyl)carbodi-imide and 0.05 M N-
hydroxysuccimide. LRP or VLDLR was coated on to the chip at 40 μg.mL-1 in 10 
mM sodium acetate buffer (pH 3) for 7 min at 5 μL.min-1, as previously described 
(Croucher et al. 2007), to a level of 2000 response units (VLDLR) or 2000 to 10000 
response units (LRP). The un-occupied binding sites were blocked using 1 M 
ethanolamine, pH 8.5. Analytes (tPA, tPA:PAI) were buffer exchanged into running 
buffer (10 mM HEPES (pH 7.4), 140 mM NaCl, 1 mM CaCl2, 0.05% v/v Tween-20) 
before applying to the BIAcore chip at 20 μL.min-1. A serial dilution of analytes 
ranging from 500 – 15 nM were used to allow kinetic analyses. tPA:PAI complexes 
were prepared by incubating tPA with SerpinE1 (1:1 molar ratio) or SerpinB2 (1:3 
molar ratio) for 60 min at 37 ˚C. An excess of SerpinB2 could be used and not 
removed from the tPA:SerpinB2 solutions as un-reacted SerpinB2 does not bind 
LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007; Cochran et al. 2009; 
Cochran et al. 2011). SDS-PAGE confirmed the presence of tPA:SerpinE1 or 
tPA:SerpinB2 complexes with minimal/negligible residual free tPA or SerpinE1 
(Fig. 3.1). In all cases the analyte concentration refers to the concentration of tPA 
present. Regeneration of the chip was achieved using 100 mM H3PSO4. All buffers 
were filtered and degassed before use. For kinetic analysis, a blank cell was used 
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Figure 3.1: Representative gel showing preformed tPA:PAI complexes. 
Stock solutions were prepared by incubating tPA with SerpinE1 (1:1 molar ratio) 
or SerpinB2 (1:3 molar ratio) for 60 min at 37 ˚C and used for comparison of 
kinetic interactions with LRP and VLDLR using Surface Plasmon Resonance. 
Excess PAI-2 could be utilised to make the complexes as residual (free) PAI-2 
does not interact with LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007; 




3.3.6. Statistical Analysis 
Statistical significance was determined using Students t-test and was performed 
using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego 

















3.4.1. Cell surface expression profiles of tPA, uPA and potential 
receptors on U-937, THP-1 and Peripheral Blood Monocytes. 
 
To ascertain basal cell surface expression levels of the plasminogen activation 
systems by the U-937, THP-1 cell lines compared to peripheral blood monocytes 
(PBMs), immunofluorescence assays were undertaken on all cells using flow 
cytometry.  As described in chapter 2, the uPA system was detected at the cell 
surface of both cell lines, with highest expression observed on the THP-1 cell line 
corresponding to a 17 and 39 fold increase in specific fluorescence intensity 
compared to the U-937 and PBMs respectively (Tab. 3.1). Conversely, surface 
bound tPA was detectable on PBMs whilst absent from both monocytic cell lines 
(Tab. 3.1).   
 










Ligand Relative MFI ± SEM 
uPA 4.27 ± 1.27 71.19 ± 0.96 1.82 ± 0.5 
tPA ND ND 5 ± 0.9 
LRP 5.0 ± 0.8 9.14 ± 1.17 15.7 ± 1.3 
VLDLR 19.4 ± 3.2 145 ± 18 70.5 ± 0.8 
Annexin 2A (P36) 67.0 ± 4.6 43 ± 4 68.78 ± 5.9 
S100A10 (P11) ND 18 ± 9 ND 
Mannose Receptor 
(CD206) 
ND ND ND 
Data represents mean fluorescence intensity (MFI), with relevant matched isotype control values 
subtracted (n=3, ± SEM). ND = not detected. 
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Both LRP and VLDLR were detected on all cell types. The PBMs exhibited the 
highest LRP expression with 1.7 and 3 fold higher mean fluorescence intensity 
compared to the THP-1 and U-937 cell lines, respectively (Tab. 3.1). The THP-1 
cell line was found to have the highest VLDLR cell surface level with 2 and 7.5 fold 
higher mean fluorescence intensity compared to the PBMs and U-937 cells, 
respectively (Tab. 3.1). As tPA is reported to also bind the mannose receptor and 
the annexin II heterotetramer (AIIt), cell surface profiles for these antigens were 
undertaken. All cell types expressed detectable levels of annexin 2A (p36) with 
comparable expression between the U-937 cell line and PBMs, whilst the THP-1 
cell line exhibited 1/3 less detectable P36 (Tab. 3.1). Interestingly the THP-1 cell 
line was found to also express p11, the second component of the AIIt, whilst it was 
not detectable on the surface of either the U-937s or the PBMs. It was not possible 
to detect the mannose receptor (CD206) on any cells (Tab. 3.1). 
 
3.4.2. Tissue  Plasminogen Activator; cell surface binding potential 
 (exogenous protein addition) 
 
Since at least one known tPA receptor, p36, was detected, we tested the binding 
of exogenous tPA to PBMs. When incubated on ice to minimise internalisation 
and/or proteolytic activity, the binding of tPA to PBMs was saturable within 40 min, 
showing maximum binding at about 200 nM (Fig. 3.2A).  A negative control BSA-
Alexa488 did not bind to the cell surface at the highest equivalent tPA 
concentration (Fig.3.2B). We next tested the contribution of LDLRs to the direct 
binding of tPA to PBMs. Pre-incubation of the cells with RAP significantly reduced 
cell surface binding of exogenous tPA to PBMs (Fig. 3.2C) by 30%. This level of 
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inhibition was consistent with previous studies using human umbilical vein 
endothelial cells (Mulder et al. 1997), indicating that LDLR family members are 
functional cell surface receptors for tPA in addition to the potentially numerous 
other receptors represented by the non-RAP inhibitable binding interactions. 
Furthermore, tPA bound only to the CD14-positive stained (i.e. PBM) cells within 
the cell suspension, indicating that the other blood cell types present did not bind 
measurable amounts of tPA (Fig. 3.2D).   
Figure 3.2: Characterisation of Actylise-tPA binding to PBMs. (A) Plot 
showing the concentration dependence of the binding of Alexa488-labelled 
Actylise-tPA to the surface of PBM. (B) Binding of 200 nM Alexa488-labelled 
Actylise-tPA or Alexa488-BSA (control) to the cell surface of PBM.  (C) Plot 
showing the effects of RAP on cell surface binding of Alexa488-labelled Actylise-
tPA using flow cytometry. Data within A, B and C plots, represents the geometric 
mean (GM) fluorescence, corrected for auto-fluorescence, n=3 ± SEM. (D) Two 
dimensional flow cytometry dot plot showing Alexa488-labelled Actylise-tPA 
binding (515 nm) to CD14 positive (660 nm) cell population. 
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Of note, significantly more Actylise-tPA:Alexa488 bound to the PBMs (> 4 fold at 100 
nM or 200 nM) compared to the U-937 and THP-1 cell lines which bound 
comparable levels (Fig. 3.3A). The specificity of tPA binding to the U-937 cell lines 
was confirmed using the negative control, BSA-Alexa488, which did not bind to the 
cell surface at the highest equivalent tPA concentration (Fig.3.3B). Non-specific 
binding of Actylise-tPA was not tested for the THP-1 cell line and therefore cannot 

































Figure 3.3: Exogenous tPA binding potential of cell models. A) The U-937 and THP-
1 monocytic cell lines were incubated on ice for 40 min in the absence (auto fluorescence) 
or presence of Actylise-tPAAlexa488 at concentrations indicated.  Unbound Actylise-
tPAAlexa488 was then removed via centrifugation and cell surface bound Actylise-tPAAlexa488 
measured using flow cytometry.  B) Specificity of Actylise-tPA binding to the U-937 cell 
line was confirmed using 100 nM BSAAlexa488 under the same conditions. Data represents 
the geometric mean (GM) fluorescence (panel A and B) with background (auto 




3.4.3. tc-tPA mediated cell surface plasmin generation 
To obtain a quantitative indication of the cell surface plasminogen activation 
potential, whole cell plasmin generation assays were conducted.  Saturation of the 
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cell surface with exogenous tc-tPA caused a significant increase in cellular plasmin 
activity (Fig. 3.4). As expected from previous work showing inhibition of cell surface 
tPA by SerpinB2 on the MCF-7 and HeLa cell lines (Lobov et al. 2008), SerpinB2 
was also able to inhibit cell surface tc-tPA on PBMs at similar concentrations (Fig. 
3.4). SerpinE1 was overall more efficient at inhibiting plasmin formation compared 
to SerpinB2, resulting in 95 - 100% inhibition at all concentrations used (Fig. 3.4). 
However, at 50 nM SerpinB2 inhibited about 80% of plasmin formation while at 












Figure 3.4: Plot showing inhibition of PBM-mediated plasminogen activation 
by exogenous SerpinE1 and SerpinB2. Freshly isolated PBMs were pre-
incubated in the absence or presence of 100 nM tc-tPA where indicated.  Then 
glu-plasminogen was added at a final concentration of 0.25 μM and the rate of 
plasmin formation in the absence (grey) or presence of either SerpinE1 or 
SerpinB2 (50, 100, 200 nM), was analysed using Spectrozyme PL substrate (ADI).  
Assays were conducted over 2 hs at 37 C.  Data represents mean ± SEM, (n=3), 




Investigation of plasmin formation at the cell surface in the absence or presence 
of SerpinB2 was also conducted using the U-937 and THP-1 cell lines.  Low levels 
of intrinsic plasmin generation were detected (Fig.3.5), which is indicative of low to 
negligible endogenous of either tPA or uPA levels on these cell lines (see Table 
3.1). The addition of tc-tPA resulted in a significant enhancement of cell surface 
plasmin activity on both cell lines (Fig 3.5) reflecting the ability if these cells to 
specifically bind exogenous tPA (see Fig 3.3). At tc-tPA to SerpinB2 concentration 
ratios of 2:1, 1:1 and 1:2, SerpinB2 was able to inhibit the rate of plasmin formation 
on the U-937 cell line by 60%, 70% and 80%, respectively when compared to no 
SerpinB2 control (Fig. 3.5).  Importantly, these results were consistent with those 
obtained using freshly isolated PBMs (Fig. 3.4). Conversely at the same 
concentration ratios SerpinB2 was only able to inhibit the rate of plasmin 
generation on THP-1 cells by 18%, 30% and 43%, respectively (Fig 3.5). It is 
important to note that the THP-1 cell line was shown to have significantly more 
surface bound endogenous uPA compared to the U-937 cell line and PBMs (Table 
3.1). Furthermore, pro-uPA is activated by plasmin, therefore addition of 
exogenous tc-tPA may also increase uPA activity. Therefore the reduced efficiency 
of SerpinB2 to inhibit plasmin generation at the cell surface of the THP-1 cell line 
may be attributed to the variability in ratios of SerpinB2 to total plasminogen 
















Figure 3.5:  Inhibition of cellular plasminogen activation by SerpinB2.  U-937 
(un-filled) and THP-1 (filled) cells were pre-treated in the absence or presence of 
100 nM tc-tPA where indicated.  Then glu-plasminogen was added at a final 
concentration of 0.25 μM and the rate of plasmin formation in the absence or 
presence of SerpinB2 (50, 100, 200 nM), was analysed using Spectrozyme PL 
substrate (ADI).  Assays were conducted over 2 hs at 37 C.  Data represents 





3.4.4. Endocytosis of Tissue Plasminogen Activator by Monocytic 
 Cell Lines and Peripheral Blood Monocytes 
 
As tPA bound to the cell surface generated plasmin and this activity was inhibited 
by SerpinB2 we next examined the internalisation of Actylise-tPA:SerpinB2 
complexes by the  U-937 and THP-1 cell lines.  A moderate but significant increase 
in SerpinB2Alexa488 internalisation was observed for both cell lines upon pre-
incubation with 50 nM Actylise-tPA compared to no exogenous Actylise-tPA 
controls (Fig. 3.6).  As these cells were incubated on ice in the absence (control) 
or presence of Actylise-tPA to facilitate binding of exogenous tPA prior to 
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incubation at 37 °C with SerpinB2Alexa488 this data represents internalisation of 



















































Figure 3.6: Tissue Plasminogen Activator facilitated internalisation of 
SerpinB2:Alexa488 by the (A) U-937 and (B) THP-1 monocytic cell lines.  Cells 
were incubated in the absence (control) or presence of 50 nM exogenous 
Actylise-tPA on ice for 40 min.  Excess Actylise-tPA was removed by 
centrifugation, the cells were then resuspended in 10 nM SerpinB2:Alexa488 and 
incubated at 37C for 1 h.  Surface bound SerpinB2:Alexa488 was quenched on ice 
for 30 min with 4 μg.mL-1 rabbit-α-Alexa488 prior to analysis using flow 
cytometry.  Data represents geometric mean (GM) fluorescence with 
background (auto-fluorescence) removed, n=3 ± SEM. * p<0.05 significantly 
different from cell line control. 
 
 
We next investigated the internalisation of Actylise-tPA complexes by freshly 
isolated PBMs in the absence or presence of either SerpinB2 or SerpinE1. Blood 
samples were collected and cells isolated using OptiPrepTM for immediate use in 
flow cytometry experiments and PBMs selected for, using anti-CD14 antibodies 







Figure 3.7:  Identification of Peripheral Blood Monocytes. Freshly isolated 
blood monocytes where initially gated for based on side and forward scatter (i) 
then viable cells within this gate where selected using propidium iodide exclusion 
(695/40A) (ii) Cells where pre-stained with α-CD14 MAb, detected using α-
mouse:Alexa633 and positive cells gated further for analysis (iii). Actylise-
tPA:Serpin complex internalisation was therefore assessed on PI negative, α-




PBMs were found to endocytose both Actylise-tPAAlexa488 and Actylise-
tPAAlexa488:Serpin complexes using a quenching internalisation assay (Fig. 3.8).  
Cells were pre-treated with 100 nM Actylise-tPA:Alexa488 and excess unbound 




complexes cleared in this assay were those formed at the cell surface.  
Comparison of clearance efficiency between Actylise-tPA only, Actylise-
tPA:SerpinB2 and Actylise-tPA:SerpinE1 was assessed at 37 C, over a 30 min 
period. In the absence of serpins, increasing levels of Actylise-tPA:Alexa488 were 
internalised over the time course (Fig. 3.8).  Interestingly, SerpinE1 was found to 
enhance Actylise-tPA uptake from the cell surface after 20-30 min incubation time 
whilst SerpinB2 did not (Fig. 3.8).  At the 20 min time point SerpinB2 treated cells 
exhibited a slight, but significant (p = 0.023, n=3) increase in tPA clearance 
compared to tPA alone, however this was not sustained and at 30 min the amount 
of tPA only was comparable to tPA:SerpinB2 (Fig. 3.8). 
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Figure 3.8: Internalisation of Actylise-tPAAlexa488 by PBMs. Cells were 
incubated on ice for 40 min in the absence (auto-fluorescence) or presence of 100 
nM Actylise-tPAAlexa488 after which, excess protein was removed by centrifugation.  
Cells were then resuspended in binding buffer in the absence (tPA only) or 
presence of 100 nM SerpinB2 or SerpinE1, where indicated and incubated at 37 
C for 10, 20 or 30 min.  Remaining cell surface bound Actylise-tPAAlexa488 was 
then quenched by addition of 4 μg.mL-1 rabbit-α-Alexa488 and incubated on ice for 
30 min with 10 µg.mL α-CD14 MAb. Indirect detection of CD14 was performed by 
a further 30 min incubation on ice in the presence of α-mouse:Alexa633 prior to 
analysis using flow cytometry.  Data represents geometric mean (GM) 
fluorescence with background (auto-fluorescence) removed, n=3, ± SEM. * p<0.05 
significantly different from tPA only control. 
 
 
This differential effect on tPA endocytosis by SerpinB2 and SerpinE1 was 
surprising as SerpinB2 has previously been shown to enhance the uptake of uPA 
from the surface of prostate cancer cells, albeit not to the same extent as SerpinE1 
(Croucher et al. 2007). As these experiments were conducted using Alexa488 
labelled Actylise, which contains a mixture of sc and tc-tPA the significant but 






indicative of tc-tPA clearance only, as SerpinB2 does not efficiently inhibit sc-tPA. 
This is supported by the 2-fold difference in internalisation of Actylise-
tPA:SerpinE1 after 30 min as SerpinE1 is known to be an efficient inhibitor of both 
sc and tc-tPA (Thorsen et al. 1988). 
 
To address this and confirm that SerpinB2 not only inhibited (i.e., bound) to cell 
surface tPA but was itself subsequently endocytosed as a tPA:Serpinb2 complex, 
internalisation assays using SerpinB2Alexa488 and exogenous active-tPA or PPACK-
inactivated tPA were performed. Furthermore comparison of SerpinB2Alexa488 
internalisation via Actylise-tPA and tc-tPA was undertaken. Cell surface bound 
PPACK-inactivated Actylise-tPA significantly reduced the internalisation of 
SerpinB2 by 25% compared to the active control (Fig 3.9A) whilst inactivation of 
tc-tPA reduced internalisation of SerpinB2 by 90% (Fig. 3.9B), indicating that 
SerpinB2 bound at the PBM cell surface was subsequently endocytosed as a tc-











Figure 3.9: Actylise and tc-tPA dependent internalisation of SerpinB2.  (A) 
Freshly isolated PBM were incubated on ice for 40 min in the absence (auto-
fluorescence) or presence of 100 nM Actylise-tPA.  Excess Actylise-tPA was 
then removed by centrifugation and cells were incubated for a further 15 min on 
ice in the absence (control) or presence of 100 μM PPACK (itPA). 
SerpinB2Alexa488 was then added at a final concentration of 10 μM and the cells 
incubated for 1 h at 37 C.  Cell bound SerpinB2Alexa488 was quenched using 4 
μg.mL-1 rabbbit-α-Alexa488 for 30 min on ice prior to analysis using flow 
cytometry.  (B) Freshly isolated PBMs were prepared as per (A), substituting 
100nM purified tc-tPA for 100 nM Actylise-tPA. Data represents normalised (to 
control), geometric mean (GM) fluorescence with background (auto-
fluorescence) removed, n=3, ± SEM. * p<0.05 significantly different from control. 
 
In order to characterise the mechanisms involved in the clearance of tPA and 
tPA:serpin complexes from the cell surface of PBM the roles of scavenger proteins 
and the LDL receptor family were investigated.  Where previous internalisation 
assays had been conducted on pre-treated (addition of exogenous Actylise-tPA) 
cells, pre-formed complexes were used to characterise internalisation pathways 
allowing for pre-treatment with inhibitors, followed by addition of Actylise-tPA.  
RAP, a commonly used antagonist of ligand binding specific to the LDLR family, 
significantly inhibited Actylise-tPA:Alexa488/complex internalisation by 80 to 90% in 









































































Figure 3.10: Role of LDLR family and scavenger receptors in the 
endocytosis of tPA.  (A) Freshly isolated PBMs where initially gated on side 
and forward scatter, selecting viable cells based on morphology (i) Cells where 
pre-stained with α-CD14:PE-TR MAb and positive cells gated for analysis (ii). 
Actylise-tPA:serpin complex internalisation was therefore assessed α-CD14 
positive cells and quantitated on Alexa488 positive fluorescence intensity (iii). 
(B) Freshly isolated PBMs were incubated for 15 min at 37 C in the absence 
(control) or presence of either 300 nM RAP or 300 μg.mL-1 Fucoidin, after which 
100 nM tPAAlexa488 or tPAAlexa488:serpin complexes were added and the cells 
incubated for a further 20 min at 37 C.  Cell bound tPAAlexa488 and complexes 
were quenched using 4 μg.mL-1 rabbbit-α-Alexa488 for 30 min on ice prior to 
analysis using flow cytometry.  Data represents normalised (to control) geometric 
mean (GM) fluorescence with background (auto-fluorescence) removed, n=3, ± 
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scavenger receptors was also able to inhibit internalisation, however to a much 
lesser extent then RAP with 20 – 10 % inhibition observed.  Importantly, the 
combined percentage of inhibition for RAP and Fucoidin in the endocytosis of 
Actylise-tPAAlexa488, Actylise-tPAAlexa488:SerpinB2 or Actylise-tPAAlexa488:SerpinE1 
totalled 94%, 83% and 99% respectively (Fig. 3.10).   
 
This finding indicates that the LDLR family plays a predominant role in the 
clearance of tPA and tPA:serpin complexes from the cell surface of PBMs whilst 
scavenger receptors contribute a minor role.  As tPA clearance is reported to be 
facilitated via the mannose receptor by liver cells (Kuiper et al. 1988; Otter et al. 
1991; Nguyen et al. 1992) and expression of the mannose receptor has been 
reported for primary macrophages (Noorman et al. 1995) immunofluorescence 
assays were conducted to assess cell surface expression of the mannose receptor 
(CD206) by the peripheral blood monocytes used in these experiments.  There 
were no detectable levels of the mannose receptor found within three independent 
assays indicating that this receptor was not involved in the fucoidin dependent 
clearance of tPA or tPA:serpin complexes by the PBMs (see Table. 3.1). 
 
Given the dominance of the LDLR family of endocytosis receptors in cell surface 
tPA clearance we next investigated their role in direct binding of tPA to PBM’s.  
Cells were pre-incubated in the absence (control) or presence of RAP for 15 min 
prior to the addition of tPAAlexa488 followed by further 30 min incubation on ice.  
 86 
Under these conditions RAP was able to reduce cell surface binding of tPAAlexa488 
by 30 % (Fig. 3.11), confirming previous studies (Mulder et al. 1997).   
Figure 3.11: Role of LDLR family in the cell surface binding of Actylise-tPA.  
Freshly isolated PBMs were incubated for 15 min on ice in the absence (control) 
or presence of 300 nM RAP after which 100 nM tPAAlexa488 was added and the 
cells incubated for a further 40 min on ice.  Cell bound tPAAlexa488 was then 
analysis using flow cytometry.  Data represents normalised (to control) geometric 
mean (GM) fluorescence with background (auto-fluorescence) removed, n=3, ± 
SEM. * p<0.05 significantly different from control. 
 
 
3.4.5. Surface plasmon resonance analysis of tc-tPA and tc-tPA:PAI 
 complexes with LDLR members. 
 
To obtain a more quantitative analysis of the role of LRP and VLDLR in the cell 
surface interactions of tPA and tPA:serpin complexes the kinetics of binding of 
these ligands to immobilized LRP and VLDLR were analysed using surface 
plasmon resonance (SPR). Initial specificity analyses using overlay plots of 
sensorgrams indicated that tPA:SerpinE1 bound more strongly to LRP than tPA 
alone or in complex with SerpinB2 (Fig. 3.12A). This effect was less obvious with 
VLDLR (Fig. 3.12B). For kinetic analyses a serial dilution of ligands were used, 




















which revealed dose dependent binding for all of the analytes (Fig. 3.12) and 
complex binding interactions of tc-tPA:SerpinE1 to both LRP and VLDLR. 
Nevertheless, in both cases, the data best fit competitive heterogeneous analyte 
models, suggesting the presence of a relatively low and a high affinity binding site 
within the complex for both LRP (KD1 ~ 21.2 nM, KD2 ~ 0.95 nM, respectively) and 
VLDLR (KD1 ~ 139 nM; KD2 ~ 23 nM) (Table 3.2).  tc-tPA and tc-tPA:SerpinB2 also 
bound to LRP and VLDLR. However, these data were best fit by a one-binding site 
model with tc-tPA and tc-tPA:SerpinB2 binding with very similar, moderate 
affinities to LRP (KD 67 – 57 nM) and VLDR (KD 124 – 98 nM), respectively. The 
higher affinity binding (KD2) of tPA:SerpinE1 to both LRP and VLDLR was due to a 
substantial (100 to 16 fold, respectively) decrease in the dissociation rate constant, 
indicating much slower dissociation of the complex (Table 3.2). The binding affinity 
of tc-tPA and tc-tPA:PAI complexes for LRP was generally higher than that 
obtained with VLDLR (Table 3.2). To our knowledge, there is no previously 
published data describing the binding of tc-tPA:SerpinB2 to LRP and VLDLR 
however the affinities reported here for the binding of tc-tPA and tPA:SerpinE1 to 
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Figure 3.12: Surface plasmon resonance analysis of the interaction between 
tc-tPA, tc-tPA:SerpinB2 and tc-tPA:SerpinE1 and VLDLR or LRP. 
Sensorgrams showing the does dependent binding of analytes (15-500 nM) to 







Table 3.2: Surface Plasmon Resonance kinetic analysis of the interaction 
between LDLRs and tc-tPA or tc-tPA:serpin complexes. 
 
 LRP 
Analyte Model ka (1/Ms) kd (1/s) KD (nM) 2 
tPA 1:1 5.22 x 105 3.51 x 10-3 67 1.52 





2.21 x 105 4.69 x 10-3 21.2 
5.61 
4.62 x 104 4.38 x 10-5 0.95 
 VLDLR 
tPA 1:1 4.18 x 105 51.7 x 10-3 124 2.55 





5.37 x 105 74.8 x 10-3 139 
5.07 
2.00 x 105 4.60 x 10-3 23.0 
Binding data was fitted to normalised sensorgrams using the BIAevaluation 3.0 software. 




The results presented here show that both SerpinB2 and SerpinE1 inhibit the 
enzymatic activity of cell surface bound tPA and that tPA:serpin complexes formed 
at the cell surface are subsequently endocytosed, predominantly via an LDLR 
dependent pathway. While both tPA:serpin complexes are internalised, only 
inhibition by SerpinE1 accelerates tPA endocytosis.  The differences in 
endocytosis of these ligands may be explained by the kinetic data obtained for the 
binding of tPA and tPA:SerpinE1 to LRP and VLDLR using SPR.  The formation of 
complexes between SerpinE1 and either tPA or uPA are thought to cause a 
conformational change within SerpinE1 resulting in it exposing a high affinity 
binding site for LRP (Horn et al. 1998; Stefansson et al. 1998) or potentially 
VLDLR, which contributes directly to the enhanced endocytosis of tPA:SerpinE1 
or uPA:SerpinE1 complexes from the cell surface. Indeed work by Cochran et al. 
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(2011) showed the importance of an LDLR minimal binding motif present in the α-
helix D of SerpinE1 but not SerpinB2 that is responsible for the higher affinity 
interaction and enhanced endocytosis of uPA:SerpinE1 complexes.   
  
Both LRP (Strickland et al. 2002; Croucher et al. 2006) and VLDLR (Strickland et 
al. 2002; Croucher et al. 2007) play a pivotal role in the rapid clearance of surface 
bound uPA:SerpinE1 and uPA:SerpinB2 complexes. Like SerpinE1, SerpinB2 has 
been shown to accelerate uPA internalisation due to an increased affinity of 
uPA:SerpinB2 for LRP and VLDLR compared to uPA alone (Croucher et al. 2006; 
Croucher et al. 2007). It is possible that formation of the uPA:SerpinB2 complex 
results in a conformational change within uPA as SerpinB2 does not bind to either 
LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007). Importantly, tc-tPA 
alone and tc-tPA:SerpinB2 show almost identical one-site binding affinities for LRP 
and VLDLR, suggesting that complex formation does not significantly alter the 
binding interaction of tc-tPA to LRP or VLDLR.  Furthermore, especially in regards 
to VLDLR binding, the similar KD values obtained for the lower affinity binding 
interactions of tPA:SerpinE1 compared to those observed for tPA or tPA:SerpinB2 
(Table 3.2) suggests that no functional conformational change occurs within the 
tc-tPA molecule upon complex formation. Therefore it is likely that the differences 
in KD values for LRP and VLDLR observed between tc-tPA:SerpinE1 and tc-tPA 
or tc-tPA:SerpinB2 are related to exposure of the high affinity cryptic binding site 
within SerpinE1.  Of note, comparison of the binding affinities of tc-tPA and tc-
tPA:serpin for LRP and VLDLR reveals a preference of these ligands for LRP 
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(Table 3.3). In contrast, uPA and uPA:serpin appear to bind with higher affinities 
to VLDLR compared to LRP (Table 3.3). However, the significance of these 
differences is unclear at this stage. 
 
Table 3.3: Comparison of tc-tPA/tc-tPA:PAI  to uPA/uPA:PAI affinities for LRP 
and VLDLR  
 LRP VLDLR 
Analyte KD (nM) KD (nM) 
tPA 67  124  
tPA:SerpinB2 66  131  




uPA  200  *  31.2  ^ 
uPA:SerpinB2  32.6  *  4.68  ^ 
uPA:SerpinE1 0.226 € 1.6 € 
84.8 ^ 
1.51 ^ 
Previously published data: * (Croucher et al. 2006), ^ (Croucher et al. 2007), € (Skeldal et al. 2006) 
 
 
Interestingly, RAP inhibited the direct binding of Actylise-tPA to the PBM cell 
surface by approximately 30%. This observation is similar to that reported by 
Mulder et al. (1997), where pre-treatment with RAP resulted in a 25% reduction of 
tPA binding to the cell surface of HUVECs. The identities of other receptors 
responsible for the remaining proportion of tPA binding are potentially numerous, 
of which p36 may partially contribute to total tPA binding on these cells, as 
previously published (Brownstein et al. 2004). The absence of the mannose 
receptor on our freshly isolated PBMs cells was not surprising as it is indicative of 
a monocyte versus a differentiated macrophage phenotype (Noorman et al. 1995). 
That fucoidin inhibited the clearance of tPA and tPA:serpin complexes from the 
surface of PBMs by about 10 – 20%, suggests that other scavenger receptors 
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present on PBMs play a minor role in the binding and subsequent endocytosis of 
these ligands. 
 
The traditional role of tPA in fibrinolysis and of SerpinE1 as a regulator of tPA is 
well characterised.  However in recent years it has become increasingly clear that 
tPA is not restricted to maintaining homeostasis of coagulation and fibrinolysis 
within the vasculature.  tPA has been found to induce matrix metalloproteinase-9 
gene expression in rat kidney interstitial fibroblast and promote activation of murine 
myofibroblasts (Hu et al. 2007), control permeability of the blood brain barrier 
(Yepes et al. 2003), facilitate migration of monocytes across the BBB into the 
central nervous system (Reijerkerk et al. 2008) and coordinate macrophage 
migration under inflammatory conditions (Cao et al. 2006).  Interestingly, this 
diversity in function appears to be dependent on tPA interaction with LRP, which 
initiates activation of signalling cascades, whilst not always requiring the proteolytic 
activity of tPA. Expression of both tPA and SerpinB2 by monocytes, macrophages 
and myeloid progenitors within normal bone marrow (McWilliam et al. 1998), 
suggests a physiological role for SerpinB2 as an inhibitor of tPA associated with 
derivatives of the myeloid stem cells. The differential endocytosis mechanisms 
identified in our work suggest that while SerpinE1 and SerpinB2 both function 
similarly in the control of plasmin generation by tPA at the cell surface, they may 
have opposing effects on the non-classical roles of tPA and activation of signalling 
cascades via LRP or indeed VLDLR. 
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The molecular mechanisms and biological significance of a role for VLDLR in the 
endocytosis of tPA or tPA:PAI complexes are poorly understood.  VLDLR is not 
found within the liver, however it is expressed at varied levels throughout the body 
(Strickland et al. 2002). Therefore, whilst the SPR analyses indicated that tPA and 
tPA:PAI bound to VLDLR with approximately 2-fold lower binding affinities than to 
LRP (Table 3.2), it is plausible that VLDLR may also play an important role in local 
clearance of tPA and tPA:PAI complexes. This could be through removal of 
proteolytic activity and/or potentiation of downstream signalling cascades through 




4. Biochemical analysis of SerpinB2 reveals chaperone-

















SerpinB2 exists primarily as a non-glycosylated 47 kDa intracellular protein and is 
significantly up-regulated during cellular stress responses, differentiation, 
proliferation and innate immunity.  However, a defined serine protease binding 
partner for intracellular SerpinB2 has not yet been described, suggesting additional 
functions for this protein, independent of its role as a serpin. The distribution of 
SerpinB2 within the nucleus and cytosol, combined with high expression during 
cellular stress is consistent with a role in cellular pathways associated with stress 
responses. Molecular chaperones are classical stress response proteins, which 
act to stabilise unfolded proteins and can promote refolding and/or degradation of 
misfolded proteins (Hartl et al. 2011). Therefore, we have investigated a potential 
role for SerpinB2 in functional activities classically associated with intracellular 
protein stress responses by assessing its function as a molecular chaperone. As 
molecular chaperones have been shown to bind specifically to misfolded or 
aggregated proteins via hydrophobic interactions (Hartl et al. 2011), we conducted 
ELISA based binding assays and found that SerpinB2 preferentially binds 
misfolded proteins. SerpinB2 was also found to be an efficient inhibitor of 
amorphous aggregation in some but not all models tested and an efficient inhibitor 
of amyloid beta peptide aggregation measured in real-time. Our results indicate 
that while SerpinB2 binds specifically to misfolded proteins the interaction does not 
promiscuously shield inappropriate protein-protein interactions. This suggests that 
whilst not a universal chaperone, SerpinB2 does exhibit chaperone-like activity, 
which may contribute to its cytoprotective functions in vivo. 
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4.2. Introduction 
SerpinB2 is a member of the Serine Protease Inhibitor super family and exists 
within the extracellular or intracellular environment. Secreted as a 47 kDa or 
glycosylated 60 kDa protein, extracellular SerpinB2 is thought to function as an 
inhibitor of the urokinase plasminogen activator and to a lesser extent, tissue-type 
plasminogen activator (Kruithof et al. 1995) (Lobov et al. 2008; Lee et al. 2010). 
However, the majority of SerpinB2 is found within the intracellular environment, as 
a 47 kDa protein. Whilst the 47kDa SerpinB2 maintains its inhibitory activity (Al-
Ejeh et al. 2004), a target intracellular protease has not yet been defined, which 
suggests a role independent of the classical inhibitory mechanisms, characteristic 
of Serpins (Law et al. 2006). Importantly, SerpinB2 expression appears to be 
associated with inflammation and cellular stress (recently reviewed in (Schroder et 
al. 2010; Lee et al. 2011; Medcalf 2011)). 
 
The main physiological producers of SerpinB2 are cells of the myeloid lineage, i.e 
monocytes and macrophages (Kruithof et al. 1995). It is not surprising then, that 
high SerpinB2 expression profiles have been described for activated microglial 
aggregates, co-localised with senile plaques in brain sections from Alzheimer’s 
disease patients (Akiyama et al. 1993; Walker et al. 2006). More recently however, 
an association of SerpinB2 with Amyloid Lateral Sclerosis (ALS) was described, 
whereby, primary cultures of cortical neurons isolated from the SOD1 (G93A 
mutation) transgenic animal model, incubated under oxidative stress conditions, 
showed an 8 fold increase in SerpinB2 mRNA expression, relative to non-
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transgenic control models, cultured under the same conditions (Boutahar et al. 
2011).  Furthermore, SerpinB2 was recently identified as one of the 9 core 
“Activity-regulated Inhibitor of Death (AID)” genes that mediate neuroprotection by 
N-methyl-D-aspartate (NMDA) receptor-induced calcium signalling. Within 3 h 
after injection of other glutamate analogues, such as kainic acid, into the brain 
SerpinB2 expression is increased by greater than 1800-fold (Zhang et al. 2009). 
Whilst adenoviral over-expression of SerpinB2 in the brain was protective against 
this insult (Zhang et al. 2009), the functional mechanism was not defined. Taken 
together these results suggest a potential role for SerpinB2 at sites of inflammation 
within the CNS. 
 
Importantly, disruption of normal protein homeostasis (proteotoxic stress) is 
integral to the pathophysiology of both acute injury associated inflammation, 
neuronal dysfunction and age related neurodegeneration. Therefore, cellular 
quality control systems, such as the molecular chaperone network, are essential 
for maintaining proteostasis (Morimoto 2008). Chaperones are traditionally defined 
as molecules which interact with other proteins undergoing folding or unfolding 
conformational changes, specifically stabilizing intermediate non-native forms and 
either facilitating their conformational arrangement into a functional native state 
(foldases) or preventing aggregate formation between misfolded intermediates 
(holdases) (reviewed in (Tyedmers et al. 2010; Hartl et al. 2011)). Aberrant protein 
conformations are problematic in that they may become cytotoxic either through 
loss or gain of function and as such, form the basis of disease (Carrell and Lomas 
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1997). Furthermore, overloading of the chaperone network in response to cellular 
stress gives rise to protein aggregates which accumulate and may also become 
cytotoxic (Bucciantini et al. 2002).  
 
As alluded to above SerpinB2 is one of the most up-regulated proteins in neurons 
and cells of the myeloid lineage in response to infections and inflammatory 
mediators, representing up to 1% of total intracellular protein following cellular 
stress (Schroder et al. 2010; Lee et al. 2011; Medcalf 2011). However, the 
relationship between the up-regulated expression, protein interactions, and the 
putative cytoprotective role of SerpinB2 is unclear. Of interest, chaperone activity 
has been described for other members of the serpin super family, such as sHsp47 
(SerpinH1/H2 (Gettins 2002)) (Sauk et al. 2005), which is a collagen binding/carrier 
molecule and human alpha(1)-antitrypsin (AAT) (SerpinA1), which has been 
shown to inhibit protein aggregation using a variety of common substrate models  
(Zsila 2010).  More recently, chaperone functions have also come to include 
macro-complex assembly, protein transport and direction of deleterious protein 
conformations into proteolytic degradation pathways, in addition to their protein 
folding functions (Hartl et al. 2011).  In this context, some extracellular, non-
inhibitory serpins function as transport proteins, for example; SerpinA6 is a major 
transporter of glucocorticoids and progestins within blood (Westphal 1986; 
Hammond et al. 1987; Pemberton et al. 1988; Hammond 1990) and SerpinA7 is a 
thyroxine transporter (Pemberton et al. 1988). Therefore, given the precedent 
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within the literature we hypothesised that SerpinB2 may also function within 
cellular pathways as a chaperone.  
 
4.2.1. Specific Aims 
A defining characteristic of chaperones is their ability to bind to misfolded or 
unfolded proteins (substrates), via hydrophobic residues which are normally buried 
within the three-dimensional structure of the native protein (Feder and Hofmann 
1999; Schroder and Kaufman 2005; Nardai et al. 2006; Korcsmaros et al. 2007). 
Protein aggregation is also driven by hydrophobic forces and primarily results in 
amorphous protein structures or highly ordered fibrillar aggregates (termed 
amyloid), which are defined by β-strands that run perpendicular to the long fibril 
axis (cross-β structure) (Westermark et al. 2007; Eichner et al. 2011). Importantly, 
the latter is characteristic of neurodegenerative disorders such as Alzheimer’s 
disease, Huntington disease, Parkinson’s disease and ALS (Muchowski and 
Wacker 2005). Therefore, the specific aims of this chapter were to investigate the 
possibility that SerpinB2 could act as a chaperone using in vitro biochemical 
analysis of these key characteristics.  Specifically, an ELISA based assay was 
utilised to examine the binding of SerpinB2 to misfolded substrates. We then 
assessed the ability of SerpinB2 to inhibit amorphous forming aggregation models 
in real-time using a light scattering microplate based assay. Finally, we aimed to 
investigate the ability of SerpinB2 to inhibit fibrillar aggregation, using the 
aggregation prone amyloid-β 1-40 amino acid peptide, or the rapidly aggregating 
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amyloid-β 1-42 amino acid peptide, associated with Alzheimer’s disease, within 





Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd 
(Sydney, Australia). Bovine serum albumin (BSA), bovine Cu/Zn superoxide 
dismutase (SOD1), Rabbit muscle creatine phosphokinase (CPK), dithiothreitol 
(DTT), iodoacetic acid, monoclonal antibody against ovalbumin, o-
phenylenediamine dihydrochloride (OPD), ovalbumin (SerpinB14), porcine citrate 
synthase (CS), Thioflavin-T, casein, thimerosal, protease inhibitor cocktail and 
urokinase plasminogen activator from human urine (uPA) were all from Sigma-
Aldrich. were from Bio-Rad Laboratories, Inc. Human recombinant αB-crystallin 
was a kind gift from Dr Heath Ecroyd (University of Wollongong) (Horwitz et al. 
1998). Monoclonal antibody against human SerpinB2 (#3750) was from American 
Diagnostica Inc.  Microtitre 96 and 384 well plates were from Greiner. Tissue 
culture supernatant containing antibody against human clusterin from the 
hybridoma clone "G7" (5-10 ug.mL-1) (Humphreys et al. 1999) and purified human 
clusterin from whole blood were a kind gift from Professor Mark Wilson (University 
of Wollongong). Amyloid-beta peptide 1-40 (Aβ1-40) and NH4OH was from Anaspec. 
Amyloid-beta 1-42 (Aβ1-42) was from Biopeptide, USA. Millex syringe filters (0.45 
µm) were from Millipore. The concentration of protein in solution was estimated 
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using the BioRad Dc Protein Assay kit, according to the manufacturer’s 
instructions, using BSA as the standard. 
 
4.3.2. Expression and Purification of Recombinant SerpinB2 
Wild-type human SerpinB2 (47 kDa) was purified from E. coli (M15) using the 
pREP4/pQE-9 expression system, followed by a secondary purification using 
anion exchange chromatography. Briefly, purified pQE9/SERPINB2 vectors 
were transformed into electro-competent M15 [pREP4] cells using standard 
methods. Cells were cultured overnight at 37 °C with shaking in TB containing 
100 μg/mL ampicillin and 25 μg/mL kanamycin. A 20 mL aliquot of this starter 
culture was added to 1 L TB and grown to an OD600 of ~0.6. Expression of 
SerpinB2 was induced by the addition of 0.5 mM IPTG and the culture incubated 
overnight at 18°C. Cells were collected by centrifugation at 10,000 g for 10 min. 
Pelleted cells were resuspended in 15 mL of ice-cold loading buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 7.0, containing protease inhibitor cocktail) and 
lysed using a French press (Thermo, USA). The cell lysate (~20 mL) was then 
incubated with 2.5 μg of DNase for 30 min on ice and cell debris pelleted by 
centrifugation at 17,000 g for 30 min. The supernatant was loaded onto 3 mL 
equilibrated TALON metal affinity resin at a rate of 1 mL/min. Unbound proteins 
were removed using 20 column volumes of loading buffer. Bound protein was 
eluted from the column using elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
150 mM imidazole, pH 7.0). Samples were buffer exchanged into 20 mM Tris, 
pH 8 using PD10 column and then loaded onto a mono-Q (5/50 GL) anion 
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exchange column (GE Healthcare) at room temperature. The column was then 
washed with 20 bed volumes of 20 mM Tris, pH 8 prior to elution of bound protein 
by a NaCl gradient with salting buffer (20 mM Tris, 1 M NaCl, pH 8), increasing 
NaCl concentration from 0 to 80% over 2 h, with flow rate at 1 mL.min-1. Purified 
SerpinB2 was then buffer exchanged by dialysis, PD10 columns or Amicon Ultra-
4 centrifugal filter units (MWCO 10 KDa) into PBS (140 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.4 mM KH2PO4, 0.02% NaN3 pH 7.4). Purity and integrity of 
the recombinant protein was assessed by SDS PAGE (Fig. 4.1). Purified protein 
was stored at 4 C until required.  
 
 
Figure 4.1: Representative gel showing visualisation of recombinant 
SerpinB2 protein following anion exchange chromatography. Fractions 
(Lanes 1-5) (20 µL) were prepared using non-reducing sample buffer and 
resolved by 10% SDS PAGE (see section 4.3.8). Purified monomeric SerpinB2 
(*) and polymerised SerpinB2 (¥) was recovered with minimal low molecular 
weight impurities (§) and lanes 1-4 pooled for use in experiments. Precision dual 
























Recombinant SerpinB2 made in house was used interchangeably with 
recombinant SerpinB2 from SerpinB2 Pty Ltd/Biotech Australia (Sydney, 
Australia), with comparable results. 
 
4.3.3. Heat denatured Casein (HDC) 
PBS was heated to 70 ºC and 1 % w/v casein added followed by continuous stirring 
for 2-3 h at 70 ºC. The solution was then cooled prior to the addition of 0.01% w/v 
Thimerosal and pH adjusted to 7.4. 
 
4.3.4. End-point binding assays 
Protein substrates in PBS were incubated overnight in 96 well microplates as 
follows: BSA (1 mg.mL-1) was incubated at 37 C in the absence (control) or 
presence of 20 mM DTT (reducing misfolded); creatine phosphokinase or citrate 
synthase (250 µg.mL-1) were incubated at 4 C (control) or 43 C (heat denaturing); 
(lysozyme 1 mg.mL-1) was incubated overnight at 37 C in the absence (control) 
or presence of oxidative stress buffer (OSB) (100 µM CuSO4, 4 mM H2O2). 
Unbound protein was removed by 2 x 5 min washes with wash buffer (1 x PBS, 
0.1% triton-X100). Plates were then incubated for 1 h with blocking buffer (1 x PBS 
containing 0.02% (w/v) NaN3 and 1% BSA). Unless otherwise stated wells were 
then incubated with 5 mM iodoacetic acid (IAA) in PBS at 37 C for 1 h to acetylate 
free sulphydryl groups of cysteine residues.  Prepared plates were then incubated 
with either a serial dilution (6.25 - 250 µg.mL-1, 1.3 nM – 5.3 µM) or fixed 
concentration of SerpinB2 (100 µg.mL-1), SerpinB14 (ovalbumin) (250 µg.mL-1, 5.5 
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µM; negative control) or clusterin (50 µg.mL-1, 800 nM; positive control) for 1.5 h 
at 37 C.  The plates were then washed 3 times with wash buffer and incubated 
with blocking buffer for 1 h at 37 C prior to the addition of primary monoclonal 
antibodies to either SerpinB2 (1:1000), SerpinB14 (1:30000), or clusterin (25 
µL.well-1 hybridoma culture supernatant) and incubated at 37 C for 1.5 h.  Wash 
and blocking steps with heat misfolded casein (HDC 1% w/v in PBS, containing 
0.04 % thimerosal) were repeated prior to the addition of HRP conjugated 
secondary antibody (1:2000) in HDC/PBS. After 1 h at 37 C the plates were 
washed 3 x 10 min with TBS-T buffer (50 mM Tris, 150 mM NaCl, 0.05% v/v 
Tween-20) followed by 3 x 10 min washes with TBS (50 mM Tris, 150 mM NaCl). 
Bound antigens were detected using 2.5 mg.ml-1 ortho-phenylenediamine (OPD) 
substrate in citrate buffer (50 mM citric acid, 100 mM Na2HPO4, pH 5) containing 
0.03% H2O2 and absorbance at 490 nm was measured after 10 min using a 
Spectramax 250 plate reader (Molecular Devices, USA) and Softmax Pro 
software.  Unless otherwise stated, the volume per well for all protein solutions and 
buffers was 100 μL. All incubation and wash steps were conducted at 37 C with 
gentle agitation. Assays were conducted in triplicate and data analysed in 
GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego 
California USA, www.graphpad.com), with background controls subtracted. 
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4.3.5. Light Scattering Assays 
 
4.3.5.1. Heat Denaturing Stress: 
Working solutions of CS (706 nM) in the absence or presence of an equimolar ratio 
of either SerpinB2, αB-crystallin (positive control) or SOD1 (negative control) were 
prepared in filtered 40 mM HEPES-KOH Buffer, pH 7.5 then aliquoted into wells of 
a 384 well microplate and incubated at 43 C for 4 h. Turbidity measurements 
(absorbance at 360 nm, A360) were acquired at 5 min intervals using a FLUOstar 
Optima plate reader (BMG Labtech, Germany).  
 
4.3.5.2. Reducing Stress: 
BSA (15 µM) or BSA with either SerpinB2 (21 µM), αB-crystallin (50 µM) (positive 
control) or SerpinB14 (22 µM) (negative control) were prepared giving 1:1 
weight/weight ratios in filtered reducing buffer (PBS, 20 mM DTT, 0.02% NaN3, pH 
7.4) then aliquoted into wells of a 96 well microplate in triplicate and incubated at 
37 C overnight. Turbidity measurements (absorbance at 360 nm, A360) were 
acquired at 5 min intervals using a FLUOstar Optima plate reader (BMG Labtech, 
Germany). 
 
4.3.5.3. Oxidative Stress: 
Working solutions of lysozyme only or lysozyme and SerpinB2, α-crystallin or 
SerpinB14 (negative control) at 20:1 molar ratios (French et al. 2008), were 
prepared in filtered PBS then aliquoted into wells of a 384 well microplate and 10 
x oxidative stress buffer (OSB: Filtered PBS, 1 mM CuSO4, 40 mM H2O2, 0.02% 
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NaN3) added to all wells just prior to plate incubation at 37 C for 4 h. Absorbance 
readings (360 nm) were acquired at 5 min intervals using a FLUOstar Optima plate 
reader (BMG Labtech, Germany). 
 
4.3.6. Fibril formation - Amyloid-β: 
4.3.6.1. Amyloid-β 1-40 Peptide 
Prior to use amyloid-β 1-40 peptide (Aβ1-40) was resuspended in 20 mM NH4OH to 
a final concentration of 1 mM, then diluted to 500 µM with milli-Q H2O. The samples 
were then aliquoted and frozen at -80 °C until required, as recommended by the 
supplier. This preparation step was conducted by Dr Heath Ecroyd (University of 
Wollongong) who generously supplied this reagent as a gift for use on this project. 
 
On the day of the experiment an aliquot was diluted to 50 µM with ice cold 
phosphate buffer (0.45 µm filtered 50 mM NaH2PO4, 100 mM NaCl, pH 7.4). 
Working solutions of Aβ1-40 (25 µM) in the absence or presence of 2.5 µM 
SerpinB2, αB-crystallin and SOD1 (negative control) were prepared on ice in 
phosphate buffer. Aggregation of the Aβ1-40 peptide was monitored in real time by 
following thioflavin-T fluorescence. 10 µM thioflavin-T (thio-T) was added and 
solutions immediately transferred to wells of a 384 well microplate and incubated 
for 12 h at 37 °C. Samples were excited at 440 nm and fluorescence intensity 
(emission 485+/-10 nm) was acquired at 5 min intervals using a FLUOstar Optima 
plate reader (BMG Labtech, Germany). Assays were conducted in duplicate, 
repeated twice and data analysed in GraphPad Prism version 5.00 for Windows, 
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GraphPad Software, San Diego California USA, www.graphpad.com, with 
background controls (buffer containing 10 µM thio-T) subtracted. 
 
4.3.6.2. Amyloid-β 1-42  Peptide  
Given the propensity of amyloid-β (Aβ) to aggregate, stock solutions were 
prepared as previously described (Bolognesi et al. 2010). Prior to use amyloid-β 
1-42 peptide (Aβ1-42) was dissolved at 1 mg.mL-1 in trifluoroacetic acid (TFA) 
followed by sonification for 30 s. TFA was then removed over night by lyophilisation 
and the Aβ1-42 was then redissolved in 1 mL hexafluoroisopropanol (HFIP), 
aliquoted and HFIP removed by speed-vac. Samples were then frozen at -20 °C 
until required. All preparation steps were carried out at 4 °C with pre-chilled 
reagents. On the day of the experiment an aliquot was resuspended on ice in 
filtered Milli-Q H2O, mixed using a sample oscillator (Millipore) for 60 s and 
immediately placed back on ice.  10 x PBS was then added to give a 250 µM Aβ1-
42 working stock in PBS and the sample placed in an ice cold sonication bath for 
30 s prior to use. These solutions of Aβ1-42 were then used in thio-T assays at 25 
µM, final concentration, as described for Aβ1-40 (section 4.4.5.1) with the following 
exception in method; aggregation of Aβ1-42 was monitored in real time by adding 
25 µM thio-T. 
 
4.3.6.3. Scanning electron microscopy (SEM) 
Aβ1-42 peptide (25 µM) was incubated for 12 h at 37 °C in the absence or presence 
of 2.5 µM SerpinB2, αB-crystallin or SOD1. Samples from each reaction were 
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resuspended at a total protein concentration of 0.1 mg/mL in PBS and 2 µL of each 
sample was blotted onto carbon coated nickel 400 mesh grids covered in formvar 
resin (Gilder TEM grids, Proscitech, Townsville, Australia), incubated for 5 min at 
RT, washed three times with filtered dH2O and negatively stained with 1% uranyl 
acetate in milli-Q dH2O. The specimens were then visualised using a JSM7500FA 
cold Field Emission Gun Scanning Electron Microscope (JEOL) with an 
acceleration voltage of 20.0 kV and a working distance of 8 mm (spot size setting 
of 8). The detector used was a transmission electron detector (TED) mounted 
beneath the specimen platform. Secondary electron images were taken with a 
semi in-lens detector at a working distance of 8.0 mm. SEM imaging was kindly 
conducted by Patrick Constantinescu (University of Wollongong). 
 
4.3.7. Protease:Serpin complex formation 
End-point samples were taken from thio-t assays, as described in section 4.3.5.2. 
Briefly, SerpinB2 (2.5 µM) was incubated for 12 h at 37 °C in the absence (control) 
or presence of 25 µM Aβ1-42 and 25 µM thio-T. Samples from each reaction were 
then taken and incubated in the absence or presence of uPA (1.25 µM) for 30 min 
at 37 °C. Formation of protease:SerpinB2 complexes were then assessed by 
western blotting. Briefly, samples were resolved by 10 % SDS PAGE and 
transferred onto ImmobilomTM-P PVDF (Millipore, USA) membrane, using a Bio-
Rad Mini Trans-Blot system.  The membrane was prepared and protein blotting 
apparatus was assembled according to the manufactures instructions with 
electrophoresis conducted at 4oC for one h at 100 V.  Once the transfer was 
complete (ensured by complete transfer of pre-stained markers (BioRad, 
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Australia)), blots were blocked with 10% skim milk powder in Tris-buffered saline 
(TBS) with 0.05% (v/v) Tween-20 (TBST) overnight at 4oC.  The blots were then 
rinsed three times with TBST for 5 min per wash.  Rabbit α-uPA polyclonal antibody 
(1:500) or mouse α-SerpinB2 monoclonal antibody (1:1000) were applied in 2% 
milk/TBST and blots were incubated for 2 h, at RT on a shaker.   The membrane 
was washed with TBST for 10 min, followed by three 5 min rinses with TBST.  The 
blot was then re-blocked with 6% milk/TBST for 30 min at RT followed by one rinse 
with TBST for 5 min.  Detection of bound primary antibody was conducted using 
the appropriate horse radish peroxidise (HRP) labelled secondary antibody, which 
was applied at a final concentration of 1:5000 in 2% milk/TBST for 1 h, at RT.  
Three 5 min rinses with TBST were conducted to remove unbound secondary 
antibody followed by three 5 min rinses with TBS. 
 
Protein detection was visualised by an enhanced chemiluminescence (ECL) 
reaction using SuperSignal® Substrate for Western Blotting as per manufacturer’s 
instructions (Progen, Australia). The membranes were exposed to X-ray film in a 
X-Omatic Cassette (Kodak) for 5 to 30 min depending on the strength of the signal.  
The film was then placed in Developer solution (Kodak) for 2 min, rinsed in water 




4.3.8. Protein Concentration Assay 
Unless otherwise specified, the concentration of protein in solution was estimated 
using the BioRad Dc Protein Assay kit, according to the manufacturer’s 
instructions, using BSA as the standard.  Absorbance was measured at 750 nm 
using a Molecular Devices SpectraMax 250 plate reader, and SoftMax® Pro 
software (Molecular Devices, USA).  
 
4.3.9. Sodium Dodecyl Sulphate – Polyacrylamide Gel 
 Electrophoresis (SDS-PAGE) 
 
All SDS PAGE analysis was conducted using 10% polyacrylamide resolving gel 
and 4% polyacrylamide stacking gel in a Bio-Rad Mini Protean Gel system (Bio-
Rad, Australia).  Samples of 30 μL were prepared with 5 x non-reducing sample 
buffer and boiled for 5 min prior to loading.  Electrophoresis was run at 160 V for 
2 h in 1 x SDS running buffer.  Bio-Rad low molecular weight markers were used 
to determine approximate protein size.   
 
4.4. Statistical analysis 
Statistical significance was determined by Students t-tests using GraphPad Prism 
version 5.00 for Windows, GraphPad Software, San Diego California USA 






4.5.1. End-point binding assays 
The ability of SerpinB2 to interact with native or misfolded client proteins, routinely 
used in the biochemical analysis of chaperone activity, was first determined using 
an ELISA approach. SerpinB2 was found to bind preferentially, in a saturable 
manner, to reduction (DTT)-stressed BSA (Fig 4.2A), oxidised lysozyme (Fig 
4.2B), and heat-stressed CPK (Fig 4.2C), as negligible binding to native proteins 
was detected. Analysis of specific binding affinities, determined by non-linear fit 
with one-site binding model (Y=Bmax*x/(Kd+x)), between SerpinB2 and reduction-
stressed BSA or heat-stressed CPK were similar with apparent KD of 0.705 µM (± 
0.131 µM SEM) and 0.818 µM (± 0.114 µM SEM), respectively, whilst the apparent 
KD between SerpinB2 and oxidative-stressed lysozyme was 1.927 µM (± 0.323 µM 
SEM) (Tab 4.2).  In contrast, SerpinB2 bound at low levels to both native and heat-
stressed CS (Fig. 4.2D). 
 
Low levels of SerpinB14 (ovalbumin) (negative control) were also found to interact 
preferentially with reduction-stressed BSA (Fig.4.2.E) and oxidised lysozyme 
(Fig.4.2.F). However, comparison of fold increases in binding interaction observed 
for each Serpin shows a 285 fold increase for SerpinB2 interaction with misfolded 
BSA – relative to native BSA - compared to 17.5 fold increase observed for 
SerpinB14 (Fig.4.2.E). Furthermore an 8-fold increase in SerpinB2 interaction with 
oxidised-lysozyme was observed – relative to native lysozyme - compared to a 3 
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fold increase in SerpinB14 (Fig.4.2F). In contrast, SerpinB2 binding interaction with 
heat misfolded CPK increased 5-fold – relative to control CPK- whilst there was no 
detectable interaction observed between SerpinB14 and either native or heat-
stressed CPK (Fig.4.2G); nor native or heat-stressed CS (Fig.4.2H), which 











































































































































































































































Figure 4.2: SerpinB2 binds preferentially to misfolded proteins. Left panel: 
Dose dependent binding of SerpinB2 to native and misfolded proteins was 
determined using an ELISA system with relevant specific antibodies and controls.  
(A) BSA (1 mg.mL-1) was incubated overnight at 37 °C in the absence (native 
control) or presence of 20 mM DTT (Reduced BSA) (B) Lysozyme (1 mg.mL-1) was 
incubated overnight at 37 °C in the absence (control) or presence of OSB (100 µM 
CuSO4 and 4 mM H2O2; Oxidised Lysozyme) (C) CPK and (D) CS (250 µg.mL-1) 
were incubated overnight at 4 °C (control) or 43 °C (heat misfolded). Right panel: 
Fold increase in SerpinB2 or SerpinB14 (control) interaction with misfolded 
substrates, compared to controls. ELISA plates containing (E) BSA, (F) 
Lysozyme, (G) CPK and (H) CS were prepared as per (A - D) and specific binding 
of either SerpinB2 or SerpinB14 (250 µg.mL-1) was determined as above. Data has 
been normalised to control (native) protein and represents mean fold increase in 
detectable interactions ± SEM, n=3. Asterisks denote significant differences, 
***p<0.001. ****p<0.0001, NS = not significant. 
 
 
Table 4.1:  Kinetic parameters for binding of SerpinB2 to misfolded protein 
substrates. 
Stressed 
Substrate appKD ± SEM (µM) BMAX ± SEM DF R2 
BSA 0.705 (0.131) 2.006 (0.109) 22 0.897 
Lysozyme 1.927 (0.323) 0.893 (0.066) 19 0.958 
CPK 0.818 (0.115) 2.096 (0.090) 22 0.945 
CS N.D    
Specific binding was analysed by a non-linear fit regression using GraphPad. The data best fit a 













4.5.2. Real-time protein aggregation 
 
4.5.2.1. Amorphous aggregation models 
Given that SerpinB2 binds specifically to some unfolded proteins, we next tested 
its ability to inhibit the stress-induced aggregation of the same client proteins. 
When tested at the same w/w ratio to client protein, SerpinB2 (21 µM) inhibited the 
DTT-induced aggregation of BSA (15 µM) to the same extent as αB-crystallin (50 
µM) a well characterised chaperone (positive control) (Fig.4.3.A and B). 
Interestingly, this level of aggregation inhibition was only observed when the real-
time light scattering assay was conducted within a 96 well microplate (Fig.4.3.A).  
When the assay was conducted within a 384 well plate, under the same conditions, 
SerpinB2 was found to be less efficient (Fig.4.3.C). The variability in chaperone 
activity observed between the two plate formats may be related to aggregation 
dynamics, whereby loss of chaperone function is correlated with increasing rate of 
substrate aggregation (Lindner et al. 2001). This is supported by the finding that a 
1 mg.mL-1 solution of BSA/DTT aggregated faster and to a greater extent within 
the 384 well plate (Fig.4.3.C), compared to that within a 96 well plate (Fig.4.3.A) 
as is shown by the A360 trace over time.  Regardless, in both assay formats 
SerpinB2 was able to at least partially inhibit BSA aggregation suggesting potential 
chaperone activity for this serpin under reducing conditions. In comparison, 
SerpinB14 (22 µM) enhanced aggregation of BSA within the 96 well plate based 
assay, when used at the same w/w ratio as SerpinB2 (Fig.4.3.A). Furthermore, 
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when incubated alone under the same conditions, the serpins and αB-crystallin did 
not aggregate (Fig.4.3B). 
 
 
Figure 4.3. SerpinB2 inhibits aggregation of BSA under reducing stress. 
BSA (1 mg.mL-1) was incubated for 15 h at 37 °C in the presence of 20 mM DTT 
in the absence or presence of SerpinB2, αB-crystallin or SerpinB14 (1:1 w/w) 
within either a (A) 96 or (C) 384 well plate.  Controls are shown in panel (B and 
D) for each experiment respectively. In all assays, aggregation was determined 
in real time by assessing changes in turbidity (A360 nm). Data = mean ± SEM 
with appropriate background controls subtracted, n=3. 
 
We next investigated the chaperone activity of SerpinB2 under oxidative stress 
using the substrate lysozyme, as previously described (French et al. 2008). 
SerpinB2 is known to polymerise under these conditions (Wilczynska et al. 2003; 




































































Lobov et al. 2004), however the physiological function of this property is unknown. 
SerpinB2 enhanced aggregation of lysozyme incubated at 37 °C in oxidative stress 
buffer (OSB) at a molar ratio of 20:1 (Lysozyme:SerpinB2) (Fig. 4.4.A). SerpinB14 
(negative control) used at the same molar ratio (20:1) also enhanced aggregation 
of lysozyme, however the affect was greater than that seen for SerpinB2 (Fig. 
4.4.B). It is important to note that incubation of SerpinB2 or SerpinB14 only in the 
presence of OSB did not result in detectable protein aggregation (Fig. 4.4.B.). 
 
 
Figure 4.4: SerpinB2 enhances amorphous aggregation of Lysozyme 
under oxidative stress. Lysozyme (70 µM) was incubated at 37 °C for 4 h under 
oxidative stress conditions in the absence or presence of (A) SerpinB2 or (B) 
SerpinB14 (20:1 molar ratio). In all assays, aggregation was determined in real 
time by assessing changes in turbidity (A360). Data represents mean ± SEM 
with appropriate background controls subtracted, n=3.  
 
 
We next investigated SerpinB2 chaperone activity in the presence of CS, under 
heat denaturing conditions (Fig. 4.5).  SerpinB2 had no effect on CS aggregation 
at a 1:1 molar ratio and was indistinguishable to SOD1 (negative control), which 




within the end-point binding assays (refer to Fig.4.1), whilst αB crystallin reduced 




Figure 4.5: SerpinB2 does not inhibit amorphous aggregation of Citrate 
Synthase (CS) under heat stress. CS was incubated in the absence or 
presence of (A) SerpinB2, αB-crystallin or (B) SOD1 at 1:1 molar ratio for 4 h at 
43 °C. Also shown in (B) are protein only controls. In all assays, aggregation was 
determined in real time by assessing changes in turbidity (A360). Data 
represents mean ± SEM with appropriate background controls subtracted, n=3. 
 
 
4.5.2.2. Amyloid-β peptide Fibril formation 
Given the co-localisation of SerpinB2 with microglial aggregates, in association 
with senile plaques of Alzheimer’s patients (Akiyama et al. 1993), up-regulation of 
SerpinB2 by microglia following activation by incubation with amyloid-β 1-42 
peptide for 24 h (Walker et al. 2006) and other published works showing 
interactions between amyloid-β and other Serpin family members (Schubert 1997; 
Janciauskiene et al. 1998; Kinghorn et al. 2006; Chiou et al. 2009) we also 
investigated the potential for SerpinB2 to inhibit fibril formation of amyloid-β peptide 
(Aβ) using a standard thio-T fluorescence assay. SerpinB2 was able to completely 


































inhibit Aβ1-40 peptide from aggregating at a 10:1 molar ratio of Aβ1-40:SerpinB2 
(Fig.4.6.A). The efficiency was comparable to that of αB-crystallin used at similar 
molar ratios (Fig.4.6.A). SerpinB2 was not as efficient as αB-crystallin at inhibiting 
the faster aggregating Aβ1-42 peptide (Fig.4.6.B). SerpinB2 was able to inhibit fibril 
formation by Aβ1-42 peptide during the first 5 h of incubation as seen by the 
extended lag phase, but this was not sustained as a substantial increase in thio-T 
fluorescence was observed in the latter part of the real-time assay (Fig.4.6.B). In 
comparison, αB-crystallin completely inhibited Aβ1-42 fibril formation for the 






Figure 4.6:  SerpinB2 inhibits the formation of amyloid fibrils in vitro. 
Amyloid peptide (A) Aβ1-40 or (B) Aβ1-42 were incubated at 37oC in the absence 
or presence of SerpinB2, αB-crystallin or SOD1 (negative control) at 10:1 
Aβ:protein molar ratio for 11 h. (C) No fibril formation was observed in protein 
samples alone. Fibril formation was determined using Thioflavin-T (25 µM) and 
change in relative fluorescence (490 nm) over time. Data represents mean 
fluorescence intensity with background controls subtracted, n=2. 
 
As a complementary approach to analyse the ability of SerpinB2 to inhibit Aβ 
peptide fibril formation, samples taken from Aβ1-42 solutions supplemented (or not) 
with SerpinB2, αB-crystallin or SOD1, and incubated for 12 h at 37oC were 
analysed by scanning electron microscopy (SEM). As expected under these 
conditions we observed the formation of fibrillar structures within both the Aβ1-42 
(Fig.4.7.A) and Aβ1-42:SOD1 (negative control) (Fig.4.7.B) solutions, indicating that 
SOD1 was unable to prevent fibril formation and this was consistent with results 





































































































obtained within the thio-T assays (Fig.4.6). Importantly, Aβ1-42 fibrilar structures 
were absent from the Aβ1-42:SerpinB2 (Fig.4.7.C) or Aβ1-42:αB-crystallin (Fig.4.7.D) 







Figure 4.7: Scanning Electron Micrographs of Aβ1-42 (25 µM) fibril 
formation in the absence (A) or presence of either (2.5 µM) SOD1 (B) 
(negative control), SerpinB2 (C) or αB-crystallin (D). Samples were incubated 
at 37oC of 12 h prior to mounting onto carbon coated nickel 400 mesh grids 
covered in formvar resin and visualised using a JSM7500FA cold Field 
Emission Gun Scanning Electron Microscope (JEOL) with an acceleration 





Previous work investigating the interactions between Aβ peptide and SerpinA1 
(alpha1-antichymotrypsin) (Janciauskiene et al. 1998) or SerpinI1 (neuroserpin) 
(Kinghorn et al. 2006) suggests that Aβ binding occurs within the β-sheet A of 
serpins, which in turn, obstructs complete RCL insertion upon protease inhibition 
and results in loss of inhibitory function (ref Fig. 1.1). To investigate this potential 
interaction between SerpinB2 and Aβ peptide we used end-point samples taken 
from the real-time assay shown in Fig. 4.6.B, and assessed SerpinB2 inhibitory 
activity by formation of uPA-SerpinB2 complexes using a gel-shift assay and 
western blotting. Samples were resolved and membranes probed for SerpinB2 
(Fig. 4.8). As expected, SerpinB2 only (positive control) (Fig. 4.8, Lane i) consisted 
of monomer and high molecular weight species indicative of polymerised SerpinB2 
(Wilczynska et al. 2003; Lobov et al. 2004). In the absence of Aβ1-42, SerpinB2 was 
able to form a high molecular weight complex with uPA (Fig. 4.8, Lane ii orange 
arrows). A small amount of cleaved SerpinB2 was present in this sample (Fig. 4.8, 
Lane ii; blue arrow), which is indicative of SerpinB2 acting as a uPA substrate 
(Silverman et al. 2001). Importantly, the bands corresponding to uPA:SerpinB2 
complex formation are diminished in the presence of Aβ1-42 peptide (Fig.4.8 lane 
iii;  orange arrows). Furthermore, the loss of signal intensity for complex formation 
coincided with an increased signal intensity for cleaved SerpinB2 (Fig. 4.8, Lane 
ii; blue arrow), indicating that the inhibitory activity of SerpinB2 is compromised in 










Figure 4.8. Aβ1-42:SerpinB2 complex formation inhibits Serpin activity. 
SerpinB2 was incubated for 11 h at 37 oC in the absence or presence of 10 molar 
excess Aβ1-42 peptide. SerpinB2 (2.5µM) activity was then assessed by complex 
formation with uPA (1.25 µM) at a 2:1 Serpin:protease molar ratio. Samples (15 
µL) were fractionated under non-reducing conditions by SDS PAGE and 
analysed by western blot. Detection of SerpinB2 was conducted with relevant 
primary and HRP-conjugated secondary antibodies as stated in the methods. 
















 SerpinB2 + + +  
 uPA - + +  
 Aβ1-42 - - +  
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4.6. Discussion 
Disruption of normal protein homeostasis (proteotoxic stress) is integral to the 
pathophysiology of both acute injury associated inflammation, neuronal 
dysfunction and age related neurodegeneration (Hipp et al. 2014). As described in 
section 4.2, recent research has shown that SerpinB2 expression is massively 
upregulated in neurons and immune cells after stress.  These observations, and 
the role of other serpin molecules in modulating proteostasis through chaperone-
like activities, such SerpinH1/H2 (Gettins 2002; Sauk et al. 2005), SerpinA1  (Zsila 
2010), SerpinA6 (Westphal 1986; Hammond et al. 1987; Pemberton et al. 1988; 
Hammond 1990) and SerpinA7 (Pemberton et al. 1988), led us to assess SerpinB2 
for chaperone activity, as a potential mechanism for the putative cytoprotective role 
described for SerpinB2. 
 
A defining characteristic of chaperones is their ability to bind to misfolded or 
unfolded proteins (substrates), via exposed hydrophobic residues which are 
normally buried within the three-dimensional structure of the native protein (Tompa 
and Csermely 2004; Schroder and Kaufman 2005). We show here that SerpinB2 
also binds preferentially to misfolded-stressed BSA, CPK and lysozyme, compared 
to their respective native-conformation controls and to either native or misfolded 
conformations of CS.  This shows that SerpinB2, like known chaperones such as 
αB-crystallin (Carver and Lindner 1998) and clusterin (Humphreys et al. 1999), is 
able to identify misfolded proteins. Whether the association of SerpinB2 with 
misfolded substrates occurs via hydrophobic interaction remains to be 
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investigated. Of note however, 44% of the amino acid residues within the highly 
mobile C-D loop of SerpinB2 are hydrophobic. Furthermore, the finding by 
(Wilczynska et al. 2003) that SerpinB2 undergoes redox sensitive conformational 
rearrangements via disulphide bond formation between C79, located within the C-
D loop, and C161 at the bottom of helix F, is of interest. Disruption of this bond by 
site directed mutagenesis (C79S), was shown to significantly increase the surface 
hydrophobicity of SerpinB2, as determined by an observed increase in the 4,4′-
Dianilino-1,1′-binaphthyl-5,5′-disulfonic acid dipotassium salt (bis-ANS) binding, a 
common dye used to identify or block pockets of hydrophobicity (Musci and 
Berliner 1985). It is tempting therefore, to speculate that these hydrophobic 
characteristics described for SerpinB2 contribute to the preferential binding of 
SerpinB2 to misfolded proteins and as such warrant further investigation. 
Interestingly, SerpinB14, used here as a negative control, also bound, 
preferentially, to misfolded-stressed BSA and lysozyme, compared to their relative 
controls, but not CPK or CS. Importantly, the fold increase in binding of SerpinB2 
to misfolded substrate, relative to controls, was consistently higher in magnitude 
than that seen for SerpinB14. Given the sequence identity of 36% (Benarafa and 
Remold-O'Donnell 2005) and sequence similarity of 33% between SerpinB2 and 
SerpinB14, it is possible that SerpinB14 contains exposed regions of 
hydrophobicity, which contribute to these observed binding interactions. 
 
Importantly, the ability of molecular chaperones to identify and interact with 
misfolded substrates typically corresponds with protection of the substrate from 
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aggregation (Hartl et al. 2011). In this respect, we show here that SerpinB2 
significantly inhibited the formation of amorphously structured BSA aggregates 
under reducing conditions and that this protective effect was indistinguishable from 
that of a classical chaperone, αB-crystallin at the same BSA:chaperone (1:1 w/w) 
ratio. It was therefore surprising to find that under oxidative conditions lysozyme 
aggregation was enhanced by SerpinB2. However, this observation is supportive 
of the increased hydrophobicity of SerpinB2 upon disruption of the C79-C161 
disulfide bond, described by Wilczynska et al. (2003), which would also occur 
under reducing conditions. In the presence of oxidative stress, formation of the 
C79-C161 disulfide bond would be favourable, potentially not allowing the increase 
in hydrophobicity and disrupting chaperone activity by decreasing hydrophobic 
interactions.  The loss or gain of chaperone activity in response to changes in redox 
states, pH or temperature is well documented, for example, Hsp33 is a redox 
sensitive chaperone found in bacteria and is activated under oxidative conditions 
(Graumann et al. 2001) (Kumsta and Jakob 2009). Furthermore, the chaperone 
activity of clusterin was found to been enhanced by reduction in pH (Poon et al. 
2002), whilst that of αA-crystallin is enhanced by increased temperature (Bova et 
al. 1997). Interestingly, the increased chaperone activity described for αA-crystallin 
coincided with increased hydrophobicity, as determined by BIS-ANS binding 
assays (Das and Surewicz 1995). Of note, SerpinB2 alone did not aggregate in 
the presence of oxidative stress, therefore it seems most likely that SerpinB2 
interaction with lysozyme, possibly through disulphide bond formation, enhances 
the rate of aggregation. Therefore it is possible that the substrate model used for 
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investigation of SerpinB2 chaperone activity, under oxidative stress conditions 
may not be suitable and further experiments are required to characterise the 
efficiency of SerpinB2 to inhibit aggregation undergoing oxidative stress.  
 
SerpinB14 was found to enhance aggregation of BSA and lysozyme under the 
same experimental conditions for SerpinB2. Interactions between lysozyme and 
SerpinB14, undergoing heat-stress have been reported previously (Matsudomi 
1986; Matsudomi 1987) and thought to occur via electrostatic attraction and 
sulfhydryl-disulfide interchange. Recent investigation of the interaction between 
heat-stressed lysozyme and ovalbumin shows incorporation of both molecules into 
amyloid like fibril formations (Sugimoto et al. 2011). Whether fibril aggregation 
occurred between lysozyme and SerpinB14, or indeed SerpinB2 in the presence 
of oxidative stress is unknown however, the increase in relative turbidity suggests 
that SerpinB14 is interacting with both BSA and lysozyme, and therefore is 
contributing to amorphous aggregation through an unknown mechanism. In 
contrast, αB-crystallin completely inhibited BSA and lysosome aggregation under 
these assay conditions. Importantly, the preferential binding of SerpinB14 to either 
BSA or lysozyme in the plate based assays did not correlate with chaperone 
activity within the amorphous aggregation models investigated. Neither SerpinB2 
or SerpinB14 were effective inhibitors of amorphous aggregation by citrate 
synthase under heat denaturing conditions, whilst αB-crystallin reduced 
aggregation by approximately 50%. 
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Whilst rapid aggregation is largely driven by hydrophobic forces and primarily 
results in amorphous aggregates, the formation of fibrillar aggregate structures is 
slower and gives rise to neurodegenerative diseases (Chiti and Dobson 2006). 
Interestingly, Serpins A1, A3 (Eriksson et al. 1995) (Aksenova et al. 1996) and I1 
(neuroserpin) (Kinghorn et al. 2006) have previously been shown to inhibit fibril 
formation by the Aβ peptides, associated with Alzheimer’s disease.  Therefore, we 
next investigated the potential chaperone activity of SerpinB2, using Aβ peptides 
within fibril formation assays. Importantly, SerpinB2 was able to inhibit fibril 
formation by Aβ1-40 peptide at a molar ratio of 10:1 Aβ:SerpinB2 and this was 
indistinguishable from the inhibitory efficiency of αB-crystallin, at the same molar 
ratio. The inhibition of Aβ1-40 fibril formation by αB-crystallin, under similar assay 
conditions used herein, has been previously described (Dehle et al. 2010) and is 
consistent with our findings. 
 
In similar experiments, SerpinB2 was found to inhibit Aβ1-42 fibril formation over a 
5 h period, however this effect was not sustainable and an increase in fibril 
formation as assessed by Thio-T fluorescence was observed between the 5 and 
10 h time periods. Conversely, no Aβ1-42 fibrillar forms were observed, by SEM, 
within an alternate experiment, in the presence of SerpinB2 or αB-crystallin.  
Fibrillar aggregation follows a classical sigmoidal trajectory whereby the initial 
phase (lag phase) of the time course consists of dimer and trimer formations, 
increasing in subunit association until nuclei form, at which point rapid 
polymerisation/elongation (growth phase) occurs until the reaction reaches 
 129 
equilibrium and plateaus (Jarrett and Lansbury 1993). In this context it is possible 
that SerpinB2 interacts directly with the monomeric form of Aβ1-42 peptide, either 
blocking initial nucleation, as is suggested by the lack of fibril formation observed 
within the SEM experiment, or by reducing the rate of elongation of pre-existing 
nuclei (seeds) by sequestering soluble monomers. 
 
Interestingly, early experiments conducted by Fraser et al. (1993) reported the 
association of Aβ peptide with SerpinA3, via 10 amino acid residues within the N-
terminal region of the peptide. It has since been shown that Aβ1-42 peptide interacts 
directly with SerpinA3 via either the carboxyl-terminal segment (peptide) and β-
sheet C of the serpin or the amino-terminal segment (peptide) and β-sheet A 
(Janciauskiene et al. 1998).  Furthermore, Kinghorn et al., (2006) reported a direct 
interaction between SerpinI1 (neuroserpin) and Aβ1-42 which was shown to 
obstruct serpin function and inhibited SerpinI1 polymer formation. As both 
conformational rearrangements of SerpinI1 require RCL insertion into β-sheet A, 
this work corroborates Aβ1-42-Serpin (β-sheet A) interactions previously described 
for SerpinA3  (Janciauskiene et al. 1998).  Therefore, we have utilised a similar 
gel-shift assay to that described by Kinghorn et al. (2006) and shown that Aβ 
peptide interactions with SerpinB2 result in the same reduction of serpin function 
as described for SerpinI1 (Kinghorn et al. 2006). Whilst a reduction in serpin-
protease complex formation was observed, experiment confirmation of the 
proposed β-amyloid binding site within β-sheet A of SerpinB2 is required. 
Nonetheless, we have shown that SerpinB2 interacts with both forms of Aβ peptide 
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and the binding interaction is consistent with those recently described for other 
serpin members. Importantly, the loss of serpin function supports the observation 
that SerpinB2 may bind to monomeric Aβ peptide, thereby limiting nucleation or 
the rate of polymerisation by reducing the concentration of peptide in solution. 
 
Taken together the work presented here provides preliminary evidence that 
SerpinB2 may function within proteostasis networks, as a chaperone-like protein. 
In this context we show that SerpinB2 identifies and binds preferentially to 
misfolded proteins and displays holdase-like chaperone activity towards 
amorphous aggregations within a reducing, but not oxidative or heat stressed 
environment. Whether this variation in chaperone-activity is related to functional 
conformational rearrangement and activation, is not clear, but warrants further 
investigation. SerpinB2 also exhibits efficient chaperone-like activity towards Aβ 
peptide, consistent with previous works for other serpins. Further investigation of 
the proposed function of SerpinB2, within proteostasis networks is required at a 
cellular level. Therefore, experiments investigating the cytoprotective 
characteristics of SerpinB2 within a cell based, protein aggregation model are 
described in chapter 5. 
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5. SerpinB2 protects cells from proteotoxic stress 




























Up-regulation of SerpinB2 in response to cellular stress is well-established, the 
intracellular pathways in which SerpinB2 may function, however, are poorly 
defined. Key to cell survival are protein quality control systems which maintain 
proteostasis through the chaperone and protein degradation pathways. SerpinB2 
has been implicated within these networks via identification of potential intracellular 
binding partners, such as proteasome subunit beta type 1 (PSMB1, a component 
of the proteasome) (Fan et al. 2004) and the ubiquitin-like interferon stimulated 
gene-15 (ISG15) (Giannakopoulos et al. 2005), which are functional components 
of the ubiquitin-proteasome degradation pathway. In this context, the mutant Httexn-
1 model of protein aggregation and proteotoxicity (Olshina et al. 2010) was utilised 
to investigate the cellular processing of misfolded protein by SerpinB2 null mouse 
embryonic fibroblasts and provides evidence of impaired inclusion body (IB) 
formation and proteasome activity in the absence of SerpinB2. Furthermore, this 
work suggests that SerpinB2 may exert its cytoprotective characteristics through 
regulation of autophagy.  
 
5.2. Introduction 
SerpinB2 is a member of the Serine Protease Inhibitor super family that has been 
localised to both the extracellular and intracellular environment of numerous cell 
types including keratinocytes, endothelial, epithelial, monocytic and neuronal cells 
(Lee et al. 2011). Secreted as a 47 kDa or glycosylated 60 kDa protein, 
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extracellular SerpinB2 is thought to function as an inhibitor of the urokinase 
plasminogen activator and to a lesser extent, tissue-type plasminogen activator 
(Kruithof et al. 1995). The majority of SerpinB2 is, however, retained within the 
intracellular environment as a 47 kDa protein (Lee et al. 2011). The main producers 
of SerpinB2 are cells of the myeloid lineage which up regulate SerpinB2 
expression during cell developmental phases, such as proliferation and 
differentiation, or in response to pathology, especially inflammation and cellular 
stress (Schroder et al. 2010; Lee et al. 2011). As yet an intracellular protease target 
for this serpin has not been defined which suggests a role independent of the 
classical inhibitory mechanisms characteristic of serpins (Law et al. 2006).  
 
Of interest are the intracellular networks upregulated in response to cellular stress 
and the role SerpinB2 may pay within these pathways. We have previously shown 
that SerpinB2 binds preferentially to unfolded proteins following reductive, 
oxidative or heat stress (Chapter 4). Furthermore, SerpinB2 was found to inhibit 
amorphous aggregation of reduction-stressed BSA, but not other models, and fibril 
formation of both amyloid-β 1-40 or 1-42 peptides (Chapter 4). These chaperone-
like characteristics of SerpinB2 suggest a role within quality control systems that 
maintain proteostasis. The isolation or removal of deleterious proteins from the 
intracellular compartment is key to cell survival and is facilitated through either the 
ubiquitin/proteasome degradation pathways or autophagy and the lysosomal 
degradation pathway (Tyedmers et al. 2010).   
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The 26S proteasome is an ATP-dependent proteolytic macro-complex that is found 
within the cytoplasm and nucleus (Peters et al. 1993; Brooks et al. 2000). 
Comprising of a proteolytic core (20S complex), the proteasome forms a cylindrical 
structure, which incorporates 28 protein subunits arranged into 4 rings (Gallastegui 
and Groll 2010). The proteolytic component of the proteasome is made up of seven 
β-subunits (β1 to β7) that are buried within the core of the complex. Proteasome 
activity is tightly regulated with assembly and disassembly of the macro-complexes 
facilitated by proteasome assembly chaperones; and access to the enzymatic core 
- via the 19S regulatory subunits, which cap the 20S complex - is mediated by a 
tightly regulated network of deubiquitinating enzymes (DUBs), shuttling factors and 
unfoldase chaperones (reviewed in (Adams 2004; Nalepa et al. 2006; Herrmann 
et al. 2007). Proteins are targeted to the proteasome for degradation through 
modification with ubiquitin or ubiquitin-like adapter proteins, such as SUMO, Nedd8 
and interferon stimulated gene-15 (ISG15) (Kerscher et al. 2006). In the context of 
proteostasis, the proteasome system functions to recycle functional proteins that 
are no longer required by the cell or to protect cells through the clearance of 
soluble, misfolded proteins, thereby preventing protein aggregation (Tyedmers et 
al. 2010). However, the proteasome does not function in the clearance of insoluble 
protein aggregates (Bence et al. 2001; Verhoef et al. 2002). Therefore, alternative 
quality control mechanisms, such as the autophagy-lysosomal degradation 




Macro-autophagy (herein referred to as autophagy) involves the complex cascade 
of steps that give rise to the formation of double-membrane structures, which 
incorporate substrates such as protein aggregates and damaged organelles, for 
degradation via the lysosome (He and Klionsky 2009; Nakatogawa et al. 2009). 
The class III phosphatidylinositol 3-kinase (PtdIns3K) complex mediates initiation 
of the pathway through formation of the phagophore membrane. Recruitment of 
autophagy specific (Atg) proteins into the phagophore, facilitates elongation of the 
membrane and encapsulation of target substrates (Suzuki et al. 2007; Kawamata 
et al. 2008), resulting in the formation of a complete vesicular compartment, known 
as the autophagosome. This vesicle is transported along the microtubule network 
via dynein and microtubule-associated proteins, such as the HDAC6 (Iwata et al. 
2005), to the lysosome where autophagosome-lysosome fusion results in 
formation of the autolysosome and cargo degradation by lysosomal proteases 
occurs. Basal levels of autophagy activity within cells (under normal physiological 
conditions) are low and regulation (positive or negative) of the pathway is tightly 
controlled throughout each phase from phagophore initiation to neutralisation of 
the autolysosome (He and Klionsky 2009). Interestingly, the initial seeding of the 
phagophore is negatively regulated by B-cell lymphoma-2 (Bcl-2) inhibitory 
interaction with Beclin-1 (Liang et al. 1998; Pattingre et al. 2005), a component of 
the PtdIns3K complex.  
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SerpinB2 expression was recently shown to stabilise Beclin-1 and promote 
autophagy (Chuang et al. 2013). Furthermore, SerpinB2 was found to interact with 
the β-subunit type-1 component of the proteasome 20S core chamber, following 
GST-pulldown experiments (Fan et al. 2004), and SerpinB2 was identified as a 
target for the ubiquitin-like adapter protein, ISG15, following mass spectrometric 
analysis of anti-ISG15 immunoprecipitates (Giannakopoulos et al. 2005). Taken 
together, these findings provide evidence for a possible role of SerpinB2 within 
proteostasis pathways which warrants further investigation.  
 
5.2.1. Rationale and Aims 
Given the in vitro chaperone-like activity of SerpinB2 (Chapter 4) and evidence in 
the literature implicating SerpinB2 within autophagy and the ubiquitin/proteasome 
pathways, we hypothesise that SerpinB2 may function in cellular stress response 
pathways that involve binding to misfolded proteins. Therefore, using mouse 
embryonic fibroblasts (MEF) from control (wild-type) mice or the SERPINB2 null 
mouse model (Dougherty et al. 1999) we investigated the potential role of 
intracellular SerpinB2 in proteostasis. To this end we employed an intracellular 
aggregation model to investigate the processing of aberrant proteins and the affect 
SerpinB2 may have on i) Cell viability ii) Inclusion body formation and iii) Protein 




5.3. Materials and Methods 
 
5.3.1. Materials 
Recombinant human SerpinB2 (47 kDa) was purified from E. coli (M15) using the 
pREP4/PQE-9 expression system as described in section 4.3.2. ISOLATE RNA 
Mini Kit and BioScript One-Step RT-PCR kit were from Bioline. 20 μm filter caps 
were from Millipore and Polyfect was from Qiagen Pty Ltd, RPMI1640, tissue 
culture flasks, Lipofectamine2000, fetal calf serum (FCS), trypsin EDTA. Sytox-red 
was obtained from Invitrogen. Polybrene, gelatin, MG-132 and propidium iodine 
were from Sigma Aldrich. 
 
5.3.2. Generation of Mouse Embryonic Fibroblast primary cell lines. 
MEFs were isolated from wild-type and SerpinB2-/-mice as previously described 
(Dougherty et al. 1999; Schroder et al. 2010). Briefly, a pregnant female 
C57/Black-6 mouse was euthanised at day 13.5 post coitus by CO2 asphyxiation. 
The uterine horns containing the embryos were dissected from the mouse and 
placed in sterile PBS on ice. The uterine wall was cut and each embryo removed 
and separated from its amniotic sac. A scalpel blade was used to remove the head 
and liver and the remaining tissue was resuspended in 10 ml of trypsin-EDTA. The 
embryos were finely minced with a scalpel blade for approximately 1 min and then 
incubated at 37 ºC for 5 min. The tissue was homogenised by passing gently 
through an 18 gauge needle several times and allowed to settle for 5 min at room 
temperature. The supernatant (cell suspension) was transferred to a tube 
containing 20 mL of pre-warmed RPMI + 10% FCS and centrifuged for 5 min at 
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300 x g. The cell pellet was resuspended in RPMI1640 + 10% FCS and plated on 
0.1% gelatin (passage 0). Primary cultures were then continually passaged until 
spontaneous immortality was obtained. This work was conducted by Dr Wayne 
Schroder, Queensland Institute of Medical Research (QIMR). 
 
Mouse embryonic fibroblasts were maintained in RPMI-1640 containing 10% FCS 
and cultured at 37 °C with 5% CO2. 
 
5.3.3. Generation of stable MEF cell lines expressing human 
 SerpinB2.  
 
Human WT SerpinB2 cDNA was cloned into the Xho1 restriction sites of a murine 
stem cell virus (MSCV)-based retroviral vector (pMIG) (Szymczak et al. 2004; 
Brummer et al. 2006; Brummer et al. 2008), giving rise to pMIGSerpinB2 constructs  








Figure 5.1: Schematic representation of pMIG retroviral construct containing 
SerpinB2 cDNA. This vector contains an internal ribosome entry site (IRES) 
between the SerpinB2 open reading frame (1.2 kb) and a Green Fluorescent 
Protein (GFP) reporter, driving expression of both from a single promoter. Correct 
insertion of human SerpinB2 cDNA was confirmed by DNA sequencing of 
constructs Dr S Lobov, University of Wollongong NSW. 
 
For the production of stable cell lines, retrovirus packaging cell line, PlatE cells 
(Jomar Biosciences Pty Ltd, Welland, South Australia), were transfected with the 
pMIG constructs using Polyfect, according to the manufacturer’s instructions. Viral 
supernatants were collected 48 h later, filtered through 20 μm filter caps, 8 μg/mL 
of polybrene was added and supernatant was added to MEFs. Positive cells were 
selected by cell sorting on a FACS Vantage (Becton Dickinson), based on the 
bicistronic expression of GFP. Cell genotype was verified by rt-PCR and SerpinB2 
expression within SerpinB2-/- (WT rescue) MEF cells was observed by western blot 
detection system. 




5.3.4. Reverse-transcription PCR 
Extraction of total RNA from cell lines and subsequent rt-PCR was conducted 
using the ISOLATE RNA Mini Kit and BioScript One-Step rt-PCR kit (both from 
Bioline), as per the manufacturer’s instructions. The concentration and purity of 
RNA obtained using this kit was then assessed by absorbance at 260 nm and 
260/280 ratio using a NanoDrop 2000c Spectrophotometer (Thermo Fischer 
Scientific, VIC, Australia) (Table 5.1). 
Table 5.1: Characterisation of total RNA samples extracted from various 
untransduced and pMIG transduced Mouse Embryonic Fibroblast lines. 
Cell Line* 
Conc. mRNA 
sample (ng.µL-1) 260/280 nm Ratio 
Volume used in 
PCR (µL) 
WT MEF 307.2 2.10 4.0 
WT(vector) MEF 523.5 2.18 2.5 
SerpinB2-/- MEF 371.2 2.12 3.4 
SerpinB2-/-
(Vector) MEF 636.3 2.16 2.0 
SerpinB2-/- (WT 
rescue) MEF 791.2 2.16 1.6 
U-937** 256.9 2.08 5.0 
*Refer to Results section 5.4.1 for a description of the various MEF cell lines 
**Human histocytic lymphoma cell line, used as a positive control for SerpinB2 expression 
(Kruithof et al. 1986) 
 
rt-PCR was performed using a Eppendorf, (Mastercycler Pro S) thermal cycler and 
conducted in 25 µL reaction volumes containing 1.3 µg mRNA (Tab. 5.1), 12.5 µL 
2 x One-step RT-PCR Buffer, 1 µL One-step enzyme mix, forward 5′-
CTGCTACCCGAAGGTTCTG-3′ and reverse 5′-GGAAGCAACAGGAGCATGC-3′ 
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murine SERPINB2 primers, 0.5 µL RNAse sample and 8 µL DEPC-treated water. 
Cycling conditions were as previously described (Schroder et al. 2010) with one 
cycle of 50 °C for 2 min and one cycle of 95 °C for 2 min, followed by 45 cycles of 
94 °C for 5 s, 60 °C for 10 s, and 72 °C for 40 s. The resulting PCR products were 
analysed by 2% agarose gel electrophoresis and ethidum bromide staining. 
 
5.3.5. Whole cell Lysis 
MEF cells were harvested from confluent 25 cm2 tissue culture flasks using 
standard trypsinisation methods, washed twice with ice cold PSB then incubated 
on ice with 500 µL RIPA mammalian cell lysis buffer (65 mM Tris-base, 150 mM 
NaCl, 8.5 mM MgCl, 10% v/v Gycerol, 0.1% v/v Triton-X100, 12 mM Na-
deoxycholate, 5 mM Ethylenediaminetetraacetic acid (EDTA), 1 mM α-
phenylmethylsulfonyl fluoride (PMSF)). Samples were then used for protein 
detection via Western Blot. 
 
5.3.6. Western Blot Development 
Proteins fractionated by SDS PAGE were blotted onto ImmobilomTM-P PVDF 
(Millipore, USA) membrane using a Bio-Rad Mini Trans-Blot system as per 
manufacturer’s instructions. After transfer, the PVDF membranes were blocked 
with 10% skim milk powder in Tris-buffered saline (TBS) with 0.05% (v/v) Tween-
20 (TBST) overnight at 4oC.  After washing in TBST the primary antibody (α-
SerpinB2 MAb (ADI#3750)) was applied at a final concentration of 1:500 in 2% 
milk/TBST and blots were incubated for 2 hs at RT on a shaker. The membrane 
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was extensively washed with TBST then re-blocked with 6% milk/TBST for 30 min 
at RT followed by one wash with TBST for 5 min.  Detection of bound primary 
antibody was conducted using the appropriate horseradish peroxidise (HRP) 
labelled secondary antibody, which was applied at a final concentration of 1:5000 
in 2% milk/TBST for 1 h at RT.  Three 5 min washes with TBST were conducted 
to remove unbound secondary antibody followed by three 5 min washes with TBS. 
 
Protein detection was visualised by an enhanced chemiluminescence (ECL) 
reaction using SuperSignal® Substrate for Western Blotting (Progen, Australia) as 
per manufacturer’s instructions. The membranes were exposed to X-ray film and 
developed for analysis. 
 
 
5.3.7. Mammalian Transfection using the Huntingtin exon1 
 polyglutamine (polyQ) expansion cell model. 
 
Huntington's disease is caused by autosomal dominant mutations in the HTT gene 
resulting in expansion of a polyQ sequence near the amino-terminus of the 
huntingtin (Htt) protein that promotes its aggregation (Hatters 2008). Wild type 
alleles of the HTT gene encode polyQ sequences that range between 7 and 36 
contiguous glutamine residues and mutant Htt is considered to contain >36 and up 
to 250 contiguous glutamine residues (Hatters 2008). In the current work we used 
a well-established Htt aggregation model comprising an exon 1 fragment fused to 
either 25 polyQ or 46 polyQ sequences (Olshina et al. 2010; Ramdzan et al. 2010; 
Polling et al. 2014). While longer expansions are more pathogenic, it has been 
previously demonstrated that aggregation of the 46 polyQ Htt exon 1 fusion protein 
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occurs in an experimentally tractable timeframe in a process that is well 
characterised (Olshina et al. 2010). 
 
Untransduced or pMIG construct transduced MEFs were seeded into 6-well plates 
(in triplicate) containing 19 mm coverslips (2x105 cells per well) 24 h before 
transfection with 200 ng of pcDNA3.1-mCherry (control) or pcDNA3.1-Huntingtin 
exon1-polyglutamine variants fused C-terminally to mCherry (Httex125Q-mCherry 
or Httex146Q-mCherry) expression vectors (Ramdzan et al. 2010; Polling et al. 
2014), using Lipofectamine2000 (Invitrogen) as per manufacturer’s instructions. At 
24, 36 and 48 h post-transfection, coverslips were removed prior to harvesting the 
remaining cells for analysis of cell viability by flow cytometry (described below). 
Cells grown on coverslips were then fixed by incubation in freshly prepared ice 
cold PBS containing 4% paraformaldehyde (PFA) for 10 min prior to mounting on 
microscopy slides using mounting solution (1 x PBS containing 50% glycerol). The 
fixed cells were then visualised using a Nikon Eclipse TE2000-E (Nikon 
Instruments) with FITC (ex 470-490, em 520-560) and Cy3 (ex 510 – 560 nm, em 
565 - 625 nm) filter sets and 60x Plan Apo ∞/0.10-0.22 WD 0.13 oil emersion 
lens. For analysis of cell viability, cells were harvested by brief trypsinisation, 
washed in phosphate buffered saline (PBS), incubated on ice with 5 nM Sytox-red 
in PBS and then analysed by flow cytometry (Becton Dickinson). All data obtained 
was analysed using FLOJO software version 7.1 (Treestar, Inc). 
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5.3.8. Huntingtin aggregation assay 
Monomeric Httex1-46Q-Cerulean-MBP fusion protein was aggregated as previously 
described (Ramdzan et al. 2010).  Briefly, recombinant Httex1-46Q-Cerulean-MBP 
was thawed from frozen stocks, diluted to 9 μM, and rapidly mixed with a 1:20 
stock of TEV protease. After 10 min Httex1-46Q-Cerulean was diluted, with or 
without SerpinB2, to a final concentration of 2 μM and at a 1:1 final molar ratio of 
SerpinB2: Httex1-46Q-Cerulean. Duplicate samples were taken at intervals and 
total protein was determined by cerulean fluorescence (43,000 M-1.cm-1 at 434 
nm). Samples were then centrifuged at 13,000 x g for 30 min and supernatant 
collected as soluble fraction.  
 
 
5.3.9. Ligand binding assay  
Aggregate ligand blots were performed as previously described (Yerbury et al. 
2007). Httex1-46Q-Cerulean (1 μg) was spotted on nitrocellulose membrane and 
then blocked with 1% (w/v) heat denatured casein in PBS buffer. SerpinB2 (10 
μg/ml solution) or control proteins SerpinB14 (10 μg/ml solution) and clusterin (10 
μg/ml solution) were then incubated with separate membranes for 2 h, at RT. 
Bound interactors were detected using antibodies to either SerpinB2 (1:1000; 
Abcam, UK; ab137588), SerpinB14 (1:30000; Sigma-Aldrich, C6534), or α-
clusterin (neat hybridoma culture supernatant) and subsequent HRP conjugated 




5.3.10. SerpinB2 Immunostaining  
WT MEF cell lines were transiently transfected with Httex146Q:mCherry expression 
vector as described above, fixed with 4% paraformaldehyde (PFA), permeabilized 
with  0.1% triton X-100  and then blocked using 5% FCS, 1% BSA 0.1% triton-
X100 in PBS. Cells were then incubated in the presence of either rabbit anti-mouse 
SerpinB2 polyclonal antibody (2 µg.ml-1; diluted in 1% BSA, 0.1% TX-100 in PBS) 
(Lee et al. 2015) or matched isotype control rabbit IgG antibody (2 µg.ml-1; 
ABCAM; ab171870), followed by wash steps and binding detected using goat anti-
rabbit IgG Alexa Fluor®488-conjugated secondary antibody (ABCAM; ab181448 
1:500 dilution). Cells were then imaged using laser scanning confocal microscopy. 
Imaging of SerpinB2 immunofluorescence was kindly conducted by Natalie 
Farrawell, University of Wollongong. 
  
5.3.11. GFPu Ubiquitin-Proteasome System (UPS) reporter assay 
To quantify UPS activity we used the fluorescent UPS reporter GFPu, which relies 
on a 16 amino acid degron (ACKNWFSSLSHFVIHL) (CL1) fused to the carboxyl 
terminus of GFP (Gilon et al. 1998; Bence et al. 2001; Bence et al. 2005). 
Degradation of polypeptides containing the degron is specific to the proteasome, 
therefore loss of GFP signal is indicative of ubiquitin dependent proteasome 
activity. GFPu was transfected into MEF cell lines as previously described (section. 
5.3.5) and the level of GFP fluorescence in the absence or presence of 250 nM 
MG-132 was determined using flow cytometry (Becton Dickinson), 48 h post 
transfection. Data represents viable cells only, as determined by propidium iodide 
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exclusion and was normalised to MG-132 treated cells after removal of background 
autofluorescence.  
 
5.3.12. Autophagy reporter assay  
Autophagy dysfunction was assessed using the Lyso-ID autophagy reporter (Enzo 
Life Sciences) as previously described (Francois et al. 2013). WT and SerpinB2-/- 
MEF cell lines were seeded into a 96-well plate 24 h before addition of an 
autophagy inhibitor, 3-methyladenine (3-MA, 0-5 mM; Adipogen) or an autophagy 
inducer, verapamil (0-100 µM; Enzo Life Sciences). MEF cells were then cultured 
overnight and autophagy quantified using Lyso-ID kit (ENZO), as per 
manufacturer’s instructions. Briefly cells were washed and incubated with the 
Lyso-ID red dye for 30 min at RT before measuring the level of red fluorescence 
per cell on the IncucyteZoom automated imaging system (ESSEN Bioscience). 
Data shown is corrected for background fluorescence. This experiment was 
conducted by Natalie Farrawell, University of Wollongong. 
 
5.3.13. Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism 5. Comparison of growth 
curves was conducted using nonlinear fit, exponential growth equation 
(Y=Y0*exp(k*X)) to generate doubling times of respective cell lines. 
Corresponding K values (rate constant) obtained from the analysis were compared 
by One-way anova, applying the Tukey-Kramer multiple comparison test. Cell 
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viability assays were analysed by 2-way anova with Bonferroni’s multiple 




5.4.1. Generation of stable MEF cell lines expressing human 
 SerpinB2 of Mouse Embryonic Fibroblast Cell Lines. 
 
To investigate the role of SerpinB2 as a stress protein we used spontaneously 
immortalised WT and SerpinB2-/- MEFs that had been retrovirally transduced with 
either pMIGGFP or pMIGSerpinB2 vectors. Using this method three new cell lines were 
made, consisting of two empty vector control lines, MEFWTpMIG [WT(vector)], 
MEFSERPINB2-/-:pMIG [SerpinB2-/-(vector)] and a SerpinB2 knock-in line, 
MEFSERPINB2KI:pMIG [SerpinB2-/-(WT rescue)]. Efficiency of gene introduction was 
assessed by flow cytometry, with the GFP positive population for each cell line 




Figure 5.2: Generation of SERPINB2-/- WT rescue cell line. Spontaneously 
immortalised MEF cell lines established from control (WT) and SerpinB2-/- mice 
were transduced with mouse stem cell retroviral pMIGGFP. Transduction 
efficiency of the parental lines was determined by GFP expression within the 
transduction control cell lines (empty vector), WT (vector) and SerpinB2-/- 
(vector) and the human SerpinB2 knock in (SerpinB2-/- WT rescue) cell line using 
flow cytometry. Cells were gated as GFP negative or positive based on parental 
lineage i) WT, ii) SerpinB2-/-, iii) SerpinB2-/- (WT rescue); iv) WT (vector) v) 
SerpinB2-/- (vector). Data represents a minimum of 5000 viable cells as 
determined by PI exclusion. 
 
To confirm SerpinB2+/+, SerpinB2-/- status of the parental lines and transduced cell 
lines we next conducted RT-PCR amplification of murine SERPINB2 transcripts 
using fresh RNA extracts from all MEF cell lines (Fig.5.3A). As expected, the WT 
and WT (vector) cell lines screened positive for the presence of murine SERPINB2 
gene transcript as is evident by the 270 bp band within lanes 2 and 4 (Fig. 5.3A). 
i, WT ii. SerpinB2-/- iii. WT rescue 
iv. WT (vector) v. SerpinB2-/- (vector) 
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Importantly, no corresponding band was observed for the SerpinB2-/-, SerpinB2-/-
(vector) and SerpinB2-/-(WT rescue) cell lines, (lanes 6, 8 and 10 respectively, 
Fig.5.3A) confirming their murine SerpinB2 null genotype. Comparable banding 
intensity was observed for all cell lines corresponding to GAPDH amplification (250 
bp) thus confirming the presence of equal template within rt-PCR starting sample 
and equal loading of the sample onto the visualisation gel. Given the sequence 
homology between human and murine SerpinB2 and the potential for non-specific 
amplification of the human gene using the PCR primers designed to target the 
murine gene, we also included mRNA extracted from the human U-937 monocytic 
cell line as a negative control.  
 
We next confirmed expression of SerpinB2 protein via western blot analysis of 
whole cell lysates. We were unable to detect protein expression within the WT and 
WT(vector) cell lines due to the lack of a sufficient antibody specific for murine 
SerpinB2 detection via western blot analysis, at the time these experiments were 
conducted.  Importantly, clear expression of human SerpinB2 was detectable 
within the whole cell lysates of the SerpinB2-/-(WT rescue) cell line, confirming 










Figure 5. 3: SERPINB2 gene and protein expression in mouse embryonic cell lines 
(MEF). A) Reverse transcription-PCR screening for murine SERPINB2 gene. Fresh 
mRNA extracts were prepared and equal quantities of template (1.3 µg) used for rt-PCR 
amplification by BioScript One-Step RT-PCR kit.  Predicted Murine SERPINB2 product 
size is 270 bp (red arrow). Rt-PCR product was visualised by electrophoresis on a 2% 
Agrose gel. Lanes: 2. WT 4. WT(vector) 6. SerpinB2-/- 8.  SerpinB2-/-(vector) 10. SerpinB2-
/-(WT rescue) and 12. U937 cell line (negative control) show samples containing primers 
specific for murine SERPINB2. Amplification of GAPDH (positive control) for each cell line 
can be seen in adjacent odd numbered lanes. B) Western blot analysis of MEF whole 
cell lysates for detection of human-SerpinB2 epression. Lanes: 1 SerpinB2-/-(WT rescue). 
2. SerpinB2-/-(vector). 3. SerpinB2-/-.  4. WT(vector). 5. WT. Detection of human SerpinB2 
was conducted using anti-human SerpinB2 MAb (ADI ##3750) and relevant HRP 
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We next assessed the effect, if any, the pMIG transduction had on the growth rates 
of the respective MEF cell lines relative to parental (non-transduced) cells. Growth 
curves were constructed from a 72 h time course with measurements taken every 
12 h.  Non-linear curves were fitted and analysed by application of the exponential 
growth equation with least squares (ordinary) fit (Fig. 5.4.A). Using this method of 
analysis it was possible to calculate the mean doubling times for each cell line, 
being 57.57 h (WT), 61.4 h (WT(vector)), 53.58 h (SerpinB2-/-), 53.17 h (SerpinB2-
/-(vector)) and 71.11 h (SerpinB2-/-(WT rescue)) (Fig. 5.4.B). The overall growth 
trend observed across cell lines was comparable as can be seen by the spread in 
the calculated doubling times (Fig. 5.4.B) however, the mean doubling time of 
71.11 h for the SerpinB2-/-(WT rescue) cell line was 10 to 20 h longer than the 
time required for population doubling by all other cell lines. We therefore conducted 
a one way anova analysis using the rate constants (K) obtained from the 
exponential growth fit, and found that there was a significant difference in growth 
rates between cell lines (p=0.0052, n=5). Further comparison using the Tukey-
Kramer post test (CI = 95%) ascertained that this difference was only present 
between SerpinB2-/-(WT rescue) and SerpinB2-/- or SerpinB2-/-(vector) cell lines 
(Tab. 5.2). Importantly, the pMIG transduction did not significantly alter the growth 

















lines. There was no difference observed between the WT and SerpinB2-/- parental 
lines, indicating that the cell models did not contain metabolic biases. Therefore 
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Figure 5.4: MEF growth rates. Parental and pMIG transduced MEF cell lines 
were cultured for 72 h and growth rates determined every 12 h by relative change 
in absorbance at 490 nm using MTS reagent. A) Non-linear curves were fitted to 
data points and B) mean doubling times (symbols) calculated using the 
exponential growth equation. Bars indicat  the variance in mean doubling times. 
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Table 5.2: Multiple comparisons of growth rate constants for MEF cell lines. 











WT - NS NS NS NS 
WT(vector) NS - NS NS NS 
SerpinB2-/- NS NS - NS NS 
SerpinB2-/-(vector) NS NS NS - NS 
SerpinB2-/-(WT 
rescue) NS NS ** ** - 
ns = not significant, ** = significantly different (p<0.05). 
 
5.4.2. SerpinB2 protects MEFs from proteotoxic stress of Huntingtin 
 protein expression/aggregation. 
 
In order to test the hypothesis that SerpinB2 is involved in proteostasis pathways 
within the intracellular environment we utilised wild type (Httex125Q-mCherry) and 
mutant (Httex146Q-mCherry) huntingtin-mCherry mammalian expression vectors 
as an intracellular protein aggregation model. Htt polyQ expansion is characterized 
by the aggregation of Htt and decreased cell survival in a polyQ-expansion 
dependent manner within neuronal models (Arrasate et al. 2004). Therefore we 
conducted transient transfection experiments using the MEF cell lines to 
investigate Httex1 aggregation and processing in the absence or presence of 
SerpinB2, relative to controls. Initially, proteotoxic stress was determined by 
quantification of cell viability using flow cytometry and SytoxRed staining at 24, 36 
and 48 hs post transfection.  Using flow cytometry, cells were firstly gated based 
on forward and side scatter (Fig. 5.6.A.i) to remove debris from the analysis. This 
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population was then gated based on mCherry (660_20, green laser 561 nm) and 
GFP (515_20, blue laser 488 nm) expression (Fig. 5.6.A.ii). Analysis of cell viability 
by SytoxRed (660_20, red laser 633 nm) exclusion (Fig. 5.6.A.iii) was then 
conducted on mCherry and GFP positive cells only (Q2 of Fig. 5.6.A.ii) within the 
pMIG transduced cell lines or mCherry positive cells (Q1 of Fig. 5.6.A.ii) within the 
parental lines. The percentage of viable cells determined by this gating method 
was then normalised against the relevant mCherry control populations to allow for 
potential bias arising from the transfection process or possible differences in 
transfection efficiency and vector expression between cell lines.   
 
Using this model, a significant difference in cell viability between SerpinB2 null and 
SerpinB2 expressing cell lines was observed and this was most obvious 48 h post 
transfection (Fig 5.5.B). Cell viability was reduced to 60% and 45% at this time 
point for Httex125Q-mCherry (Fig. 5.5.B.i) and Httex146Q-mCherry (Fig. 5.5.B.ii) 
expressing SerpinB2-/-(vector) cells compared to 100% viability observed for the 
WT (vector) cell line respectively. The latter observation [WT(vector)] is consistent 
with previous work using wild-type MEFs that showed no difference in toxicity 
responses between cells expressing Httex125Q and Httex197Q (King et al. 2008).  
Importantly, cell viability was partially recovered with the reintroduction of SerpinB2 
by pMIG transduction, SerpinB2-/-(WT rescue), showing normalised cell viability of 
89% and 84% for Httex125Q-mCherry (Fig. 5.5.B.i) and Httex146Q-mCherry (Fig. 
5.5.B.ii) expressing cells which was significantly different to the SerpinB-/- (vector) 
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Figure 5.5: SerpinB2 protects MEFs from Huntingtin protein toxicity. 
Parental and pMIG transduced MEF cell lines were transiently transfected with 
either Httex125Q-mCherry (WT), Httex146Q-mCherry (mutant) or mCherry 
(control) expression vectors and cell viability assessed at 24, 36 and 48 h post 
transfection using flow cytometry. A) Representative gating of data; (i) initial 
removal of debris (ii) mCherry(660_20 green)/GFP(515_20 blue) positive cells were 
selected for analysis of (iii) cell viability using SytoxRed(660_20 red) exclusion. B) 
Comparison of cell viability in the absence (SerpinB2-/-(vector)) or presence 
(WT(vector)) and (SerpinB2-/-(WT rescue)) of SerpinB2 following transfection 
with either (i) Httex125Q-mCherry or (ii) Httex146Q-mCherry. Effects of pMIG 
transduction on cell viability following transfection with Httex146Q-mCherry was 
assessed by comparison to parental lines; iii) SerpinB2-/- and iv) WT. Data 
represents mean percentage of viable cells normalised to mCherry only controls, 
n=3, ± SEM. Significant difference to WT(vector) (i) and (ii) or parent line (iii) 



















i) Httex125Q-mCherry. ii) Httex146Q-mCherry. 
 
iii) Httex146Q-mCherry iv) Httex146Q-mCherry 
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Comparison of the MEF parental cell lines and their respective pMIG transduction 
control cell lines, 48 h post transfection with Httex146Q-mCherry was also 
conducted to assess the effects if any of the mouse stem cell virus (MSCV - pMIG 
transduction) on cell viability. Interestingly there was a significant difference 
between the percentage of viable cells determined for SerpinB2-/-(vector) 
compared to the SerpinB2-/- parental cell line (p<0.05) (Fig. 5.5.B.iii), whilst no 
difference was observed between the WT (vector) and WT cell lines (Fig. 5.5.B.iv). 
Suggesting that pMIG transduction is impacting on the cell viability of SerpinB2-/- 
cell lines, however given that there was no significant difference in doubling times 
for these cell lines (Fig. 5.4), it seems they are more sensitive to the accumulative 
effect of GFP and Httex146Q-mCherry expression. This sensitivity may be 
attributed to by the constitutive expression of GFP, which has previously been 
shown to have a cytotoxic effect within some cell models (Liu et al. 1999). The cell 
viability of Httex146Q-mCherry expressing SerpinB2-/- MEF cells (parental line, no 
GFP) at 48 h post transfection was also found to be significantly reduced compared 
to the WT (p<0.001) and WT (vector) (p<0.001) cell lines, confirming the cytotoxic 
effect of Htt expression in the absence of SerpinB2. Importantly, WT rescue of the 
SerpinB2-/- cell line (WT rescue) was shown to significantly increase cell viability 
(p<0.05), indicating that reintroduction of SerpinB2 into the SerpinB2-/- cells not 
only facilitated recovery of cell viability due to the pMIG transduction process but 
also that resulting from the proteotoxicity of Httex146Q-mCherry expression. 
Altogether, this supports a potential role for SerpinB2 in cellular protection against 
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proteotoxicity. It was not possible, however, to identify within these experiments, 
potential protein aggregation pathways associated with this observation.  
 
Therefore, Httex146Q:mCherry aggregation and processing was visualised by 
microscopy at 24 and 48 h post transfection. Expression of Httex146Q-mCherry or 
mCherry only (data not shown) was clearly visible after 24 h in all cell lines with 
mCherry fluorescence appearing evenly dispersed throughout the cytosol 
(Fig.5.6).  At this time point, inclusion bodies (IB) were observed within the WT 
(Fig.5.6A) and SerpinB2-/- (WT rescue) (Fig.5.6C) cell lines, transfected with the 
mutant huntingtin expression vector (Httex146Q-mCherry). However, negligible 
inclusion formation was observed within the SerpinB2-/- cell lines (Fig.5.6B). This 
subtle difference in IB profile became more distinct 48 h post transfection, whereby 
a clear difference in phenotype between cell lines with respect to formation of IB 
in the absence or presence of SerpinB2 was observed (Fig. 5.6).  Importantly, the 
WT rescue cell line showed clear recovery of wild-type phenotype verifying that 
the difference observed between the WT (vector) and SerpinB2-/- (vector) cell lines 
was due to absence or presence of SerpinB2. As expected, no observable IBs 
formed within cells transfected with the mCherry control vector during the course 








Figure 5.6: Photomicrographs showing expression and cellular processing of 
Httexn146Q:mCherry by Mouse Embryonic Fibroblasts (MEF). Inclusion body formation 
(blue arrows) within (A) WT (vector), (B) SerpinB2-/- (vector) or (C) SerpinB2-/- WT rescue 
MEFs, 24 or 48 h post transfection with Httex146Q-mCherry using Lipofectamine2000. Cells 
were visualised using a Nikon Eclipse TE2000-E (Nikon Instruments) with FITC (ex 470-490, 
em 520-560) and Cy3 (ex 510 – 560 nm, em 565 - 625 nm) filter sets and 60x Plan Apo ∞




A) SerpinB2 WT 
B) SerpinB2 -/- 
C) SerpinB2 -/- (WT Rescue) 
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We next compared the partitioning of Htt in wild-type and SerpinB2-/- MEFs. 
Previous work has established that overexpression of Httex1 containing expanded 
polyQ repeats (including 46Q used in this study) produces a dense round inclusion 
in the cytoplasm or nucleus (Kaganovich et al. 2008; Polling et al. 2014), while 
wild-type or 25Q expansion does not. Following expression of Httex125Q-mCherry 
in wild-type MEFs we observed small, Htt-positive foci in ~15% of cells (Fig. 5.7A). 
These foci were < 2 μm in diameter and were counted separately to inclusions 





Figure 5.7:  Differential partitioning of Httexn1 in WT vs SerpinB2-/- MEF 
A. Inclusion formation in wild-type versus SerpinB2-/- MEFs 48 h post 
transfection with either Httex125Q-mCherry or Httex146Q-mCherry. Two types of 
Htt foci were observed, small (< 2um; white arrow heads) and large (> 2 um; 
white arrows); B. Distribution of Htt in MEFs was quantified as diffuse, small foci, 






There was an increase in the proportion of cells containing these small foci (from 
~ 15% to ~ 40%) in the absence of SerpinB2 (Fig. 5.7B), indicating a significant 
shift in localisation of Httex125Q in SerpinB2-/- cells. Following expression of 
Httex146Q in wild-type MEFs we observed a large proportion of cells containing 
inclusions (~ 30%) that were not present in 25Q-expressing cells (Fig. 5.7A and 
5.7B). However, ~ 15% of cells still contained small Htt foci in 46Q-expressing wild-
type cells. In contrast, the proportion of cells containing inclusions was reduced 
and the number of cells containing smaller fluorescent foci increased following 
expression of Httex146Q-mCherry in SerpinB2-/-MEFs (Fig.5.7A and 5.7B). 
 
Given that the expression of SerpinB2 modulated cellular inclusion formation and 
cell viability we tested the ability of recombinant SerpinB2 to supress the in vitro 
fibril formation of Httex146Q fused to the monomeric cyan fluorescent protein, 
Cerulean. As previously reported (Olshina et al. 2010), activation of purified 
recombinant Httex146Q-Cerulean through cleavage of the protective mannose 
binding protein (MBP) with TEV protease, resulted in the formation of insoluble 
Httex146Q-Cerulean fibrillar aggregates over 72 h (Fig. 5.8A). Whilst the presence 
of SerpinB2 modestly attenuated the formation of insoluble Httex146Q-Cerulean 
aggregates within this assay, there were no apparent changes in morphology of 
the Httex146Q-Cerulean insoluble fibrils formed, in the absence or presence of 
SerpinB2 (Fig. 5.8B). We next investigated the potential for SerpinB2 to interact 
directly with Httex146Q-Cerulean using a solid phase ligand blotting assay and 
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immunodetection, as previously described (Yerbury et al. 2007). Interestingly, 
SerpinB2 was found to interact with non-aggregated Httex146Q-Cerulean, but not 
to aggregated material (Fig. 5.8C-D).  Only negligible binding of SerpinB14 
(negative control) to non-aggregated Httex146Q-Cerulean could be detected, whilst 
no interaction between SerpinB14 and aggregated Httex146Q-Cerulean was 
observed. Conversely, clusterin (positive chaperone control) bound both soluble 
and insoluble Httex146Q-Cerulean (Fig. 5.8C-D), which is consistent with previous 





As SerpinB2 was found to interact with soluble Httex146Q-Cerulean and inhibit 
aggregation, albeit at modest amounts, we next examined a possible interaction 
between SerpinB2 and aggregated Httexn146Q-mCherry within the WT cell line, by 
immuno-staining.  Using this method there was no evidence of SerpinB2 co-
localisation with Httexn146Q-mCherry, indicating that SerpinB2 is not sequestered 
into IBs containing Httexn146Q-mCherry aggregates (Fig.5.7). However, it is 
Figure 5.8: SerpinB2 attenuates Htt42q fibril formation in vitro. A. Soluble 
Htt remaining in Httex146Q-Cerulean aggregation reactions in the absence or 
presence of SerpinB2 (equimolar ratio); B. TEM images of fibril formation at 72 
h; C.Representative ligand blot (n = 3) showing differences in binding of 
SerpinB2 to soluble and aggregated Httex146Q. Binding was determined by 
immunoassay. SerpinB14 or clusterin binding to soluble and aggregated 
Httex146Q are also shown. Data was kindly provided by Natalie Farrawell, 
University of Wollongong. 
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possible that SerpinB2 interacts, transiently, with the soluble oligomeric form of 
Httexn146Q-mCherry, which would not be detectable within this system. Of note, 
these experiments confirmed the presence of detectable amounts of endogenous 
SerpinB2 protein within the WT cell line (Fig. 5.7.B). 
 
   
  
 
Fig. 5.9: Huntingtin does not co-localize with SerpinB2. Photomicrographs 
showing (A) expression of Httex146Q:mCherry in WT MEFs following transient 
transfection for 48 – 72 h and (B) SerpinB2, detected using rabbit anti-mouse 
serpinB2 polyclonal antibody and goat anti-rabbit IgG Alexa Fluor®488-
conjugated secondary antibody immunostaining. (C) Image overlay showing 
cellular distribution of Httex146Q:mCherry and SerpinB2. Control staining was 
conducted on non-transfected WT MEFs for (D) SerpinB2 and (E) Rabbit IgG 
antibody used as an isotype control. Cells were imaged using laser scanning 




SerpinB2 has previously been shown to interact with the β-subunit of the 
proteasome proteolytic core (Fan et al. 2004) and recent work has shown that 
SerpinB2 co-localises with Beclin-1 and promotes the degradation of the NOD-like 
A B C 
D E 
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receptor-3 (NLR3) via the autophagy-lysosomal degradation pathway (Chuang et 
al. 2013). Taken together these works suggest SerpinB2 may function within 
protein degradation pathways, which led us to investigate if SerpinB2 influences 
proteasomal or autophagy-lysosomal degradation pathways. To investigate this, 
we conducted cellular based assays to compare proteasomal degradation activity 
in the absence or presence of SerpinB2 utilising a proteasome reporter GFPµ 
(Bence et al. 2001; Bence et al. 2005).   
 
5.4.3. SerpinB2 null MEFs have impaired proteasome activity 
 compared to wild-type MEFs. 
 
SerpinB2 has previously been shown to interact with the β-subunit of the 
proteasome proteolytic core (Fan et al. 2004) and recent work has shown that 
SerpinB2 co-localises with Beclin-1 and promotes the degradation of the NOD-like 
receptor-3 (NLR3) via the autophagy-lysosomal degradation pathway (Chuang et 
al. 2013). Taken together these works suggest SerpinB2 may function within 
protein degradation pathways, which led us to investigate if SerpinB2 influences 
proteasomal or autophagy-lysosomal degradation pathways.  
 
We thus first conducted cellular based assays to compare proteasomal 
degradation activity in the absence or presence of SerpinB2 utilising a proteasome 
reporter.  In these assays, WT and MEFSerpinB2-/- cell lines were transiently 
transfected with the proteasome reporter expression vector containing GFPµ, 
which relies on a 16 amino acid degron (ACKNWFSSLSHFVIHL) (CL1) fused to 
the carboxyl terminus of GFP (Gilon et al. 1998; Bence et al. 2001; Bence et al. 
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2005). Degradation of the degron is specific to the proteasome, therefore changes 
in GFP signal is indicative of proteasome activity.  Cells were analysed by flow 
cytometry 48 h post transfection, following an overnight incubation in the absence 
or presence of proteasome inhibitor, MG-132. Normalisation of the GFP signal 
against MG-132 treated cells (100% inhibition) provides a basis to compare 
relative levels of proteasome activity. Larger relative loss of GFP signal in the 
absence of MG132 suggests a more efficient UPS. Interestingly, the loss of GFP 
signal within the WT cell line was 70% compared to 40% loss, observed in the 
SerpinB2-/- cell line (Fig.5.10.A), indicating that the proteasomal degradation 
pathway is impaired in the absence of SerpinB2.  
 
Whilst the GFP signal following MG132 treatment was normalised in order to 
quantitate GFP degradation, it is important to note that the histograms showing 
GFP signal intensity is comparable between cell lines (Fig.5.10.B). Therefore 
indicating that the difference observed in GFP degradation was not due to 
variability in transfection or expression efficiency between cell lines and that basal 
levels of proteasome activity appears to be comparable between the two cell lines.  
Furthermore, a dose response analysis of cell viability after 48 h treatment with 
MG132 revealed half maximal inhibitory concentration values of ~10 μM for both 
cell lines (data not shown), indicating that toxicity issues were not responsible for 
this difference. These data suggest that the absence of SerpinB2 in cells places 























Figure 5.10: SerpinB2-/- exhibit impaired proteasome activity. (A) Wild-type and 
SerpinB2-/- Mouse Embryonic Fibroblast cell lines were transiently transfected with 
proteasome reporter GFPµ then incubated overnight in the absence or presence of 
[250 nM] MG-132, where indicated. Data has been normalised to geometric mean 
GFP (515/20A) signal of MG132 viable cells only, as determined by propidium iodide 
exclusion (695/40).  (B) Overlay of MG132 treated MEF cell lines showing maximum 
GFPµ signal following inhibition of p26 proteasome. Representative histograms for 
(C) WT or (D) SerpinB2-/- showing GFP signal intensities in the absence (Blue 
histogram) or presence (Red histogram) of MG132, grey histograms represent MEF 
autofluorescence controls (non-transfected).   
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5.4.4.  Autophagy-lysosomal degradation pathway dysregulation in 
 SerpinB2 null MEFs. 
 
We next investigated a potential role for SerpinB2 within the autophagy-lysosomal 
degradation pathway. WT and SerpinB2-/- MEF cell lines were cultured overnight 
in the absence or presence of either an autophagy promoter (Verapamil) or 
inhibitor (3-Methyladenine (3-MA)), then the number of acidic (autolysosome and 
lysomsomal) vesicles quantified using the Lyso-ID kit as previously described 
(Francois et al. 2013). Interestingly, basal level autophagy (indicated by cellular 
fluorescence) was significantly increased in SerpinB2-/- MEFs compared to WT 
cells (Fig. 5.11). Addition of verapamil, a known Ca2+ channel antagonist which 
induces autophagy through the Ca2+-calpain–Gαs pathway (Williams et al. 2008), 
resulted in a dose dependent increase in fluorescence in both cell lines, however 
fluorescent signal was significantly increased within SerpinB2-/- MEFs compared to 
WT MEFs (Fig. 5.11A), suggesting dysregulation of autophagy pathways.  
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Figure 5.11: Autophagy is dysregulated in SerpinB2-/- MEF. Wild-type and 
SerpinB2-/- Mouse Embryonic Fibroblast cell lines were incubated in the absence 
or presence of either (A) verapamil (activator) or (B) 3-MA (inhibitor) overnight and 
autophagy function quantified by addition of Lyso-ID red dye. Data shown 
represents mean (± SEM) fluorescence intensity per cell as determined by 
IncucyteZoom automated imaging system with background subtracted. Data kindly 
provided by Natalie Farrawell, University of Wollongong. 
 
In the presence of 3-MA, an inhibitor of class III phosphoinositide 3-kinases (PI3K) 
(Seglen and Gordon 1982), a small increase in fluorescence was observed in WT 
cells at the highest concentration (5 mM) (Fig. 5.9B). In contrast, while there was 




3-MA concentration (likely due to the stress placed on the cells under these 
inhibitory conditions), compared to WT cells the level of fluorescence was 




Up-regulation of SerpinB2 in response to cellular stress is well-established, the 
intracellular pathways in which SerpinB2 may function however, are poorly 
defined. Key to cell survival are protein quality control systems which maintain 
proteostasis through the chaperone and protein degradation pathways.  SerpinB2 
has been implicated within these networks via identification of potential intracellular 
binding partners, such as proteasome subunit beta type 1 (PSMB1, a component 
of the proteasome) (Fan et al. 2004), the ubiquitin-like adapter protein, interferon 
stimulated gene-15 (ISG15) (Giannakopoulos et al. 2005) and autophagy 
regulator, Beclin-1 (Chuang et al. 2013). In this context, this work utilises the 
mutant Httexn-1 model (Olshina et al. 2010; Ramdzan et al. 2010) to investigate the 
cellular processing of protein aggregates by WT and SerpinB2-/- cell lines, and 
provides evidence of impaired inclusion formation, proteasome activity and 
dysregulation of autophagy-lysosomal degradation pathways in the absence of 
SerpinB2.  
 
Huntington Disease (HD) is characterised by the accumulation of soluble and 
insoluble fibrillar protein species, resulting from polyglutamine (polyQ) expansion, 
in the N-terminus of the Huntingtin protein (MacDonald 1993) and represents one 
of nine neurodegenerative disorders termed polyQ diseases. In normal, healthy 
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humans the polyQ expansion may contain up to 35 repeats, whilst 36 upwards has 
been shown to cause cell death through classic loss and gain of function 
associated with protein aggregation, similar to those described for other 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s Disease (Bano 
et al. 2011).  Here we have utilised the highly aggregation prone region of 
Huntingtin protein, exon-1 fused to a poly-Q expansion, as a model for intracellular 
protein aggregation and found that SerpinB2 protects against the cytotoxic effect 
of Httexn-1-46Q-mCherry expression 48 h post transfection (Fig. 5.5), as determined 
by cell viabilty.  
 
Visualisation of MEFs, 24 and 48 h post transfection with either Httexn1-25Q or 
Httexn-1-46Q-mCherry, revealed morphological differences in Htt processing 
between SerpinB2-/- (vector) and WT (vector) cells lines. Clear inclusion formation 
was visible in WT (vector) cells within 24 h, becoming more pronounced by 48 h 
post transfection (Fig. 5.6.A). This was in stark contrast to the SerpinB2-/- (vector) 
cells, which exhibited diffused cellular distribution of Httexn-1-46Q-mCherry at 24 hs 
and minimal inclusion formation at 48 hs post-transfection (Fig. 5.6.B). It should be 
noted however, that visualisation of Httexn-1-46Q-mCherry processing within the 
SerpinB2-/- (vector) cell line was problematic, given the high cell loss due to the 
sensitivity of these cells to the transfection process and Httexn-1-46Q-mCherry 
expression. Importantly, recovery of WT phenotype was observed within the 
SerpinB2-/- (WT rescue) cell line (Fig.5.6.C). This return of inclusion formation 
coincided with recovery of cell viability, and supports recent research indicating 
that inclusion formation - traditionally thought to be cytotoxic and concomitant with 
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cell death - is a protective mechanism through which, cells are able to isolate the 
cytotoxic, soluble oligomeric, forms of Httexn-1 and other pernicious protein species 
(Waelter et al. 2001; Bucciantini et al. 2002; Arrasate et al. 2004; Takahashi et al. 
2008).  
 
Of interest is the finding that ubiquitinated, soluble substrates destined for 
degradation are typically deposited within juxtanuclear compartments – termed 
juxtanuclear quality control (JUNQ), whilst insoluble protein aggregates, 
characteristic of amyloid-like fibril structures are preferentially directed to 
perivascular compartments, or insoluble protein deposits (IPODs) (Kaganovich et 
al. 2008). Furthermore, it is becoming apparent that misdirection of substrates 
between these distinct quality control compartments, or delayed downstream 
processing results in increased cytotoxicity (Weisberg et al. 2012; Amen and 
Kaganovich 2015), as would be expected with the breakdown of a protein quality 
control network. Importantly, JUNQ clearance is predominantly facilitated by 
proteasomal degradation pathway (Weisberg et al. 2012; Ogrodnik et al. 2014) 
whilst IPODs are processed through the autophagy-lysosomal degradation 
pathways (Kaganovich et al. 2008). Whether SerpinB2 functions directly within 
these compartmentalisation networks either in the formation of inclusions or to 
sequester Httexn146Q-mCherry is unclear.  However, our observations of 
decreased numbers of large IPOD inclusions (Fig.5.7) and increased cell death in 
SerpinB2-null cells (Fig. 5.5) are consistent with a role for SerpinB2 in mediating 
the formation of cellular inclusions. SerpinB2 binds soluble Httexn146Q (Fig. 5.8), 
but has a modest effect on Httex146Q-Cerulean aggregation, nor does SerpinB2 
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co-localisation with Htt IPOD structures, but this does not preclude an indirect role 
in inclusion formation. An RNAi genome wide screen in in C. elegans identified 
RNA synthesis, protein synthesis, protein folding, protein transport and protein 
degradation as vital classes of genes that control polyQ protein aggregation 
(Nollen et al. 2004). This study implicated all aspects of the proteostasis network 
as modulators of protein aggregation in vivo. Hence, our data showing reduced 
numbers of large Htt46Q inclusions in the absence of SerpinB2 suggests SerpinB2 
is part of the cellular proteostasis regulation network.  
 
Given that the formation of quality control compartments are thought to appear as 
a result of protein degradation pathway overload (Hipp et al. 2014), we compared 
proteasome and autophagy function. Interestingly, the proteasomal degradation 
pathway was impaired within SerpinB2-/- null cell lines, suggesting a role within this 
protein degradation pathway. Surprisingly, the absence of SerpinB2 was found to 
negatively impact on GFPµ degradation. Given the reported interaction between 
SerpinB2 and PSMB1 by Fan et al. 2004 and the chymotrypsin-like specificity of 
this enzymatic subunit (Baldovino et al. 2006), it is plausible to hypothesise that 
SerpinB2 inhibits PSMB1 and therefore proteasome activity. This does not appear 
to be the case given that depletion of SerpinB2 reduced proteasomal activity, 
rather than enhanced it. Furthermore, it is unlikely that SerpinB2 is interacting with 
PSMB1 within the intact proteasome as this would require direct access into the 
proteasome which is tightly controlled by ubiquitin, unfoldases and an entrance as 
narrow as 13 Aº, necessitating the linearization of proteins to allow spatial 
placement within the proteolytic 20S core. It is tempting to speculate that SerpinB2 
 173 
may interact with PSMB1 during assembly and disassembly of the 26S 
proteasome, functioning to help shuttle the subunit into place, either as a substrate 
or as a non-inhibitory adapter protein. 
 
Cellular mutant Htt is known to form insoluble aggregate deposits and degradation 
has been reported to be predominantly autophagy-lysosomal degradation pathway 
dependent (Martin et al. 2015).  Here we show that the autophagy-lysosomal 
degradation pathway becomes dysregulated in the absence of SerpinB2, which is 
in keeping with recent work describing co-localisation of SerpinB2 with Beclin-1 
and Hsp90, within the membrane of autophagosomes (Chuang et al. 2013). Whilst 
it is not possible to elucidate the functional mechanism behind SerpinB2 regulation 
of autophagy, given the dynamic nature of the pathway, dissociation of Bcl-2 from 
Beclin-1 initiates seeding of the phagophore, which can wrap around aggregates 
such as those found in iPODs and gives rise to autophagosomes.  Our finding that 
loss of SerpinB2 results in decreased numbers of large IPOD inclusions and 
dysregulation of the autophagy-lysosomal degradation pathway suggests a 
possible role for SerpinB2 within this initial seeding stage of the pathway.  
 
Taken together this work indicates that SerpinB2 is a prominent component of the 
cells proteostasis networks, which exerts its cytoprotective effects through 
modulation of the protein degradation pathways. Intriguingly, loss of SerpinB2 
results in attenuation of both the proteasome and autophagy-lysosomal 
degradation pathways. Whether SerpinB2 functions within both systems or has an 
indirect effect on one, through loss of the other, remains to be shown. It is clear 
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however that SerpinB2 interacts with misfolded proteins, inhibits aggregation and 












The specific aims of this thesis were to examine; 1) the role of SerpinB2 within the 
extracellular environment as a plasminogen activator inhibitor in monocytes and 2) 
the role of SerpinB2 within the intracellular environment as a potential stress 
response protein. Accordingly, the conclusions drawn and future directions 
suggested below have been divided into two sections centred on these distinct 
cellular distribution and functions of SerpinB2.  
 
6.2. The role of Extracellular SerpinB2 as a plasminogen activator 
 inhibitor. 
 
There have been many biochemical studies conducted which have defined and 
supported the role of SerpinB2 as a classical inhibitory serpin. In vivo, SerpinB2 
can be detected at very high concentrations under specific patho/physiological 
conditions in the circulation, seminal fluid, tears, gingival crevicular fluid and saliva 
(Croucher et al. 2010). SerpinB2 has also been shown to be efficiently externalised 
on the surface of macrophage and cancer cell-derived microparticles (Schroder et 
al. 2014).  Thus SerpinB2 is present in the extracellular milieu, where it is available 
to inhibit uPA or tPA.  Moreover, SerpinB2 facilitates the rapid endocytosis of 
uPA:uPAR complexes from the surface of prostate cancer (PC-3) (Croucher et al. 
2006) and breast cancer (MCF-7) (Croucher et al. 2007; Cochran et al. 2011) cell 
lines, via members of the Low Density Lipoprotein Receptor (LDLR) family. 
Clarification of the inhibition and possible subsequent endocytosis of 
uPA:SerpinB2 complexes by monocytic cells was of interest with respect to i) 
understanding the role of SerpinB2 in modulating plasminogen activation on 
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monocytic cells in a patho/physiological context, and ii) the possible future 
development of SerpinB2 directed therapeutics for the treatment of hematopoietic 
disorders such as acute myeloid leukaemias. We confirmed (Chapter 2) that 
SerpinB2 inhibits monocytic cell surface uPA and the uPA:serpin complex is 
subsequently cleared via LRP and VLDR, showing a consistent endocytosis 
pathway to that previously described for prostate (Croucher et al. 2006) and breast 
cancer (Croucher et al. 2007) cell lines.  
 
Indeed, this work supports the development of ligand targeted therapy by Vine et 
al. (2012), which shows the selective targeting of receptor bound uPA at the cell 
surface of U937 and THP-1 cell lines, with prodrug, 5,7-dibromo-N-(p-
hydroxymethylbenzyl)isatin (N-AI) conjugated via an esterase-labile linker (N-AIE) 
to SerpinB2. The cytotoxicity of the activated (endocytosed) drug was found to 
correlate with uPA levels, whereby the THP-1 cell line (high uPA expression profile 
(Fig. 2.1)) was found to be more susceptible to the cytotoxic effects of SerpinB2-
N-AIE, compared to the U-937 cell line (low uPA expression profile (Fig. 2.1)). 
Early work investigating the expression patterns for components of the uPA system 
clearly indicate a correlation between differentiation towards macrophage 
phenotype and uPAR expression (Lanza et al. 1998; Scherrer et al. 1999). 
Importantly, uPA is the predominant plasminogen activator in leukaemic marrow, 
a characteristic not found in healthy marrow (McWilliam et al. 1998; Scherrer et al. 
1999), therefore SerpinB2 targeted therapeutics may prove successful in 
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eradicating multiple drug resistant leukemic blasts and stem cells within the 
marrow of patients and warrants further detailed preclinical investigation. 
 
As such, a thorough understanding of the role SerpinB2 plays in the inhibition of 
plasminogen activation at the cell surface of monocytes was required. SerpinB2 is 
able to inhibit other cell type surface bound tc-tPA in vitro (Lobov et al. 2008). 
Therefore, we next examined the inhibition and fate of cell surface tPA by SerpinB2 
on freshly isolated peripheral blood monocytes (PBMs). We not only confirmed that 
SerpinB2 inhibits monocyte-bound tPA but show for the first time that these 
tPA:Serpin inhibitory complexes are subsequently endocytosed, predominantly via 
an LDLR dependent pathway, thus clearing cell surface tPA activity. Definitive 
proof for SerpinB2 as a physiological inhibitor of tPA in vivo requires 
experimentation in appropriate animal models. However, co-expression of tPA and 
SerpinB2 has been shown in normal bone marrow (McWilliam et al. 1998), skin 
(Chen et al. 1993), saliva and salivary gland tissue (Virtanen et al. 2006), gingival 
fluid (Brown et al. 1995; Kinnby 2002), as well during pregnancy (Astedt et al. 
1998). Enhanced co-expression of both tPA and SerpinB2 by epithelial cells is 
indicative of some disease states, e.g. periodontal disease (Kinnby 2002), 
psoriasis and pre/eclampsia (Kruithof et al. 1995). Furthermore, in inflamed gingiva 
the local concentration of SerpinB2 and tPA in gingival fliud can reach up to 5 μg/ml 
(~100 nM) and 1.5 μg/ml (~20 nM), respectively (Brown et al. 1995; Kinnby 2002). 
Therefore, SerpinB2 may dampen tPA mediated proteolysis, which is thought to 
compromise epithelial integrity in these tissues. Taken together, these previous 
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works suggest that extracellular SerpinB2 is localized in significant concentrations 
where it may be a physiological inhibitor of cell surface tPA.  
 
Definitive identification of uPA:serpin or tPA:serpin complexes within human tissue 
or animal models has not been forthcoming, most likely due to the rapid clearance 
of PAs complexed with SerpinB2 and their subsequent degradation via the 
lysosomes. Furthermore, knock-out animal models may not offer conclusive 
phenotypes to indicate where SerpinB2 and uPA or tPA may interact. For example, 
the SerpinB2-/- murine model by (Dougherty et al. 1999) did not identify any clear 
phenotype for SerpinB2-deficient mice.  However, subtle phenotypes related to 
viral infection (Schroder et al. 2010), adipose development (Lijnen et al. 2007) and 
enhanced thrombus resolution attributable to enhanced uPA activity (Siefert et al. 
2014) have since been reported in SerpinB2 null mice. This suggests that 
development of knock-in models may offer further insight into the specific nature 
of the PA systems and their inhibitors, SerpinB2 and SerpinE1. The development 
of dual fluorescent expressing mice offers the opportunity to knock in fluorescently 
labelled tPA/uPA and SerpinB2/SerpinE1, which will identify specific organs and 
systems where co-localisation occurs. Recently the bimolecular fluorescence 
complementation (BiFC) system, which enables direct visualisation (in live cells), 
of protein interactions (Kerppola 2008), has been shown to work within a 
Drosophila model (Hudry et al. 2011). This system utilises two complementary 
fragments of the venus yellow fluorescent protein, which when brought into close 
proximity by an interaction between proteins fused to these fragments, refold to 
form a fluorescent protein (Kerppola 2008). Development of a murine models using 
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this system with uPA/tPA and SerpinB2/E1 will open up many new areas of interest 
and contribute immensely to establishing physiological context to both SerpinB2 
and SerpinE1, as mediators of proteolysis within the pericellular environment. 
 
Importantly, expression of both tPA and SerpinB2 by monocytes, macrophages 
and myeloid progenitors within normal bone marrow, has been reported 
(McWilliam et al. 1998) and is consistent with the cell surface profile analysis 
conducted here, showing very low levels of uPA compared to the U937 or THP-1 
cell line and some detectable cell surface tPA, which was absent on the malignant 
cell lines. The up-regulation of the uPA system within hematopoietic and solid 
mass tumours is well characterised and is the basis for the development of ligand 
targeted therapeutics, using SerpinB2 (Stutchbury et al. 2007; Ranson et al. 2012; 
Vine et al. 2012).  In this respect, whilst SerpinB2 clearly inhibits cell surface tPA 
(Lobov et al. 2008) and is subsequently endocytosed via LRP or VLDLR (Lee et 
al. 2010), the modest levels of endogenous tPA present on freshly isolated 
monocytes suggests that minimal, non-specific drug delivery to these cell types 
may occur. This is essential when considering the use of SerpinB2 targeted 
therapeutics for the eradication of multiple drug resistant leukemic blasts and stem 
cells within the marrow of patients, as it may tip the balance in prognostic outcome 
through increased protection of healthy tissue whilst efficiently targeting aberrant 
cell types. In conclusion, this body of work contributes towards the proof of concept 
foundations for the development of SerpinB2 directed therapeutics for the 
treatment of haematological disorders and lymphomas. 
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6.3.  Intracellular SerpinB2 – The proteostasis moderator. 
Up-regulation of intracellular SerpinB2 in response to acute and chronic 
homeostatic imbalances is consistent with a potential function within cellular stress 
response pathways. Molecular chaperones tightly regulate proteostasis within 
cells under normal and stress conditions.  The results within this thesis show for 
the first time that SerpinB2 exhibits chaperone-like activity, whereby SerpinB2 
binds preferentially to misfolded stressed proteins, inhibits amorphous aggregation 
of DTT-reduced BSA and fibril formation of Aβ1-40 and Aβ1-42.  Chaperones have 
been shown to interact with target substrates via hydrophobic interactions, whether 
the binding characteristics described here for SerpinB2 are also via hydrophobic 
interactions requires further experimentation. Surface modelling reveals the 
presence of a hydrophobic cluster, within a cavity on the surface of SerpinB2, 
which is in close proximity to the CD-loop (Fig. 6.1 B).  The CD-loop itself also 
contains hydrophobic residues, contributing to 44% of the loop sequence (Fig. 
6.1C). Early work by Wilczynska et al. (2003) showed significant changes in 
surface hydrophobicity which were dependent on the formation of C79-C161 
disulfide bond, involving the C-D loop of SerpinB2 (Fig. 6.1B). Intriguingly, 
formation of this di-sulfide bond is thought to stabilize the opening of β-sheet-A 
and promote polymersiation, however disruption of the bond, is thought to close 
the β-sheet-A, whilst resulting in a 3 fold increase in the binding of a known 
hydrophobic probe, bis-ANS (Musci and Berliner 1985). It is possible that release 
of the CD-loop from the di-sulfide bond, allows interaction between the target 
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protein and hydrophobic regions of the loop itself, whilst also opening up the region 
of hydrophobicity along helix-D (Fig 6.1B).  
 
In this context, future experiments investigating the effect of these hydrophobic 
pockets, if any, on the ability of SerpinB2 to interact with native or misfolded client 
proteins should be conducted using bis-ANS within the ELISA based end-point 
binding assays (see section 4.3.4). Pretreatment of plate bound substrates with 
bis-ANS, prior to the addition of SerpinB2, also in the presence of bis-ANS, should 
block hydrophobicity (Poon et al. 2002) and reduce detectable bound SerpinB2. 
Once established, site directed mutagenesis studies can be used to validate the 
specific residues which function within these hydrophobic pockets. Furthermore, 
the role of the CD-loop should be considered utilizing the ΔCD-loop mutant form 
of SerpinB2 (Cochran et al. 2009).  Given that SerpinB2 was shown to inhibit the 
amorphous aggregation of BSA under reducing conditions, mild reduction of 
SerpinB2 prior to use within either end-point binding or real-time aggregation 
assays may improve the chaperone efficiency of the molecule. Of note however, 
the redox sensitive conformational changes proposed by Wilczynska et al. (2003) 
are thought to open the breach region of the serpin, when the C79-C161 di-sulfide 
bond is formed. This may open a functional region of the molecule for interaction 
with binding partners and is worth consideration in future experimentation 
exploring SerpinB2 chaperone-like activity. This is of particular interest in the 





Figure 6.1: SerpinB2 molecule contains a hydrophobic cluster located 
along Helix D. A) Ribbon structure of SerpinB2 showing helices (light pink), β-
sheets (pale cyan) and hydrophobic residues (raspberry). C-D inter-helical loop 
is located between residues 66-98 (grey dotted line). Helix D is labeled for visual 
orientation. B) Hydrophobic surface residues (raspberry) reveals a cluster (blue 
dotted arrow) within proximity of the C-D loop. Cysteine residues (C79-C161) 
(red circles) essential for proposed redox sensitive conformational 
rearrangement (Wilczynska et al. 2003) C) Amino acid sequence of the C-D loop 
with hydrophobic residues (raspberry). Modelling was conducted with crystal 
structure by (Harrop et al. 1999), 1BY7, using PyMOL Molecular Graphics 








We show here that inhibition of Aβ1-42 peptide fibril formation by SerpinB2 impairs 
its classic serpin inhibitory mechanism, suggesting that Aβ1-42 peptide binds within 
the β-sheet-A region of SerpinB2. Whether the interaction occurs as a direct 
insertion of the peptide, into the breach or shutter regions of the serpin is unknown. 
However, further characterisation of this binding interaction may be obtained 
experimentally using small synthetic peptides which mimic the RCL sequence 
(Saunders et al. 2001).  Such peptides will mimic insertion of the endogenous RCL 
into β-sheet-A region of SerpinB2 and block Aβ peptide insertion, which would be 
expected to abolish chaperone activity, thus confirming this particular mode of 
action.  
 
Interestingly, the association of Serpins with Aβ peptides (within the extracellular 
environment) appears to be widespread in that Serpins A1 (α1-antitrypsin (AAT)), 
A3 (α1-antichymotrypsin (ACT)) (Abraham et al. 1988; Rozemuller et al. 1991), B2 
(Akiyama et al. 1993) and I1 (Neuroserpin) (Kinghorn et al. 2006) have all been 
shown to co-localise with senile plaques associated with Alzheimer’s Disease 
(AD). By means of in vitro studies SerpinA3 was reported to inhibit fibril formation 
by Aβ1-40 (Eriksson et al. 1995; Aksenova et al. 1996) but not Aβ1-42 (Aksenov et 
al. 1996) peptide, yet SerpinA3 reduced the cytotoxicity of Aβ1-42 but not Aβ1-40 
peptide  against rat hippocampal cell cultures (Aksenov et al. 1996; Aksenova et 
al. 1996). Furthermore, Serpins A1, A3, C1 and F2 were all found to inhibit the 
cytotoxicity of Aβ peptide added to rat pancreatic islet cell tumour line, subclone 
(I5) (Schubert 1997). Whether SerpinB2 in the extracellular space also buffers 
 185 
against the cytotoxicity of Aβ-peptide requires investigation.  Future cell based 
experiments utilising inactive (RCL blocked) SerpinB2 as a control would be useful 
in determining whether SerpinB2 interrupts endocytosis of toxic amyloid species. 
The exact role serpins play in AD progression is unclear, therefore gaining an 
understanding of how SerpinB2 inhibits Aβ-peptide fibril formation and determining 
if SerpinB2 is able to protect against the cytotoxicity of Aβ-peptide, may clarify 
whether serpins, in general, are actively involved within extracellular proteostasis 
pathways or are themselves sequestered by Aβ-peptide.  
 
Molecular chaperones are classically defined as proteins that participate in de 
novo folding, facilitate the formation of functional tertiary conformations and re-
folding of stress-denatured proteins (Jakob and Buchner 1994; Netzer and Hartl 
1998; Hartl and Hayer-Hartl 2009). These chaperones are active within the “on-
folding” pathway (Fig. 6.2A) and belong to the family of heat shock proteins (HSP) 
(Hartl et al. 2011). Alternatively, some molecular chaperones function to stabilise 
stressed proteins but do not work within the folding pathway to re-conform 
misfolded substrates into their functional native tertiary structures (Jakob and 
Buchner 1994; Ehrnsperger et al. 1997). These chaperones are functional within 
the “off-folding” pathway (Fig. 6.2B) and belong to the small heat shock protein 
(sHSP) family (Hartl et al. 2011). Importantly, molecular chaperones within either 
system bind preferentially to misfolded proteins, as does SerpinB2. Whether 
SerpinB2 functions within the “on” folding pathway is not known. Of interest, 
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Figure 6.2. SerpinB2 identified as a potential player in cellular proteostasis 
networks. Unfolded proteins are re/folded into their correct tertiary structure by 
chaperones and co-chaperones within the folding pathway (A) or enter the 
aggregate pathway (B) where they form small protein aggregates, which are either 
degraded via the ubiquitin/proteasomal degradation pathway (C) or 
sequestered into inclusion bodies such as the insoluble protein deposits (IPOD) for 
degradation via the autophagy/lysosomal degradation pathway (D). SerpinB2 
binds to misfolded protein and influences IPOD formation (Lee et al. 2015) (pathway 
B). SerpinB2 influences proteasome activity (pathway C) (Lee et al. 2015) possibly 
through interaction with proteasome subunit-β1 (red) (Fan et al. 2004). SerpinB2 
deletion results in dysregulation of the autophagy/lysosomal degradation (pathway 
D). Possibly through protective interaction with Beclin-1 (Chuang et al. 2013). 
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assembly and transport from the endoplasmic reticulum (Tasab et al. 2000). Given 
that SerpinB2 protein has been shown localized within the nucleus and cytosol it 
is plausible to consider a potential role within the on-folding pathway.  
 
The work presented within this thesis provides novel evidence that SerpinB2 may 
function within proteostasis networks, as a chaperone-like protein. SerpinB2 
identifies and binds preferentially to misfolded proteins suggesting it may interact 
with soluble oligomers and small aggregates (Fig 6.2B) and facilitate their 
trafficking into inclusion bodies or the proteasomal degradation pathway (Fig 
6.2C).  Indeed, our finding that loss of SerpinB2 results in decreased numbers of 
large IPOD inclusions (Fig. 6.2B) is consistent with a role for SerpinB2 in mediating 
the formation of cellular inclusions, which requires rearrangement of the 
cytoskeleton. In this context, investigation of potential cytoskeleton interactions for 
SerpinB2 are warranted. Intriguingly, loss of SerpinB2 also results in attenuation 
of both the proteasome (Fig 6.2D) and autophagy-lysosomal degradation 
pathways (Fig 6.2D). Whether SerpinB2 functions within both systems or has an 
indirect effect on one, through loss of the other, remains to be shown. The reported 
interaction of SerpinB2 with proteasome subunit beta type 1 (Fan et al. 2004) (Fig 
6.2C) and autophagy regulator, Beclin-1 (Chuang et al. 2013) (Fig 6.2D) suggests 
a role within both pathways. It is tempting to speculate that SerpinB2 may interact 
with PSMB1 during assembly and disassembly of the 26S proteasome, functioning 
to help shuttle the subunit into place, either as a substrate or an adapter protein.   
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We also show dysregulation of the autophagy-lysosomal degradation pathway 
suggesting a possible role for SerpinB2 within this initial seeding stage 
(phagosome formation) of the pathway (Fig. 6.2D), possibly through cytoskeleton 
rearrangement. Also of interest, dissociation of Bcl-2 from Beclin-1 initiates 
seeding of the phagophore.  Interestingly, Bcl-2 interacts with Beclin-1 through 
hydrophobic interactions so it is plausible to consider that SerpinB2 may also bind 
in a similar way, potentially obscuring the Bcl-2 binding site on Beclin-1, thus 
promoting autophagy. Of interest, SerpinB2 expression was recently shown by 
Chuang et al. (2013) to protect Beclin-1 degradation via the proteasome. 
Furthermore, Chuang et al. (2013) found that SerpinB2 associated with and 
enhanced the binding of Hsp90 and Beclin-90, suggesting a functional multi-
protein complex arrangement for SerpinB2.  
 
In this context, the role Hsp90 plays within the phagophore, in relation the 
SerpinB2 is also of interest. Hsp90 is an essential mediator of proteostasis 
networks and co-localises with co-chaperones to form macro-complexes (Hipp et 
al. 2014). Investigation of the interaction between Beclin-1, SerpinB2 and Hsp90 
is required to better understand how SerpinB2 influences autophagy. It is possible 
that the chaperone-like biochemical properties described for SerpinB2 within this 
thesis contribute to a co-chaperone like function for SerpinB2 within the Hsp90 
complex systems. Previous work has shown that the co-chaperone and ubiquitin 
ligase, CHIP, binds to Hsp70 and Hsp90, mediating ubiquitylation of target proteins 
and transporting them to the proteasome (Kettern et al. 2010). The hypothesis that 
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SerpinB2 may act as a co-chaperone or adapter protein is supported by the finding 
that SerpinB2 interacts with ubiquitin in a non-covalent manner (Lee et al. 2015). 
Furthermore, SerpinB2 has also been shown to interact with the ubiquitin-like 
adapter protein, interferon stimulated gene-15 (ISG15) (Giannakopoulos et al. 
2005) which has also been implicated in autophagy and proteosomal degradation 
pathways (Nakashima et al. 2015).  
 
Of interest then is the finding that SerpinB2 structure is unique whereby the highly 
conserved Thr203 residue, found in all other serpins, is replaced by an asparagine 
residue, resulting in the loss of a helical turn and the extension of a chain, at the 
top of the molecule near the RCL (Fig. 6.3) (Harrop et al. 1999). Importantly, this 
results in a more flexible region than that of the body of the protein. The lack of an 
intracellular protease target for SerpinB2 has confounded progression of SerpinB2 
research, particularly given numerous studies which report the characterization of 
cleaved SerpinB2, post induction of cellular stress. Intriguingly recent work by 
(Chuang et al. 2013), describing Hsp90 interaction with SerpinB2, showed that the 
pro-autophagy and Beclin-1 protective mechanisms are dependent on an active 
serpin. The authors report loss of function when using the R380A mutant of 
SerpinB2, once again suggesting a protease target. If however, SerpinB2 forms a 
functional multiprotein complex with Hsp90, or other proteins, in its proposed role 
as a co-chaperone, it is hypothesized that cleavage of the RCL by protease/s 




Figure 6.3: SerpinB2 contains a unique region of increased flexibility. 
Ribbon structure of SerpinB2 showing helices (light pink) and β-sheets (pale 
cyan). Region containing residues Glu213 to Tyr220 (blue) forms a unique 
region of flexibility within SerpinB2. RCL superimposed (red line).  Modelling was 
conducted with crystal structure by (Harrop et al. 1999), 1BY7, using PyMOL 
Molecular Graphics System, Version 1.7.4.4 Schrödinger, LLC 
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In conclusion, this work opens up an exciting new focus of research for intracellular 
SerpinB2 biology, in that SerpinB2 has chaperone-like characteristics and clearly 
influences autophagy-lysosomal and proteasomal degradation pathways. The 
cytoprotective role of intracellular SerpinB2 has remained elusive given it’s 
everywhere whilst nowhere expression profile, within many cell types under many 
varied conditions. Early work focused on an anti-apoptotic role for SerpinB2 
(discussed section 1.14.1) with confounding results. Interestingly, BCL-2 has been 
shown to inhibit both apoptosis and autophagy, furthermore over activation of the 
autophagy pathway has a pro-apoptotic effect (Pattingre et al. 2005). This raises 
the question then, if SerpinB2 is pro-autophagic and over-activation of the pathway 
results in activation of apoptosis, then how may this have influenced the early 
studies, using SerpinB2 overexpressing cell lines. Given the role of serpinB2 in 
cytoprotection it is likely that further research will uncover therapeutic targets for 
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NaCl 80 g.L-1 
KCl 2 g.L-1 
Na2HPO4 14.4 g.L-1 
KH2PO4 2.4 g.L-1 
Adjust pH as required.  Dilute 1 in 10 before use. 
 
10x TBS 
Tris-Base 500 mM 
NaCl 1500 mM 
Adjust pH as required.  Dilute 1 in 10 before use. 
 
TBST 
1x TBS (As above) 
Tween 20 500 μL.L-1 
 
Binding Buffer 
Hanks modified buffered salt 9.7 g.L-1 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 4.8 g.L-1 
CaCl2 1 mM 
MgCl2 1 mM 
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BSA 1 g.L-1 
Adjust pH to 7.4. 
 
5x SDS PAGE Sample Buffer (non-reducing) 
Tris-HCl 60 mM 
Glycerol 10% W/V 
SDS 2%  W/V 
Bromophenol Blue 0.01% W/V 
 
RPMI 1640 Growth Media 
RPMI 10.4 g.L-1 
NaHCO3 2 g.L-1 
Foetal Calf Serum 10% (v/v) 
 
Coomassie Blue Stain 
Methanol 400 mL.L-1 
Glacial Acetic Acid 100 mL.L-1 
Distilled Water 500 mL.L-1 
Coomassie Blue R-250 2 g.L-1 
 
Destain 
Methanol 400 mL.L-1 
Glacial Acetic Acid 100 mL.L-1 
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10% Acrylamide Gel 
Tris-HCL pH 8.8 0.38 M 
SDS 0.1% (w/v) 
Acrylamide/Bis 10% (w/v) 
Ammonium Persulfate APS 8% (w/v) 
NNN’N’-tetramethylethylenediamine (TEMED) 8% (w/v) 
 
4% Acrylamide Gel 
Tris-HCL pH 8.8 0.125 M 
SDS 0.1% (w/v) 
Acrylamide/Bis 5.2% (w/v) 
Ammonium Persulfate (APS) 8% (w/v) 
NNN’N’-tetramethylethylenediamine TEMED 8% (w/v) 
 
Running Buffer 
Tris-base 15 g.L-1 
Glycine 72 g.L-1 
Sodium Dodecyl Sulphate (SDS) 5 g.L-1 






Tris-Base 3.03 g.L-1 
Glycine 14.40 g.L-1 
Methanol 200 mL.L-1 
Distilled Water 800 ml.L-1 
